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ABSTRACT 
Pleiomaltinine is an alkaloid-pyrone natural product that was the first of its kind to be 
isolated in nature. Synthesis of this compound from pleiocarpamine and a reactive quinone 
methide-like pyrone is described. Furthermore, model compounds have been made that will allow 
for full testing of this new heterocycle’s biological properties. This process has also been 
rendered enantioselective using asymmetric organocatalysis with thioureas. Additionally, work 
has been conducted towards the total synthesis of vinylallene-derived natural products. Progress 
towards the syntheses of chloropupukeananin, chloropestolide A, pestalofone C, iso-A82775c, 
and maldoxin isolated from Pestalotiopsis fici are described. All of these compounds are complex 
and possess biological activities including anti-cancer and anti-HIV. The strategies applied to 
develop a selective synthesis of reactive vinylallenes are discussed and plans designed to 
overcome this synthetic challenge are shown in detail. New methodologies are presented along 
with literature precedent in these areas of research.  
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Chapter 1 
 
Pleiocarpamine Alkaloids 
 
1.1 Pleiocarpamine and related alkaloids 
 Alkaloid natural products have been a rich source of pharmaceuticals, 
agrochemicals, and a variety of new transformations for their synthesis.
1
 Pleiocarpamine 
(1) is a member of the Alstonia alkaloids derived from the plant genus with the same 
name.
2
 The group contains over 70 indole alkaloids and most members have a tetracyclic 
carbazole framework. Pleiocarpamine bears a resemblance to macroline, sarpagine, and 
ajmaline alkaloids and they likely share a similar biosynthesis. 
Scheme 1.1 Biosynthesis of Pleiocarpamine 
 
Biosynthetically, pleiocarpamine is believed to derive from tryptamine (2) and the iridoid 
monoterpenoid secologanin (3) which first forms the natural product geissoschizine (4) 
(Scheme 1.1).
3
 Further coupling between the N-1 indole nitrogen and the C-16 enol ether 
carbon would produce pleiocarpamine (1).
4
  
Sakai and Shinma achieved a partial synthesis of 16-epi-pleiocarpamine 8 from 
geissoschizine methyl ether 5 (Scheme 1.2).
5
 C/D ring cleavage was achieved through 
2 
 
treatment with cyanogen bromide and then C-N bond formation was enabled through 
transformation to the chloride 6 followed by addition of NaH. The final ring could be 
reformed by heating in AcOH and NH4OAc to give 16-epi-pleiocarpamine 8. 
Scheme 1.2 Sakai’s Synthesis of 16-epi-Pleiocarpamine 
 Geissoschizine (4) has been a popular target for total synthesis with numerous 
syntheses.
6
 Among them, Overman’s is notable for its high stereoselectivity for 
construction of the exocyclic olefin using a vinylsilane cyclization (Scheme 1.3). Starting 
from advanced intermediate 9, conjugate addition of vinyl silane cuprate reagent 10 gave 
adduct 11 in good yield. Decarboxylation and lactam opening completed the synthesis of 
the key precursor 12. Treatment with formaldehyde generated an iminium which was 
then cyclized in a stereocontrolled fashion to the indoloquinolizidine core. The synthesis 
of geissoschizine (4) was then completed using formylation of a lithium enolate.   
Scheme 1.3 Overman’s Synthesis of Geissoschizine 
 
Pleiocarpamine has never been synthesized chemically, although there are studies 
towards the dihydro product 18.
7
 Bosch and coworkers utilized a key piperidine ring 
which was immediately formed through reaction of indole 13 and pyridinium 14 followed 
by acid-catalyzed cyclization (Scheme 1.4). Compound 16 underwent Witkop 
3 
 
cyclization
8
 from C3 to the chloride. The reaction likely proceeds through 
diradical cation formation followed by closure to the indoline. The indolyl radical 
cation was successful compared to electrophilic cyclization conditions due to the strain 
involved in the formation of 17. The hemiaminal and lactam could be reduced but all 
attempts to construct the indole moiety of pleiocarpamine failed.  
Scheme 1.4 Bosch’s Synthesis of Dihydro Pleiocarpamine 
 
Boekelheide and coworkers synthesized 19,20-dihydronormavacurine (26) 
through a key base-catalyzed epoxide opening (Scheme 1.5).
9
 Initial formation of the 
piperidinone ring was followed by Wittig olefination to install the aldehyde 22. Then, a  
Scheme 1.5 Boekelheide’s Synthesis of 19,20-Dihydronormavacurine 
  
4 
 
Corey-Chaykovsky epoxidation afforded the exocyclic epoxide substrate 23. Treatment 
with NaH under an oxygen atmosphere effected ring contraction followed by C-N bond 
formation to give 24. The mavacurine skeleton 26 was then formed through an acid-
mediated alkyl shift (pinacol rearrangement). 
Plant-derived pleiocarpamine can be obtained in synthetically useful amounts 
from Alstonia angustifolia. This has been utilized to explore pleiocarpamine’s reactivity 
as well as to access higher order bisindole alkaloids. In studies by Gan and Cook, 
pleiocarpamine (1) and anhydromacrosalhine-methine (27) were stirred in 0.2 M HCl and 
the natural product macrocarpamine (28) was obtained in good yield (Scheme 1.6).
10
 
Their synthesis was unique in that the indole became electrophilic upon treatment with 
acid and the iminium generated was subsequently attacked by the vinylogous enol ether. 
It served as the first example of a proton-mediated coupling reaction to make a member 
of the Alstonia natural product family. 
Scheme 1.6 Cook’s Synthesis of Macrocarpamine  
 
Le Quesne and coworkers developed similar conditions to synthesize the bisindole 
villalstonine (30).
11
 Plant-derived pleiocarpamine (1) and the natural product macroline 
(29) were stirred in aqueous HCl and villalstonine (30) was obtained, presumably 
5 
 
following 1,4 addition by the indole and closure of the alkoxide onto the iminium 
(Scheme 1.7). 
Scheme 1.7 Le Quesne’s Synthesis of Villalstonine  
 
1.2 Pleiomaltinine: a new hybrid natural product class 
There are a number of examples of natural products with hybrid features.
12
 In 
2010, Kam and coworkers isolated a unique alkaloid-pyrone adduct from Alstonia 
angustifolia. They proposed that pleiomaltinine (31) was derived from pleiocarpamine 
(1) and 2-methylene-3,4-diketone
13
 32, which may be formed through dehydrogenation 
of the natural product maltol (33) (Figure 1.1). Pleiomaltinine is able to reverse 
multidrug-resistance in vincristine-resistant KB (VJ300) cells (IC50=12 μg/mL in the 
presence of 0.1 μg/mL of vincristine). 
Figure 1.1 Proposed Biosynthesis of Pleiomaltinine     
 
6 
 
γ-Pyrone natural products are a large class of polyketides that have been known 
since the isolation of poppy acid in 1805.
14
 These compounds possess a wide variety of 
biological activities, which lend them favorably towards biology-oriented synthesis 
(BIOS).
15
 Pyrones are six-membered cyclic unsaturated esters and the γ-isomer has the 
ketone and ether two carbons apart. 
Scheme 1.8 Biosynthesis of Pyrones    
Biosynthetically, they derive from the condensation of ketides such as malonyl-CoA 
which are then further modified (Scheme 1.8). Despite their abundance, there has only 
been a growing interest in their synthesis since the turn of the century. Trauner
16
 and 
others
17
 have led the resurgence and have synthesized numerous biologically active γ-
pyrones and derivatives.  
Shortly after we initiated studies towards pleiomaltinine and simpler analogues, 
the first example of a joined indole-pyrone product was reported.
18
 Reddy and coworkers 
developed a three component coupling of indoles, aldehydes, and kojic acid (36) under 
In(III) catalysis (Scheme 1.9). Substitution at both the 2- and 5- positions of indole were 
tolerated, and one aliphatic aldehyde was used. They obtained high yields by heating neat  
Scheme 1.9 Three Component Coupling    
 
7 
 
at 120 °C. 
Mechanistically, the authors propose the reaction to proceed through intermediate 
39 (similar to 32) which is then attacked in a Michael fashion by C-3 of the indole 34. 
Rearomatization of hemiaminal ether 40 then provides the Friedel-Crafts alkylation 
product 37. Interestingly, the investigators do not comment on whether they tried C3-
substituted indoles to block rearomatization and potentially construct a hemiaminal ether 
linkage similar to what is observed in pleiomaltinine (31). The products from this study 
Scheme 1.10 Proposed Mechanism of Indole-Pyrone Formation    
 
were screened against the Gram positive organisms Bacillus subtilis (MTCC 441), 
Staphylococcus aureus (MTCC96), Staphylococcus epidermidis (MTCC 2639) and 
Gram-negative organisms Escherichia coli (MTCC 443), Pseudomonas aeruginosa 
(MTCC 741), and Klebsiella pneumoniae (MTCC 618). A few compounds showed low 
μM MIC although most do not show more activity than the antibiotics penicillin or 
streptomycin. The compounds’ antifungal activities were also tested and the most active 
had a zone of inhibition in the 11–21 mm at the concentration of 150 μM. 
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 At the outset of our studies, we required a method to generate the quinone 
methide-like intermediate 32. Our initial proposal was to use ESIPT
19
 on the 
hydroxymethyl pyrone 41 to transfer a proton and extrude water (Scheme 1.11). Wan and 
Scheme 1.11 Proposed ESIPT Formation of Intermediate 32    
  
coworkers have shown that ESIPT can be performed on hydroxy benzyl alcohols to give 
o-quinone methides that may then be trapped by nucleophiles (eq. 2).
20
 However, efforts 
to synthesize substrate 42 proved challenging, requiring many steps and inconsistent 
yields. Therefore attention was turned to synthesize the known bromosiloxy pyrone 44.
21
 
This compound had previously been employed in alkylation chemistry with no reports of 
Scheme 1.12 Synthesis of Bromosiloxy Pyrone 37    
 
annulations or cycloadditions. Starting from commercially available and inexpensive 
compound maltol (33), silylation and radical bromination afforded the stable white solid 
44 on multi-gram scale (Scheme 1.12). 
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We considered that a quinone methide-like intermediate could be generated via 
fluoride-induced desilylation
22
 and loss of bromide. Recently, Chain and coworkers 
demonstrated Michael additions to o-quinone methides generated by a fluoride source 
(Scheme 1.13).
23
 Silyl enol ether 45 reacted with benzylic chloride 46 to generate the 
reactive intermediates in situ and produced adduct 47 in 43% yield.  
Scheme 1.13 Fluoride-induced Michael Reaction of Quinone Methides    
 
We were delighted to obtain trace amounts of cycloadduct 49 when pyrone 44 
was treated with carbazole 48 and TBAF in THF (Scheme 1.14). We then optimized the  
Scheme 1.14 Initial Synthesis of Model Alkaloid-Pyrone Adduct     
  
reaction and found that a fluoride source was not needed to effect desilylation. Methanol 
alone could promote cycloaddition, which led us to hypothesize that proto-desilylation 
had occurred possibly through the involvement of HBr. A range of Brønsted acids were 
subsequently screened and eventually we settled on anhydrous 4M HCl in dioxane as the 
optimal combination (Table 1.1). Stirring the pyrone 44 and carbazole 48 in acetonitrile 
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afforded a 81% yield of the product which was later confirmed by X-ray crystallography 
(Scheme 1.14). Addition of a proton scavenger such as 2,6-di-tBu-pyridine inhibited the 
reaction lending support to the involvement of acid as catalyst. 
Table 1.1 Optimization of the Alkaloid-Pyrone Reaction      
 
Our proposed mechanism for pyrone annulation (Scheme 1.15) begins with initial 
protonation at the carbonyl oxygen of the pyrone substrate 44.
24
 This should weaken the 
O-Si bond through hydrogen bonding and allow the counterion to deprotect the silyl  
Scheme 1.15 Proposed Mechanism for Alkaloid-Pyrone Annulation 
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group and concomitantly expel bromide. The resulting intermediate would be 
dearomatized oxidopyrylium
25
  52 which is in resonance with the proposed quinone 
methide-like intermediate 53. It is not entirely clear whether the reaction proceeds 
through a concerted inverse demand Diels-Alder reaction
26
 or Michael-Mannich 
sequence. It appears that the pyrone addition may be concerted, but is likely highly 
asynchronous.  
Support for proposed intermediate 53 was found through production of dimer 56 
(Scheme 1.16), which was obtained in variable amounts throughout the optimization 
process and could be isolated in 32% yield by omission of the carbazole. The hydrate is  
Scheme 1.16 Isolation of Pyrone Dimer 
 
isolated after workup due to the high reactivity of the α-diketone 55. We also observed 
hydroxypyrone 41 when aqueous acid was used and adduct 57 in methanolic conditions. 
Interestingly, resubjection of 41 to the reaction conditions gave some cycloadduct 49. 
The substrate scope for the pyrone annulation was found to be fairly broad as 
shown in Figure 1.2. We were able to employ indoles (as long as there was a 3-
substituent) and obtain products such as 60. In cases where the starting indole/carbazole 
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had an N-H, we isolated the open indolenine products. This was determined 
unambiguously by X-ray (Chapter 2) and for other examples using the observed 
13
C 
NMR shift of the imine. We believe that isolation of the indolenine structure may be due 
to the preference for an O-H with hydrogen bonding to the pyrone carbonyl rather than an 
N-H; conformations may also play an effect. Variations in the  
Figure 1.2 Substrate Scope of Alkaloid-Pyrones 
  
carbocycle such as cyclopent[b]indole 61 and its cycloheptyl and –octyl variants were 
tolerated. The pyrone could also be modified with 5-bromopyrone adduct 58 a viable 
substrate. Phenyl β- carboline gave product 62 as a single diastereomer; similarly ethyl  
Figure 1.3 Spartan Models of Ethyl Adduct 
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maltol could be derivatized to afford the adduct 63. Finally, a pyrrole was viable and 
gave the C2 addition product 64 in good yield. A model of the transition state for the 
production of adduct 63 shows that it is the result of a formal endo cycloaddition with 
(Z)-2-methylene-3,4-diketone intermediate 65 (Figure 1.3). DFT calculations were 
performed and the (Z) isomer was lower in energy by 1.71 kcal/mol. 
After synthesizing a number of analogues, we wanted to test the reaction on a 
complex alkaloid before using precious pleiomaltinine. There are a number of 
commercially available natural products to choose from in this regard. Ultimately we 
chose reserpine (66) for semisynthetic modification, a storied indole alkaloid.
27
  
Scheme 1.17 Synthesis of Reserpine Adduct 
  
Thankfully, application of our optimal conditions produced the annulation product 67 as 
a single diastereomer (Scheme 1.17). Examination of the X-ray of reserpine shows that  
Figure 1.4 X-ray Structure of Reserpine 
 
the pyrone would be guided to the top, convex face (Figure 1.4). This offers the 
opportunity to derivatize
28
 bioactive alkaloids with our γ-pyrone and test the new activity. 
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After the success with pyrone cycloadditions with reserpine, we next studied 
reactions with pleiomaltinine (31). To our great gratitude, Professor Kam at University of 
Malaya was able to provide us with over 30 mg of pleiocarpamine. With the alkaloid 
substrate in hand, we were able to test the key reaction immediately. At first, we tried the 
reaction in DMSO and while we observed a new product, attempts to isolate resulted in 
decomposition and over-oxidation products. The standard conditions of acetonitrile and 
HCl in dioxane were the best and produced pleiomaltinine as a single diastereomer in 
Scheme 1.18 Synthesis of Pleiomaltinine 
 
51% yield (Scheme 1.18). Both synthetic and natural pleiomaltinine gave matching 
1
H 
and 
13
C NMR spectra as well as TLC and HPLC retention values. The 
diastereoselectivity for the pyrone cycloaddition may be explained through a DFT model 
of pleiocarpamine (Figure 1.5). The pentacyclic alkaloid framework adopts a 
Figure 1.5 Model of Pleiocarpamine 
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cage-like structure which should steer the activated pyrone (protonated 2-methylene-3,4-
diketone 53) to the α, convex face. 
1.3 Other Applications of the Alkaloid-Pyrone Annulation 
 We also discovered an interesting rearrangement during our optimization process. 
When the reaction was heated to try and accelerate the reaction, we did not isolate the 
expected cycloadduct but rather the rearranged product 72 (Scheme 1.19). The pyrone 
had undergone a [1,3] transposition to the 1 position of the rearomatized carbazole. Our 
proposed mechanism involves initial opening of the hemiaminal ether to give the 
zwitterion 68. Deprotonation to the enamine
29
 would then be followed by rearomatization 
and concomitant loss of pyrone.  
Scheme 1.19 Rearrangement of Alkaloid-Pyrone Adduct 
 
The vinylogous pyrone
30
 71 would then be able to attack the stabilized allylic carbocation 
70 and give the observed product. An intermediate such as 70 has been proposed in the 
literature.
31
 The reaction was specific to N-protected substrates with the corresponding N-
H adduct 59 giving a rearrangement to N-alkylated carbazole pyrone 73 (Scheme 1.20).  
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Scheme 1.20 Rearrangement to N-Alkylated Product 
 
 We were also very interested in extending the pyrone annulation methodology to 
access pyrroloindolines, which incorporate a pyrrolidine annulated to the indole motif 
with the aminal at C-2. They are well known for their biological activity and numerous 
total syntheses of both pyrroloindoline and dimeric products have been achieved.
32
 A 
variety of methods exist to assemble this motif,
33
 including a number of asymmetric 
methods.
34
 We envisaged using our previously developed annulation conditions using  
Scheme 1.21 Proposed Synthesis of Pyrroloindolines 
 
tryptamines. In this case, instead of having the alkoxide cyclize, the pendant amine 
should attack the incipient iminium (Scheme 1.21). We started this study by testing  
reactions using tryptamine (R=H) under our acidic conditions. The reaction proceeded to 
completion but we were not able to separate the very polar compounds. Thus, we decided 
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to protect the primary amine to modulate the reactivity (Table 1.2). A methyl protecting 
group did indeed give a joined product; however based on its high nucleophilicity we 
observed N-alkylation rather than the desired pyrroloindoline formation. Electron 
withdrawing groups have been crucial in prior pyrroloindoline formations;
35
 to our 
delight we isolated some desired product when an N-tosyl group was used. Changing to 
the more electron-withdrawing nosyl group gave an increase to 5:1 pyrroloindoline to N-
alkylation. Ultimately, use of a trifluoroacetamide group gave high selectivity for the 
desired product 77; however, we observed a large amount of pyrone dimer under these 
conditions, so we switched the stoichiometry such that the tryptamine was the limiting  
Table 1.2 Optimization of the Pyrroloindoline Reaction      
 
reagent. This modification resulted in a 71% isolated yield of pyrroloindoline with only 
trace amounts of 78. 
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The structure of 77e was confirmed by X-ray crystal analysis, which showed that the 
hydroxypyrone is pointed towards the free amine (Figure 1.6). This may suggest a weak 
hydrogen bond between the aminal H and the OH since they are 2.4 Å apart. A similar 
effect in the form of a birfurcated intramolecular C-H-O hydrogen bond was reported in 
the anti-HIV drug azidothymidine.
36
 
Figure 1.6 X-Ray of Pyrroloindoline 77e 
 
We next explored the substrate scope of the reaction and found it was relatively broad 
(Figure 1.7). A variety of 5-substituted tryptamines could be employed with some  
Figure 1.7 Substrate Scope of Pyrroloindolines 
 
reduction in yield observed for halogenated substrates due to reduced nucleophilicity at 
C-5. Both 4- and 6- substituted substrates could be used, but attempts at either C-2 or C-7 
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pyrroloindolines failed. We were also able to use an N-Me substrate to obtain the 
differentially protected pyrroloindoline 86. 
We tested a tryptophan derived substrate and found that the enantiopure benzyl-
protected ester 88 gave pyrroloindoline 89 in 57% yield as a single diastereomer 
(Scheme 1.22). We believe it is this structure due to the steric bulk of the benzyl ester 
since the corresponding methyl ester gave a mix of diastereomers. Efforts to obtain an X-
ray structure are currently ongoing.  
Scheme 1.22 Use of a Tryptophan Substrate 
 
Previous examples of tryptophans reacted with carbon electrophiles show mixed results 
for both preferential exo
37
 and endo
38
 pyrroloindoline formation (Scheme 1.23). Carreira 
and coworkers used iridium catalysis to effect a reverse prenylation and pyrroloindoline 
formation (eq. 1). In this case, isolation of the exo isomer 92 in high dr was dependent on 
a bulky borane which was used to activate N-1 of 90. You and coworkers used a similar 
approach to make C-3 branched allyl substrates (eq. 2); the catalyst and ligand in this 
case controlled the exo or endo pyrroloindoline 94 selectivity. L-Tryptophan substrate 90 
was the matched case while the D enantiomer was mismatched. Finally, Tamaru and 
coworkers were able to take allyl alcohol 96 under Pd catalysis and generate endo 
diastereomer 97 in good yield and high dr (eq. 3). 
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Scheme 1.23 Literature Examples of Tryptophan Pyrroloindolines 
 
Our first attempt to deprotect the trifluoroacetamide protecting group was under 
standard basic conditions (NaOH). Instead of the N-H product we observed regeneration  
Scheme 1.24 Deprotection of N-TFA Pyrroloindolines 
 
of the starting tryptamine. Presumably, the alkoxide was deprotonated and then 
eliminated through the mechanism shown in Scheme 1.24. Ultimately, reductive 
conditions using NaBH4 gave desired free pyrroloindoline 98 in good yield.  
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1.4 Conclusion  
In summary, we have developed a general method to synthesize unusual alkaloid-
pyrone structures and applied the methodology to the synthesis of alkaloid-pyrone natural 
product pleiomaltinine. This will allow for further testing of the biological properties of 
this novel hybrid molecule. Along with the Friedel-Crafts alkylation of kojic acid with 
indoles, our work is one of the rare studies towards this class of molecules. We will next 
describe our efforts to develop a catalytic, enantioselective alkaloid-pyrone addition 
(Chapter 2). Then, I will introduce my second project of vinylallene natural products and 
relevant background information (Chapter 3). Lastly, synthetic approaches towards this 
class of natural products will be discussed (Chapter 4). 
1.5 Experimental Section 
General Information: 
1
H NMR spectra were recorded at 300, 400, or 500 MHz at 
ambient temperature with CDCl3, CD3OD, C6D6, or DMSO-d6 (Cambridge Isotope 
Laboratories, Inc.) as solvents. Data for 
1
H NMR are reported as follows: chemical shift, 
integration, multiplicity (o = overlapping, s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet) and coupling constants in Hz. 
13
C NMR spectra were recorded at 75.0, 
100.0, or 125 MHz at ambient temperature with the same solvents unless otherwise 
stated. Chemical shifts are reported in parts per million relative to the deuterated solvents. 
All 
13
C NMR spectra were recorded with complete proton decoupling. Infrared spectra 
were recorded on a Nicolet Nexus 670 FT-IR spectrophotometer. High-resolution mass 
spectra were obtained in the Boston University Chemical Instrumentation Center using a 
Waters Q-TOF API-US mass spectrometer. Melting points were recorded on a Mel-temp 
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Temp apparatus (Laboratory Devices). Analytical LC-MS was performed on a Waters 
Acquity UPLC (Ultra Performance Liquid Chromatography) (Waters MassLynx Version 
4.1) with a Binary solvent manager, SQ mass spectrometer, Water 2996 PDA 
(PhotoDiode Array) detector, and ELSD (Evaporative Light Scattering Detector). An 
Acquity UPLC BEH C18 1.7 μm column was used for analytical UPLC-MS. Preparative 
HPLC separations were carried out on a Gilson PLC 2020 Personal Purification System 
using a Sunfire C18 column.  
Purification of pleiocarpamine: Optical rotations were determined on a Jasco P-1020 
automatic digital polarimeter. UV spectra were obtained on a Shimadzu UV-3101PC 
spectrophotometer. IR spectra were recorded on a Perkin-Elmer RX1 FT-IR 
spectrophotometer. ESIMS was obtained on a Perkin Elmer API 100 instrument. 
1
H and 
13
C NMR spectra were recorded in CDCl3 using TMS as an internal standard on JEOL 
JNM-LA 400 spectrometer at 400 and 100 MHz, respectively. 
Analytical thin layer chromatography was performed using 0.25 mm silica gel 60-F 
plates. Flash chromatography was performed using 200-400 mesh silica gel (Sorbent 
Technologies, Inc.). Yields refer to chromatographically and spectroscopically pure 
materials, unless otherwise stated. HPLC grade tetrahydrofuran, methylene chloride, 
diethyl ether, toluene, acetonitrile, and benzene were purchased from Fisher and VWR 
and were purified and dried by passing through a PURE SOLV® solvent purification 
system (Innovative Technology, Inc.). Other ACS grade solvents for chromatography 
were purchased from Clean Harbors.  
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All reactions were carried out in oven-dried glassware under an argon atmosphere unless 
otherwise noted.  
Siloxypyrone 44 was prepared from the commercially available maltol using known 
literature methods. Bromo maltol was prepared from commercially available maltol using 
known literature methods. Carboline substrate S3 was prepared according to literature 
procedures.  
Isolation of pleiocarpamine: The ground stem-bark material of A. angustifolia was 
extracted exhaustively with EtOH and the concentrated EtOH extract was then 
partitioned with dilute HCl (5%) to provide a basic fraction. The basic fraction was first 
chromatographed over SiO2 (CHCl3 with increasing proportions of MeOH) to furnish 
three pooled fractions. Subsequent repeated fractionation of the first two pooled fractions 
(Column chromatography, SiO2, MeOH/CHCl3; centrifugal preparative TLC, SiO2, 
hexane/CHCl3 1:1, 0.5% aq. NH3) afforded pleiocarpamine (yield: 0.112 g/kg of stem 
bark).  
General Procedure A for Pyrone Annulation: A 10 mL oven dried round bottom flask 
was charged with siloxypyrone 44 (100 mg, 1.0 equiv, 0.31 mmol) and indole substrate 
(1.5 equiv, 0.47 mmol) in CH3CN (1.5 mL, 0.2 M) as solvent. The reaction was 
conducted under an atmosphere of argon at room temperature. The reaction was 
quenched with 10 mL of aqueous sodium bicarbonate and the product extracted from the 
aqueous layer using 5 x 25 mL of CH2Cl2. The organic layer was then dried over sodium 
sulfate and the crude material was concentrated under vacuum. The resulting oil was 
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directly chromatographed on SiO2 via flash chromatography using a gradient of 
EtOAc/MeOH to afford the annulation products as pure compounds.  
General Procedure B: Same as described for General Procedure A except using the 
indole substrate as a limiting reagent. In a typical experiment, indole substrate (50 mg, 
1.0 equiv, 0.20 mmol) and siloxy pyrone 44 (63 mg, 2.0 equiv, 0.40 mmol) were added to 
CH3CN (1.0 mL, 0.2 M). Siloxy pyrone 44 was added in batches of 0.5 equiv every 10 
minutes until all of the indole was consumed. The reaction was quenched with 10 mL of 
aqueous sodium bicarbonate and the product was extracted from the aqueous layer using 
5x 25 mL of CH2Cl2. The organic layer was then dried over sodium sulfate and the crude 
material was concentrated under vacuum and the resulting oil was directly 
chromatographed on SiO2. Purification via flash chromatography using a gradient of 
EtOAc/MeOH afforded the annulation products as pure compounds. 
6-Methyl-6,11-dihydro-4H-5a,10b-
butanopyrano[2',3':5,6]pyrano[2,3-b]indol-4-one 49: Cycloadduct 49 was prepared 
according to general procedure A using 3-siloxy-4-pyrone 44 (100 mg, 0.31 mmol, 1.0 
equiv), N-methyl tetrahydrocarbazole 48 (88 mg, 0.48 mmol, 1.5 equiv) in CH3CN (1.5 
mL, 0.2 M). 0.1 mL (0.40 mmol, 1.3 eq.) of 4.0 M HCl in dioxane was added and the 
reaction was quenched after 15 minutes using 10 mL of aqueous sodium bicarbonate. The 
crude product was purified by flash chromatography using a gradient of EtOAc/MeOH 
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(99:1 to 95:5) to obtain pure product 49 (78 mg, 0.26 mmol, 81%). White powder; Rf = 
0.21 (EtOAc/hexanes 1:1); m.p. 127-129 
o
C; IR (thin film) νmax 2937, 2858, 1645, 1631, 
1481, 1244, 1169, 932, 863, 739 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.52 (d, J=5.8 Hz, 
1H), 7.13 (ddd, J=7.6, 7.6, 0.8 Hz, 1H), 7.00 (br. dd, J=7.2, 0.8 Hz, 1H), 6.76 (dd, J=7.6, 
7.2 Hz, 1H), 6.59 (d, J=7.6 Hz, 1H), 6.24 (d, J=5.8 Hz, 1H), 2.98 (o, 2H), 2.94 (s, 3H), 
2.23 (ddd, J=6.0, 4.3, 2.3 Hz, 1H), 1.73 (o, 3H), 1.53 (o, 4H); 
13
C NMR (100 MHz, 
CDCl3) δ 172.1, 152.6, 149.1, 147.9, 142.3, 134.3, 128.3, 120.1, 119.0, 115.9, 108.7, 
101.8, 45.9, 37.5, 28.6, 27.8, 27.5, 22.9, 21.3. HR-MS: m/z Calcd. for C19H20NO3 
[M+H]
+
: 310.1443, Found 310.1442 (-0.1 ppm). 
 3,3-Dihydroxy-2'H-spiro[pyran-2,3'-pyrano[3,2-b]pyran]-
4,8'(3H,4'H)-dione 56: Dimer 56 was prepared using 3-siloxy-4-pyrone 44 (102 mg, 
0.32 mmol, 1.0 equiv) in CH3CN (0.5 mL, 0.53 M). 0.1 mL (0.40 mmol, 1.2 equiv) of 4.0 
M HCl in dioxane was added. After 15 minutes of stirring, the reaction was quenched 
using 10 mL of aqueous sodium bicarbonate. The crude product was purified by 
recrystallization from CH2Cl2 to obtain pure product 56 (27 mg, 0.10 mmol, 32%). White 
powder; Rf = 0.43 (CH2Cl2/MeOH 9:1); m.p. 156-159 
o
C; IR νmax 3374, 3368, 2929, 
1693, 1643, 1611, 1566, 1245, 1149, 993, 813 cm
-1
; 
1
H NMR (500 MHz, D2O) δ 8.04 (d, 
J=5.5 Hz, 1H), 7.30 (d, J=5.5 Hz, 1H), 6.50 (d, J=6.6 Hz, 1H), 5.68 (d, J=6.6 Hz, 1H), 
3.04 (ddd, J=18.2, 13.3, 6.6 Hz, 1H), 2.90 (dd, J=18.2, 6.3 Hz, 1H), 2.62 (dd, J=14.5, 6.3 
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Hz, 1H), 2.27 (ddd, J=14.5, 13.3, 6.6 Hz, 1H); 
13
C NMR (125 MHz, DMSO-d6) δ 190.9, 
170.8, 158.7, 154.9, 150.9, 139.6, 116.1, 105.2, 103.9, 89.7, 21.4, 19.1; HR-MS: m/z 
Calcd. for C12H11O7 [M+H]
+
: 267.0505, Found 267.0517 (+1.2 ppm). 
5a,10b-Dimethyl-5a,6,10b,11-tetrahydro-4H-
pyrano[2',3':5,6]pyrano [2,3-b]indol-4-one 60: Adduct 60 was prepared according to 
general procedure A using 3-siloxy-4-pyrone 44 (108.5 mg, 0.34 mmol, 1.0 equiv), 2,3-
dimethyl indole (71.1 mg, 0.49 mmol, 1.4 equiv) in CH3CN (1.5 mL, 0.21 M). 0.1 mL 
(0.40 mmol, 1.2 equiv) of 4.0 M HCl in dioxane was added. The reaction was quenched 
after 15 minutes using 10 mL of aqueous sodium bicarbonate. The crude product was 
purified by flash chromatography using a gradient of EtOAc/MeOH (99:1 to 95:5) to 
obtain pure product 60 (77 mg, 0.29 mmol, 84%). White powder; Rf = 0.20 
(CH2Cl2/MeOH 95:5); m.p. 118-120 
o
C; IR νmax 3241, 2964, 2927, 1621, 1579, 1451, 
1261, 1198, 1002, 831, 750 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.44 (d, J=7.3 Hz, 1H), 
7.40 (d, J=5.8 Hz, 1H), 7.28 (dd, J=7.3, 7.3 Hz, 1H), 7.25 (d, J=7.6 Hz, 1H), 7.14 (dd, 
J=7.3, 7.0 Hz, 1H), 6.39 (br. s, N-H), 6.22 (d, J=5.8 Hz, 1H), 3.39 (d, J=14.5 Hz, 1H), 
3.12 (d, J=14.5 Hz, 1H), 2.40 (s, 3H), 1.44 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 185.7, 
172.9, 154.1, 153.7, 147.8, 143.5, 142.0, 128.1, 125.1, 122.2, 119.7, 112.9, 57.1, 34.4, 
22.8, 15.8. HR-MS: m/z Calcd. for C16H16NO3 [M+H]
+
: 270.1130, Found 270.1137 (+0.7 
ppm). 
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 2-((2,3-Dihydrocyclopenta[b]indol-8b(1H)-yl)methyl)-3-hydroxy-4H-
pyran-4-one 61: Adduct 61 was prepared according to general procedure A using 3-
siloxy-4-pyrone 44 (50 mg, 0.16 mmol, 1.0 equiv) and 1,2,3,4-
tetrahydrocyclopenta[b]indole (36.9 mg, 0.23 mmol, 1.5 equiv) in CH3CN (1 mL, 0.16 
M). 0.05 mL (0.20 mmol, 1.3 equiv) of 4.0 M HCl in dioxane was added. The reaction 
was quenched after 15 minutes using 5 mL of aqueous sodium bicarbonate. The crude 
product was purified by flash chromatography using a gradient of EtOAc/MeOH (99:1 to 
95:5) to obtain pure product 61 (35 mg, 0.12 mmol, 79%). White powder; Rf = 0.24 
(CH2Cl2/MeOH 95:5); m.p. 80-82 
o
C; IR νmax 3344, 1646, 1621, 1469, 1247, 746 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.49 (d, J=5.7 Hz, 1H), 7.01 (o, 2H), 6.68 (dd, J=8.1, 7.2 
Hz, 1H), 6.41 (d, J=7.2 Hz, 1H), 6.30 (d, J=5.7 Hz, 1H), 4.73 (s, NH), 3.09 (d, J=15.6 Hz, 
1H), 2.93 (d, J=15.6 Hz, 1H), 2.35 (o, 2H), 2.13 (o, 2H), 1.85 (m, 1H), 1.64 (m, 1H); 
13
C 
NMR (125 MHz, CDCl3) δ 173.2, 156.8, 153.5, 149.6, 142.6, 132.2, 128.6, 122.8, 118.4, 
117.0, 109.9, 107.4, 64.2, 42.3, 36.1, 25.4, 23.6. HR-MS: m/z Calcd. for C17H15NO3 
[M+H]
+
: 282.1052, Found 282.1138 (+8.6 ppm). 
 3-Hydroxy-2-((2,3,4,5-tetramethyl-2H-pyrrol-2-yl)methyl)-4H-
pyran-4-one 64: Adduct 64 was prepared according to general procedure A using 3-
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siloxy-4-pyrone 44 (150 mg, 0.47 mmol, 1.0 equiv) and 2,3,4,5-tetramethylpyrrole (102 
mg, 0.83 mmol, 1.8 equiv) in CH3CN (2 mL, 0.23 M). 0.15 mL (0.60 mmol, 1.3 equiv) of 
4.0 M HCl in dioxane was added. The reaction was quenched after 15 minutes using 5 
mL of aqueous sodium bicarbonate. The crude product was purified by flash 
chromatography using a gradient of EtOAc/MeOH (99:1 to 95:5) to obtain pure product 
64 (91 mg, 0.37 mmol, 78%). Clear oil; Rf = 0.28 (CH2Cl2/MeOH 95:5); IR νmax  cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.62 (d, J= 5.5 Hz, 1H), 6.35 (d, J= 5.5 Hz, 1H), 2.96 (d, 
J= 14.4 Hz, 1H), 2.60 (d, J= 14.4 Hz, 1H), 2.14 (s, 3H), 1.92 (s, 3H), 1.80 (s, 3H), 1.21 (s, 
3H); 
13
C NMR (125 MHz, CDCl3) δ 174.1, 172.7, 160.6, 154.7, 152.8, 143.6, 130.5, 
115.2, 79.0, 34.6, 26.1, 21.7, 18.8, 17.2. HR-MS: m/z Calcd. for C14H17NO3 [M+H]
+
: 
248.1208, Found 248.1287 (+7.9 ppm). 
 5-Bromo-3-((tert-butyldimethylsilyl)oxy)-2-methyl-4H-pyran-4-one 
S1: TBS-protected bromo maltol S1 was prepared by the same procedure used to prepare 
TBS-protected maltol.
S1
 Bromo maltol (126.2 mg, 0.62 mmol, 1.0 equiv) and tert-
butyldimethylsilyl chloride (109 mg, 0.72 mmol, 1.17 equiv) were added to an oven dried 
10 mL round bottom flask with anhydrous N,N-dimethylformamide (1.5 mL, 0.41 M) 
under an atmosphere of argon. After the reaction was stirred for 5 minutes, imidazole 
(83.8 mg, 1.23 mmol, 2.0 equiv) was added in one portion. After stirring for 23 h, the 
reaction was quenched with 5 mL of aqueous sodium bicarbonate and the organic layer 
was extracted using hexanes. The product S1 (100 mg, 0.31 mmol, 51%) was sufficiently 
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pure enough to be taken forward crude to the next step. White solid; Rf = 0.4 
(EtOAc/hexanes 5:95); m.p. 86-88 
o
C ;IR νmax 3053, 2958, 2928, 2895, 1633, 1619, 
1262, 1247, 910, 827, 790 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 2.32 (s, 3H), 
0.96 (s, 9H), 0.27 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 169.5, 154.9, 151.5, 141.2, 
113.4, 25.9, 18.6, 14.9, -3.8; HR-MS: m/z Calcd. for C12H20BrO3Si [M+H]
+
: 319.0365, 
Found 319.0367 (+0.2 ppm). 
5-Bromo-2-(bromomethyl)-3-((tert-butyldimethylsilyl)oxy)-4H-
pyran-4-one S2: Bromo siloxypyrone S2 was prepared in a similar fashion to 
siloxypyrone 44.
S1
 TBS-protected bromo maltol S1 (100.0 mg, 0.31 mmol, 1.0 equiv), N-
bromosuccinimide (53.5 mg, 0.300 mmol, 0.96 equiv), and azobisisobutyronitrile (6.9 
mg, 0.042 mmol, 0.13 equiv) were added to an oven dried 10 mL round bottom flask 
containing anhydrous carbon tetrachloride (3.0 mL, 0.1 M) under an atmosphere of 
argon. The mixture was then heated to reflux at 77 °C for 2 h, after which time the 
reaction was filtered and then concentrated. The crude product was purified by flash 
chromatography using a gradient of hexanes/EtOAc (99:1 to 95:5) to obtain pure product 
S2 (97.8 mg, 0.24 mmol, 78%). White solid; Rf = 0.55 (hexanes/EtOAc 3:1); m.p. 78-82 
o
C; IR νmax 3251, 3068, 2928, 1639, 1610, 1274, 1221, 900, 827, 775 cm
-1
; 
1
H NMR (400 
MHz, CDCl3) δ 8.05 (s, 1H), 4.44 (s, 2H), 1.00 (s, 9H), 0.33 (s, 6H); 
13
C NMR (125 
MHz, CDCl3) δ 169.9, 152.1, 151.5, 141.6, 113.5, 25.9, 22.5, 18.7, -3.4; HR-MS: m/z 
Calcd. for C12H19Br2O3Si [M+H]
+
: 396.9470, Found 396.9462 (-0.8 ppm). 
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3-Bromo-6-methyl-6,11-dihydro-4H-5a,10b-
butanopyrano[2',3':5,6]pyrano [2,3-b]indol-4-one 58: Cycloadduct 58 was prepared 
according to general procedure A using 1-bromo-3-siloxy-4-pyrone S2 (97.8 mg, 0.25 
mmol, 1.0 equiv), N-methyl tetrahydrocarbazole 48 (68.2 mg, 0.37 mmol, 1.5 equiv) in 
CH3CN (1.5 mL, 0.16 M). 75 μL (0.30 mmol, 1.2 equiv) of 4.0 M HCl in dioxane was 
added. The reaction was stirred for 2 hours under an atmosphere of air. The reaction was 
quenched after 2 h using 10 mL of aqueous sodium bicarbonate The crude product was 
purified by flash chromatography using a gradient of hexanes/EtOAc (90:10 to 50:50) to 
obtain pure product 58 (60.7 mg, 0.16 mmol, 64%). White powder; Rf = 0.43 
(hexanes/EtOAc 1:1) m.p. 145-148 
o
C; IR νmax 3051, 2934, 2856, 1630, 1481, 1232, 910, 
891, 746 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.90 (s, 1H), 7.14 (ddd, J=9.3, 7.6, 1.6 Hz, 
1H), 7.00 (dd, J=7.6, 1.1 Hz, 1H), 6.77 (ddd, J= 8.7, 7.6, 1.1 Hz, 1H), 6.60 (br. dd, J=7.6 
Hz, 1H), 3.02 (o, 2H), 2.95 (s, 3H), 2.28 (m, 1H), 1.72 (o, 3H), 1.50 (o, 4H); 
13
C NMR 
(125 MHz, CDCl3) δ 167.0, 151.3, 149.0, 147.9, 141.0, 133.9, 128.4, 120.1, 119.1, 113.6, 
108.8, 102.6, 46.0, 37.7, 28.3, 27.8, 27.5, 22.9, 21.2; HR-MS: m/z Calcd. for 
C19H19BrNO3 [M+H]
+
: 388.0548, Found 388.0545 (-0.3 ppm). 
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3-Hydroxy-2-((2-methyl-1-phenyl-1,2,3,4-tetrahydro-4aH-
pyrido[3,4-b]indol-4a-yl)methyl)-4H-pyran-4-one 62: Cycloadduct 62 was prepared 
according to general procedure B using N-methyl phenyl tetrahydrocarboline S3 (50.2 
mg, 0.17 mmol, 1.0 equiv), 3-siloxy-4-pyrone 44 (113 mg, 0.35 mmol, 2.0 equiv) in 
CH3CN (0.8 mL, 0.19 M). 0.1 mL (0.40 mmol, 2.3 equiv) of 4.0 M HCl in dioxane was 
added. The reaction was quenched after 45 minutes with 10 mL of aqueous sodium 
bicarbonate. The crude product was purified by flash chromatography using a gradient of 
EtOAc/hexanes (1:3 to 100:0) to obtain pure product 62 (55 mg, 0.13 mmol, 77%). 
Yellow/brown oil; Rf =  (CH2Cl2/MeOH 95:5); IR νmax 3384, 1648, 1260, 1030, 800 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.56 (d, J= 4.7 Hz, 1H), 7.32 (o, 6H), 6.99 (dd, J= 9.6, 7.8 
Hz, 1H), 6.75 (dd, J= 7.8, 7.8 Hz, 1H), 6.58 (d, J= 7.8 Hz, 1H), 6.34 (d, J= 4.7 Hz, 1H), 
3.28 (s, 1H), 3.17 (o, 2H), 2.95 (o, 2H), 2.39 (o, 2H), 2.08 (s, 3H); 
13
C NMR (125 MHz, 
CDCl3) δ 171.4, 154.3, 140.7, 135.3, 134.0, 132.7, 132.1, 129.9, 128.7, 128.3, 122.2, 
120.5, 119.5, 116.0, 115.0, 111.7, 69.3, 51.5, 44.5, 37.6, 29.7, 26.4; HR-MS m/z Calcd. 
for C24H22N2O3 [M+H]
+
: 387.1709, Found 387.1902 (-0.7 ppm). 
 3-((Tert-butyldimethylsilyl)oxy)-2-ethyl-4H-pyran-4-one S4: TBS-
protected ethyl maltol S4 was prepared by the same procedure used to prepare TBS-
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protected maltol.
S1
 Ethyl maltol (5.0 g, 35.7 mmol, 1.0 equiv) and tertbutyldimethylsilyl 
chloride (6.14 g, 40.8 mmol, 1.14 equiv) were added to an oven dried 250 mL round 
bottom flask with anhydrous N,N-dimethylformamide (110 mL, 0.32 M) under an 
atmosphere of argon. After the reaction was stirred for 5 minutes, imidazole (4.86 g, 71.4 
mmol, 2.0 equiv) was added in one portion. After stirring for 1 h, the reaction was 
quenched with 50 mL of aqueous sodium bicarbonate and the organic layer was extracted 
using hexanes. The product S4 (6.34 g, 25.0 mmol, 70%) was sufficiently pure to be 
taken forward crude to the next step. Clear oil; Rf = 0.42 (EtOAc/hexanes 5:95); IR νmax 
2953, 2929, 2856, 1641, 1255, 1204, 884, 824, 784 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 
7.58 (d, J=6.1 Hz, 1H), 6.25 (d, J=6.1 Hz, 1H), 2.67 (q, J=7.5 Hz, 2H), 1.17 (t, J=7.5 Hz, 
3H), 0.92 (s, 9H), 0.22 (s, 6H); 
13
C NMR (125 MHz, CDCl3) δ 174.2, 158.7, 152.9, 
142.0, 115.3, 25.9, 21.7, 18.7, 10.9, -3.8; HR-MS: m/z Calcd. for C13H23O3Si [M+H]
+
: 
255.1416, Found 255.1419 (+0.3 ppm). 
 2-(1-Bromoethyl)-3-((tert-butyldimethylsilyl)oxy)-4H-pyran-4-one S5: 
Ethyl siloxypyrone S5 was prepared in a similar fashion to siloxypyrone 44.
S1
 TBS-
protected ethyl maltol S4 (5.93 g, 23.3 mmol, 1.0 equiv), N-bromosuccinimide (4.35 g, 
24.4 mmol, 1.05 equiv), and azobisisobutyronitrile (511.2 mg, 3.11 mmol, 0.13 equiv) 
were added to an oven dried 250 mL round bottom flask containing anhydrous carbon 
tetrachloride (120 mL, 0.19 M) under an atmosphere of argon. The mixture was then 
heated to reflux at 77 °C for 1 h, after which time the reaction was filtered and then 
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concentrated. The crude product was purified by flash chromatography using a gradient 
of hexanes/EtOAc (99:1 to 9:1) to obtain pure product S5 (5.76 g, 17.2 mmol, 74%). 
White solid; Rf = 0.55 (hexanes/EtOAc 4:1) m.p. 82-90 
o
C; IR νmax 3221, 1617, 1274, 
1209, 1179, 973, 944, 830 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.70 (d, J=5.7 Hz, 1H), 
6.31 (d, J=5.7 Hz, 1H), 5.45 (q, J=7.2 Hz, 1H), 1.92 (d, J=7.2 Hz, 3H), 0.97 (s, 9H), 0.29 
(s, 3H), 0.26 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 174.4, 153.9, 153.2, 140.9, 119.0, 
115.5, 68.1, 37.9, 26.0, 25.1, 22.2, 18.8, -3.6; HR-MS: m/z Calcd. for C13H22BrO3Si 
[M+H]
+
: 333.0522, Found 333.0521 (-0.1 ppm). 
6,11-Dimethyl-6H-5a,10b-butanopyrano[2',3':5,6]pyrano[2,3-b]indol-
4(11H)-one 63: Cycloadduct 63 was prepared according to general procedure B using 
1,2,3,4-tetrahydrocarbazole (300.2 mg, 1.75 mmol, 1.0 equiv), ethyl 3-siloxy-4-pyrone 
S5 (624.6 mg, 1.87 mmol, 1.07 equiv) in CH3CN (6.5 mL, 0.24 M). 0.9 mL (3.6 mmol, 
2.1 equiv) of 4.0 M HCl in dioxane was added. The reaction was quenched after 2 h using 
10 mL of aqueous sodium bicarbonate. The crude product was purified by flash 
chromatography using a gradient of EtOAc/hexanes (1:3 to 100:0) to obtain pure product 
63 (410 mg, 1.31 mmol, 75%). Red solid; Rf = 0.57 (CH2Cl2/MeOH 95:5); m.p. 58-62 
o
C; IR νmax 3383, 1650, 1250, 1027, 801 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.63 (d, J= 
5.8 Hz, 1H), 7.16 (dd, J= 7.7, 7.7 Hz, 1H), 7.07 (d, J= 7.7 Hz, 1H), 6.77 (dd, J= 9.6, 9.6 
Hz, 1H), 6.50 (d, J= 9.6 Hz, 1H), 6.40 (d, J= 5.8 Hz, 1H), 2.97 (q, J= 7.2 Hz, 1H), 2.75 (s, 
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3H), 2.25 (m, 1H), 1.80 (o, 3H), 1.56 (d, J= 7.2 Hz, 3H), 1.52 (o, 3H);
 13
C NMR (125 
MHz, CDCl3) δ 173.4, 154.6, 152.7, 148.3, 141.6, 133.0, 128.3, 121.4, 118.2, 116.2, 
112.9, 100.2, 46.3, 36.4, 28.9, 27.9, 24.5, 21.6, 20.6, 20.0 ; HR-MS: m/z Calcd. for 
C20H21NO3 [M+H]
+
: 324.1600, Found 324.1609 (+0.9 ppm). 
Reserpine adduct 67: Cycloadduct 67 was 
prepared according to general procedure B using reserpine 66 (59.8 mg, 0.98 mmol, 1.0 
equiv) and 3-siloxy-4-pyrone 44 (47 mg, 1.47 mmol, 1.5 equiv) in CH3CN (1 mL, 0.1 
M). 0.05 mL (0.2 mmol, 2 equiv) of 4.0 M HCl in dioxane was added. The reaction was 
quenched after 30 mins using 1 mL of aqueous sodium bicarbonate. The crude product 
was purified by flash chromatography using a gradient of EtOAc/hexanes (1:3 to 100:0) 
to obtain pure product 67 (35 mg, 0.048 mmol, 49%). Red oil; Rf = 0.37 (CH2Cl2/MeOH 
95:5); IR νmax 3406, 1712, 1627, 1463, 1331, 1225, 1128, 733 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3) δ 7.36 (d, J=5.7 Hz, 1H), 7.34 (o, 2H), 7.15 (dd, J=8.6, 2.2 Hz, 1H), 7.12 (d, 
J=2.1 Hz, 1H), 6.73 (dd, J=8.6, 2.2 Hz, 1H), 6.20 (d, J=5.7 Hz, 1H), 5.04 (ddd, J=11.6, 
9.5, 4.9 Hz, 1H), 4.44 (br. s., 1 H), 3.92 (s, 9H), 3.91 (m, 1H), 3.85 (s, 3H), 3.82 (m, 3H), 
3.51 (s, 3H), 3.47 (m, 1H), 3.36 (d, J=14.3 Hz, 1H), 3.22 (d, J=14.3 Hz, 1H), 3.01 (m, 
1H), 2.76 (o, 2H), 2.64 (dd, J=11.1, 4.7 Hz, 1H), 2.32 (o, 2H), 2.17 (m, 2H), 2.08 (m, 
1H), 1.96 (m, 2H);
 13
C NMR (125 MHz, CDCl3) δ 173.9, 172.6, 165.4, 154.6, 152.9, 
151.9, 142.3, 142.0, 135.9, 125.2, 122.4, 122.0, 113.1, 112.7, 106.9, 106.5, 104.6, 95.4, 
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77.6, 77.6, 63.3, 60.9, 60.8, 57.4, 56.6, 56.2, 54.2, 52.1, 50.8, 48.6, 33.5, 31.7, 29.3, 25.7, 
20.0, 16.3; HR-MS: m/z Calcd. for C39H44N2O12 [M+H]
+
: 733.2894, Found 733.2971 
(+7.7 ppm). 
3-Hydroxy-2-((9-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-
yl)methyl)-4H-pyran-4-one 72: The [1,3]-shift product 72 was prepared by refluxing 
cycloadduct 49 (49.0 mg, 0.16 mmol, 1.0 equiv) in 1,2-dichloroethane (1.5 mL, 0.11 M)  
at 84 
o
C for 16 h. The crude product was directly concentrated in vacuo and purified by 
flash chromatography using EtOAc (100%) to obtain hydroxy pyrone 72 (32 mg, 0.10 
mmol, 65%). Orange/Yellow oil; Rf = 0.66 (EtOAc/MeOH 95:5); IR νmax 3308, 3235, 
3105, 2948, 1641, 1625, 1469, 1261, 1193, 740 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.81 
(d, J=5.5 Hz, 1H), 7.52 (d, J=8.2 Hz, 1H), 7.31 (d, J=8.2 Hz, 1H), 7.22 (ddd, J=8.0, 7.0, 
1.0 Hz, 1H), 7.12 (ddd, J=8.0, 7.0, 1.0 Hz, 1H), 6.50 (d, J=5.5 Hz, 1H), 3.77 (s, 3H), 3.41 
(m, 1H), 3.02 (o, 2H), 2.88 (m, 1H), 2.67 (m, 1H), 1.92 (o, 4H); 
13
C NMR (100 MHz, 
CDCl3) δ 173.1, 154.5, 150.5, 143.7, 137.2, 136.9, 126.9, 121.3, 118.9, 118.2, 113.1, 
109.9, 108.7, 32.9, 30.1, 29.2, 27.0, 20.9, 18.2; HR-MS m/z Calcd. for C19H20NO3 
[M+H]
+
: 310.1443, Found 310.1436 (-0.7 ppm). 
 3-Hydroxy-2-((1,2,3,4-tetrahydro-9H-carbazol-9-yl)methyl)-4H-
pyran-4-one 73: Indole 73 was prepared by refluxing cycloadduct 59 (50.0 mg, 0.17 
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mmol, 1.0 equiv) cycloadduct in 1,2-dichloroethane (1.5 mL, 0.11 M) at 84 
o
C for 16 h. 
The crude product was directly concentrated in vacuo to obtain pure product 73 (42.0 mg, 
0.14 mmol, 84%). Orange/Yellow oil; Rf = 0.33 (EtOAc/Hexanes 1:1); IR νmax 3254, 
2928, 1622, 1466, 1265, 1173, 743 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.64 (d, J=5.2 
Hz, 1H), 7.50 (d, J=7.5  Hz, 1H), 7.46 (d, J=8.1 Hz, 1H), 7.19 (dd, J=7.5, 6.9 Hz, 1H), 
7.12 (dd, J=8.1, 6.9 Hz, 1H), 6.41 (d, J=5.2 Hz, 1H), 5.26 (s, 2H), 2.84 (o, 2H), 2.76 (o, 
2H), 2.00 (o, 2H), 1.90 (o, 2H); 
13
C NMR (125 MHz, CDCl3) δ 173.5, 155.0, 146.0, 
142.9, 136.3, 135.3, 127.5, 121.1, 119.3, 117.7, 113.0, 110.3, 108.9, 38.9, 23.2, 23.0, 
22.0, 21.0; HR-MS m/z Calcd. for C18H18NO3 [M+H]
+
: 296.1287, Found 296.1279 (-0.8 
ppm). 
 Pleiomaltinine 31: 3-Siloxy-4-pyrone 44 (46.0 mg, 0.14 mmol, 
2.9 equiv) and pleiocarpamine 1 (16.0 mg, 0.050 mmol, 1.0 equiv) were added to CH3CN 
(0.30 mL, 0.14 M) and 50 μL (0.20 mmol, 4.0 equiv) of 4.0 M HCl in dioxane was 
added. The reaction was quenched after 15 minutes using 1 mL of aqueous sodium 
bicarbonate and the product extracted from the aqueous layer using 5 x 10 mL of 
CHCl3/iPrOH (2:1). The organic layer was then dried over sodium sulfate and the crude 
material was concentrated under vacuum. The crude product was purified by preparative 
HPLC using a gradient of 10-90% H2O/CH3CN to obtain pure product 31 (11 mg, 0.025 
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mmol, 51%). White solid, m.p. 170-174 
o
C; Rf = 0.20 (EtOAc/MeOH 3:1), natural: Rf = 
0.19 (EtOAc/MeOH 3:1). Rf = 0.37 (CHCl3/MeOH 9:1), natural: Rf = 0.39 
(CHCl3/MeOH 9:1). IR νmax 2964, 1751, 1647, 1611, 1476, 1250, 1172, 868, 748 cm
-1
. 
HR-MS m/z Calcd. for C26H27N2O5 [M+H]
+
: 447.1920, Found 447.1936 (+1.6 ppm). 
Comparison of synthetic and natural pleiomaltinine: 
  
 
38 
 
  
39 
 
UPLC data for natural and synthetic pleiomaltinine (10 to 99% CH3CN/H2O). 
Natural: 
 
Synthetic: 
 
Coinjection: 
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General Procedure for Pyrroloindoline Formation: A 5 mL oven dried round bottom 
flask was charged with tryptamine substrate (45 mg, 1.0 equiv, 0.18 mmol) and 
siloxypyrone 44 (0.5 equiv, 0.09 mmol) in CH3CN (1.5 mL, 0.1 M) as solvent. The 
reaction was conducted under an atmosphere of air at room temperature. Siloxy pyrone 
44 was added in batches of 0.5 equiv every 5 minutes until all of the tryptamine was 
consumed. The reaction was quenched with 3 mL of aqueous sodium bicarbonate and the 
product was extracted from the aqueous layer using 3x 10 mL of CH2Cl2. The organic 
layer was then dried over sodium sulfate and the crude material was concentrated under 
vacuum and the resulting oil was directly chromatographed on SiO2. Purification via 
flash chromatography using a gradient of EtOAc/MeOH afforded the pyrroloindoline 
products as pure compounds. 
 
3-Hydroxy-2-1-(2,2,2-trifluoroacetyl)-2,3,8,8a-
tetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-4H-pyran-4-one 77e: 
Pyrroloindoline 77e was prepared according to the general procedure using N-TFA 
tryptamine 74e (45 mg, 0.18 mmol, 1.0 equiv) and 3-siloxy-4-pyrone 44 (100 mg, 0.31 
mmol, 1.8 equiv) in CH3CN (1.5 mL, 0.1 M). 0.10 mL (0.40 mmol, 2.2 eq.) of 4.0 M HCl 
in dioxane was added and the reaction was quenched after 15 minutes using 3 mL of 
aqueous sodium bicarbonate. The crude product was purified by flash chromatography 
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using a gradient of CH2Cl2/MeOH (99:1 to 95:5) to obtain pure product 77e (47 mg, 0.12 
mmol, 71%). Light orange solid; Rf = 0.31 (CH2Cl2/MeOH 95:5); m.p. 58-62 
o
C; IR (thin 
film) νmax  3354, 1683, 1621, 1467, 1191, 1141, 731 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 
7.65 (d, J=4.8 Hz, 1H), 7.11 (dd, J=7.2, 7.2 Hz, 1H), 7.04 (d, J=7.2 Hz, 1H), 6.93 (br. s, 
NH), 6.77 (dd, J=8.0, 7.2 Hz, 1H), 6.60 (d, J=8.0 Hz, 1H), 6.43 (d, J=4.8 Hz, 1H), 5.57 (s, 
OH), 5.23 (br. s, 1H), 3.89 (dd, J=9.6, 8.8 Hz, 1H), 3.28 (m, 1H), 3.21 (d, J=14.4 Hz, 
1H), 3.11 (d, J=14.4 Hz, 1H), 2.46 (dd, J=12.8, 5.6 Hz, 1H), 2.37 (m, 1H); 
13
C NMR (125 
MHz, CDCl3) δ 172.9, 156.1 (q, J=38.5 Hz), 154.6, 148.5, 147.7, 144.4, 129.3, 128.9, 
123.0, 119.5, 115.9 (q, J=287.6 Hz), 113.1, 109.5, 81.2, 55.4, 46.4 , 35.3, 35.1; 
19
F NMR 
(376 MHz, CDCl3) δ -72.8; HR-MS: m/z Calcd. for C18H15F3N2O4 [M+H]
+
: 381.0984, 
Found 381.1068 (+8.4 ppm). 
 
2,2,2-Trifluoro-N-(2-(5-methyl-1H-indol-3-
yl)ethyl)acetamide S6: 5-Me N-TFA tryptamine S6 was prepared according to a known 
procedure.
15
 5-Methyltryptamine hydrochloride (125 mg, 0.59 mmol, 1.0 equiv) was 
added to an oven dried 5 mL round bottom flask containing methanol (2.4 mL, 0.22 M) 
and NEt3 (0.17 mL, 1.2 mmol, 2.0 equiv) under an atmosphere of argon. The mixture was 
then cooled to 0 °C and ethyl trifluoroacetate (0.14 mL, 1.2 mmol, 2.0 equiv) was added 
dropwise. The mixture was allowed to warm to room temperature and stir for a further 
two hours. After quenching with 5 mL of aqueous sodium bicarbonate, the product was 
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extracted from the aqueous layer with 3x 10 mL of CH2Cl2 and dried over sodium sulfate. 
The crude product was then purified by flash chromatography using a gradient of 
hexanes/EtOAc (4:1 to 3:1) to obtain pure product S6 (134 mg, 0.53 mmol, 84%). White 
powder; Rf = 0.65 (hexanes/EtOAc 7:3); m.p. 158-162 
o
C; IR νmax 3308, 1702, 1476, 
1199, 1156, 731 cm
-1
; 
1
H NMR (500 MHz, CD3OD) δ 7.34 (s, 1H), 7.20 (d, J=8.1 Hz, 
1H), 6.96 (s, 1H), 6.91 (d, J=8.1 Hz, 1H), 3.50 (o, 2H), 2.94 (o, 2H), 2.40 (s, 3H); 
13
C 
NMR (125 MHz, CD3OD) δ 159.1 (q, J=37.0 Hz), 136.5, 128.9, 124.2, 123.7, 118.9, 
117.8 (q, J=287.3 Hz), 116.5, 112.2, 112.1, 42.0, 25.7, 21.8; 
19
F NMR (376 MHz, 
CD3OD) δ -77.1; HR-MS: m/z Calcd. for C13H13F3N2O [M+H]
+
: 271.0980, Found 
271.1045 (+6.5 ppm). 
3-Hydroxy-2-(5-methyl-1-(2,2,2-trifluoroacetyl)-2,3,8,8a-
tetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-4H-pyran-4-one 79: 
Pyrroloindoline 79 was prepared according to the general procedure using 5-Me N-TFA 
tryptamine S6 (71.1 mg, 0.26 mmol, 1.0 equiv) and 3-siloxy-4-pyrone 44 (150 mg, 0.47 
mmol, 1.8 equiv)  in CH3CN (1.5 mL, 0.21 M). 0.1 mL (0.40 mmol, 1.5 equiv) of 4.0 M 
HCl in dioxane was added. The reaction was quenched after 15 minutes using 10 mL of 
aqueous sodium bicarbonate. The crude product was purified by flash chromatography 
using a gradient of CH2Cl2/MeOH (99:1 to 95:5) to obtain pure product 79 (77 mg, 0.19 
mmol, 74%). Clear oil; Rf = 0.47 (CH2Cl2/MeOH 95:5); IR νmax 3423, 1650, 1436, 1271, 
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951, 731 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.67 (d, J=5.6 Hz, 1H), 6.93 (d, J=7.1 Hz, 
1H), 6.86 (s, 1H), 6.52 (d, J=7.1 Hz, 1H), 6.44 (d, J=5.6 Hz, 1H), 5.54 (s, 1H), 5.07 (s, 
NH), 3.87 (dd, J=9.3, 9.3 Hz,), 3.28 (ddd, J=11.4, 5.9, 5.5 Hz, 1H), 3.18 (d, J=14.6 Hz, 
1H), 3.09 (d, J=14.6 Hz, 1H), 2.42 (o, 1H), 2.32 (o, 1H), 2.26 (s, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 173.2, 156.0 (q, J=42.5 Hz), 154.6, 148.5, 146.2, 144.7, 129.7, 128.8, 
123.6, 123.4, 115.9 (q, J=288.2 Hz), 113.5, 109.5, 81.4, 55.5, 46.4, 46.2, 35.1, 20.9; 
19
F 
NMR (376 MHz, CDCl3) δ -72.8; HR-MS: m/z Calcd. for C19H17F3N2O4 [M+H]
+
: 
395.1140, Found 395.1219 (+7.9 ppm).  
3-Hydroxy-2-(5-methoxy-1-(2,2,2-trifluoroacetyl)-2,3,8,8a-
tetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-4H-pyran-4-one 80: 
Pyrroloindoline 80 was prepared according to the general procedure using 5-OMe N-TFA 
tryptamine (80.0 mg, 0.28 mmol, 1.0 equiv) and 3-siloxy-4-pyrone 44 (134 mg, 0.42 
mmol, 1.5 equiv) in CH3CN (2.2 mL, 0.12 M). 0.1 mL (0.40 mmol, 1.4 equiv) of 4.0 M 
HCl in dioxane was added. The reaction was quenched after 15 minutes using 3 mL of 
aqueous sodium bicarbonate. The crude product was purified by flash chromatography 
using a gradient of CH2Cl2/MeOH (99:1 to 95:5) to obtain pure product 80 (76 mg, 0.18 
mmol, 66%). Red solid; Rf = 0.31 (CH2Cl2/MeOH 95:5); m.p. 95-98 
o
C; IR νmax 3340, 
2927, 1689, 1652, 1493, 1455, 1257, 1188, 1020, 838 cm
-1
; 
1
H NMR (500 MHz, CDCl3) 
δ 7.67 (d, J=5.0 Hz, 1H), 7.25 (d, J=5.7, 1H), 7.16 (dd, J=6.9, 5.7 Hz, 1H), 6.66 (dd, 
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J=8.4, 6.9 Hz, 1H), 6.53 (d, J=8.4 Hz, 1H), 6.42 (d, J=5.0 Hz, 1H), 5.55 (br. s), 4.97 (br. 
s), 3.88 (m, 1H), 3.73 (s, 3H), 3.28 (m, 1H), 3.18(d, J=14.3 Hz, 1H), 3.10 (d, J=14.3 Hz, 
1H), 2.42 (m, 1H), 2.35 (s, 1H), 2.32 (m, 1H); 
13
C NMR (100 MHz, CDCl3) δ 173.0, 
156.0 (q, J=37.3 Hz), 154.7, 153.9, 147.7, 144.5, 142.3, 130.6, 117.0, 115.9 (q, J=286.5 
Hz), 114.3, 110.3, 109.8, 81.9, 56.0, 55.8, 46.3, 35.1, 35.0; 
19
F NMR (376 MHz, CDCl3) 
δ -72.8; HR-MS: m/z Calcd. for C18H15F3N2O4 [M+H]
+
: 411.1090, Found 411.1151 
(+6.1 ppm). 
 
2,2,2-Trifluoro-N-(2-(6-methoxy-1H-indol-3-
yl)ethyl)acetamide S7: 6-Methoxy N-TFA tryptamine S7 was prepared in a similar 
fashion to 5-Me N-TFA tryptamine S6.
15
 6-Methoxytryptamine hydrochloride (50.0 mg, 
0.26 mmol, 1.0 equiv) was added to an oven dried 5 mL round bottom flask containing 
methanol (1.5 mL, 0.16 M) and NEt3 (80 µL, 0.57 mmol, 2.2 equiv) under an atmosphere 
of argon. The mixture was then cooled to 0 °C and ethyl trifluoroacetate (70 µL, 0.59 
mmol, 2.2 equiv) was added dropwise. The mixture was allowed to warm to room 
temperature and stir for a further 60 minutes. After quenching with 5 mL of aqueous 
sodium bicarbonate, the product was extracted from the aqueous layer with 3x 10 mL of 
CH2Cl2 and dried over sodium sulfate. The crude product was then purified by flash 
chromatography using a gradient of hexanes/EtOAc (3:1 to 1:1) to obtain pure product S7 
(70.0 mg, 0.24 mmol, 93%). White solid; Rf = 0.36 (hexanes/EtOAc 3:1); m.p. 132-134 
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o
C; IR νmax 3370, 1638, 1264, 1020, 735 cm
-1
; 
1
H NMR (500 MHz, CD3OD) δ 7.45 (d, 
J=8.6 Hz, 1H), 6.96 (s, 1H), 6.90 (d, J=2.1 Hz, 1H), 6.71 (dd, J=8.6, 2.1 Hz, 1H), 3.81 (s, 
3H), 3.56 (o, 2H), 2.98 (o, 2H); 
13
C NMR (125 MHz, CD3OD) δ 159.1 (q, J=36.0 Hz), 
157.9, 139.1, 123.5, 122.5, 120.0, 117.0 (q, J=287.0 Hz), 112.9, 110.2, 95.9, 56.3, 42.1, 
26.0; 
19
F NMR (376 MHz, CD3OD) δ -77.4; HR-MS: m/z Calcd. for C13H13F3N2O2 
[M+H]
+
: 287.0929, Found 287.1006 (+7.7 ppm). 
3-Hydroxy-2-(6-methoxy-1-(2,2,2-trifluoroacetyl)-2,3,8,8a-
tetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-4H-pyran-4-one 81: 
Pyrroloindoline 81 was prepared according to the general procedure using 6-OMe N-TFA 
tryptamine S7 (45.0 mg, 0.26 mmol, 1.0 equiv) and 3-siloxy-4-pyrone 44 (84.0 mg, 0.26 
mmol, 1.7 equiv) in CH3CN (1.2 mL, 0.12 M). 0.10 mL (0.40 mmol, 2.5 equiv) of 4.0 M 
HCl in dioxane was added. The reaction was quenched after 1 h using 10 mL of aqueous 
sodium bicarbonate. The crude product was purified by flash chromatography using a 
gradient of CH2Cl2/MeOH (99:1 to 3:1) to obtain pure product 81 (48 mg, 0.16 mmol, 
62%). Red oil; Rf = 0.10 (CH2Cl2/MeOH 95:5); IR νmax 3322, 1624, 1460, 1264, 1155, 
800 cm
-1
; 
1H NMR (500 MHz, ) δ 7.65 (d, J= 4.6 Hz, 1H), 6.89 (d, J=7.7 Hz, 1H), 6.41 
(d, J= 4.6 Hz, 1H), 6.29 (d, J= 7.7 Hz, 1H), 6.16 (s, 1H), 5.55 (s, 1H), 5.23 (s, 1H), 3.87 
(dd, J= 9.2, 8.7 Hz, 1H), 3.73 (s, 3H), 3.29 (m, 1H), 3.17 (d, J= 14.8 Hz, 1H0, 3.08 (d, J= 
14.8 Hz, 1H), 2.40 (dd, J= 12.3, 5.6 Hz, 1H), 2.32 (dd, J= 7.2, 5.6 Hz, 1H); 
13
C NMR 
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(125 MHz, ) δ 173.1, 161.2, 156.1 (q, J= 40.2 Hz), 154.6, 149.9, 148.2, 144.4, 123.6, 
121.1, 115.9 (q, J= 280.8 Hz), 113.2, 104.8, 95.7, 81.7, 55.3, 54.9, 46.4, 35.6, 35.3; 
19
F 
NMR (376 MHz, CDCl3) δ -72.8; HR-MS: m/z Calcd. for C18H15F3N2O4 [M+H]
+
: 
411.1090, Found 411.1162 (+7.2 ppm). 
 
2,2,2-Trifluoro-N-(2-(5-fluoro-1H-indol-3-
yl)ethyl)acetamide S8: 5-Fluoro N-TFA tryptamine S8 was prepared in a similar fashion 
to 5-Me N-TFA tryptamine S6.
15 
5-Fluorotryptamine hydrochloride (50 mg, 0.23 mmol, 
1.0 equiv) was added to an oven dried 5 mL round bottom flask containing methanol (1.3 
mL, 0.16 M) and NEt3 (70 µL, 0.50 mmol, 2.2 equiv) under an atmosphere of argon. The 
mixture was then cooled to 0 °C and ethyl trifluoroacetate (60 µL, 0.50 mmol, 2.2 equiv) 
was added dropwise. The mixture was allowed to warm to room temperature and stir for 
a further 60 minutes. After quenching with 5 mL of aqueous sodium bicarbonate, the 
product was extracted from the aqueous layer with 3x 10 mL of CH2Cl2 and dried over 
sodium sulfate. The crude product was then purified by flash chromatography using a 
gradient of hexanes/EtOAc (3:1 to 1:1) to obtain pure product S8 (54.4 mg, 0.20 mmol, 
85%). White solid; Rf = 0.14 (hexanes/EtOAc 3:1); m.p. 130-132 
oC; IR νmax 3416, 3318, 
1698, 1487, 1262, 1173, 805 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 7.27 (dd, J=8.7, 4.5 
Hz, 1H), 7.22 (dd, J=9.8, 4.5 Hz, 1H), 7.10 (s, 1H), 6.85 (ddd, J=9.8, 8.7, 4.5 Hz, 1H), 
3.51 (o, 2H), 2.94 (o, 2H); 
13
C NMR (100 MHz, CD3OD) δ 157.6 (q, J=37.1 Hz), 157.5 
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(d, J=232.1 Hz), 133.2, 127.5 (d, J=10.1 Hz), 124.2, 115.9 (q, J=287.5 Hz), 111.6 (d, 
J=9.8 Hz), 111.5, 109.1 (d, J=26.6 Hz), 102.3 (d, J=23.6 Hz), 40.2, 24.1; 
19
F NMR (376 
MHz, CD3OD) δ -77.4, -127.7; HR-MS: m/z Calcd. for C12H10F4N2O [M+H]
+
: 275.0729, 
Found 275.0818 (+8.9 ppm). 
2-(5-Fluoro-1-(2,2,2-trifluoroacetyl)-
2,3,8,8atetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-3-hydroxy-4H-pyran-4-one 
82: Pyrroloindoline 82 was prepared according to the general procedure using 5-F N-TFA 
tryptamine S8 (45.0 mg, 0.16 mmol, 1.0 equiv) and 3-siloxy-4-pyrone 44 (79.0 mg, 0.25 
mmol, 1.5 equiv) in CH3CN (1.4 mL, 0.11 M). 0.10 mL (0.40 mmol, 2.4 equiv) of 4.0 M 
HCl in dioxane was added. The reaction was quenched after 1 h using 10 mL of aqueous 
sodium bicarbonate. The crude product was purified by flash chromatography using a 
gradient of CH2Cl2/MeOH (99:1 to 3:1) to obtain pure product 82 (27 mg, 0.081 mmol, 
50%). Red oil; Rf = 0.36 (CH2Cl2/MeOH 95:5); IR νmax 3364, 1628, 1489, 1260, 1022, 
796 cm
-1
; 
1H NMR (400 MHz) δ 7.67 (d, J= 4.6 Hz, 1H), 6.79 (o, 2H), 6.64 (br. s, NH), 
6.52 (dd, J= 8.6, 4.3 Hz, 1H), 6.42 (d, J= 4.6 Hz, 1H), 5.57 (s, 1H), 5.08 (s, 1H), 3.91 (dd, 
J= 8.9, 8.3 Hz, 1H), 3.28 (m, 1H), 3.17 (d, J= 14.4 Hz, 1H), 3.11 (d, J= 14.4 Hz, 1H), 
2.39 (o, 2H); 
13
C NMR (100 MHz, CDCl3) δ 172.9, 157.2 (d, J= 239.1 Hz), 156.4 (q, J= 
40.5 Hz), 154.6, 151.7, 147.1, 144.5 (d, J= 14.2 Hz), 130.5, 115.8 (q, J= 288.5 Hz), 115.6 
(d, J= 24.7 Hz), 113.1, 110.5 (d, J= 24.6 Hz), 110.0 (d, J= 8.5 Hz), 81.9, 55.7, 46.3, 35.2, 
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35.1; 
19
F NMR (376 MHz, CDCl3) δ -72.8, -124.7; HR-MS: m/z Calcd. for 
C18H14F4N2O4 [M+H]
+
: 399.0890, Found 399.0954 (+6.4 ppm). 
 
N-(2-(5-Chloro-1H-indol-3-yl)ethyl)-2,2,2-
trifluoroacetamide S9: 5-Chloro N-TFA tryptamine S9 was prepared in a similar 
fashion to 5-Me N-TFA tryptamine S6.
15 
5-Chlorotryptamine hydrochloride (100 mg, 
0.43 mmol, 1.0 equiv) was added to an oven dried 5 mL round bottom flask containing 
methanol (1.8 mL, 0.21 M) and NEt3 (0.12 mL, 0.86 mmol, 2.0 equiv) under an 
atmosphere of argon. The mixture was then cooled to 0 °C and ethyl trifluoroacetate 
(0.10 mL, 0.84 mmol, 1.9 equiv) was added dropwise. The mixture was allowed to warm 
to room temperature and stir for a further 90 minutes. After quenching with 5 mL of 
aqueous sodium bicarbonate, the product was extracted from the aqueous layer with 3x 
10 mL of CH2Cl2 and dried over sodium sulfate. The crude product was then purified by 
flash chromatography using hexanes/EtOAc (3:1) to obtain pure product S9 (110 mg, 
0.37 mmol, 87%). White solid; Rf = 0.24 (hexanes/EtOAc 4:1); m.p. 114-116 
oC; IR νmax 
3322, 2481, 1701, 1460, 1163, 800 cm
-1
; 
1
H NMR (500 MHz, CD3OD) δ 7.57 (s, 1H), 
7.30 (d, J=8.7 Hz, 1H), 7.11 (s, 1H), 7.07 (d, J=8.7 Hz, 1H), 3.53 (o, 2H), 2.96 (o, 2H); 
13
C NMR (125 MHz, CD3OD) δ 159.0 (q, J=36.3 Hz), 136.4, 129.7, 125.5, 125.2, 122.5, 
118.6, 117.3 (q, J=286.6 Hz), 113.4, 112.4, 41.6, 25.4; 
19
F NMR (376 MHz, CD3OD) δ -
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77.3; HR-MS: m/z Calcd. for C12H10ClF3N2O [M+H]
+
: 291.0434, Found 291.0516 (+8.2 
ppm). 
2-(5-Chloro-1-(2,2,2-trifluoroacetyl)-2,3,8,8a-
tetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-3-hydroxy-4H-pyran-4-one 83: 
Pyrroloindoline 83 was prepared according to the general procedure using 5-Cl N-TFA 
tryptamine S9 (63.0 mg, 0.22 mmol, 1.0 equiv) and 3-siloxy-4-pyrone 44 (104 mg, 0.33 
mmol, 1.5 equiv) in CH3CN (1.9 mL, 0.10 M). 0.10 mL (0.40 mmol, 1.8 equiv) of 4.0 M 
HCl in dioxane was added. The reaction was quenched after 1 h using 10 mL of aqueous 
sodium bicarbonate. The crude product was purified by flash chromatography using a 
gradient of CH2Cl2/MeOH (99:1 to 3:1) to obtain pure product 83 (29 mg, 0.070 mmol, 
32%). Clear oil; Rf = 0.54 (CH2Cl2/MeOH 95:5); IR νmax  3423, 1651, 1436, 1267, 952, 
732 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.65 (br. d, 1H), 7.10 (o, 1H), 7.04 (d, J=7.4 Hz, 
1H), 7.01 (s, 1H), 6.51 (d, J=8.8 Hz, 1H), 6.42 (br. d, 1H), 5.58 (s, 1H), 5.30 (br. s, 1H), 
3.90 (dd, J= 9.5, 8.5 Hz, 1H), 3.29 (m, 1H), 3.18 (d, J=14.2 Hz, 1H), 3.10 (d, J=14.2 Hz, 
1H), 2.38 (o, 2H); 
13
C NMR (100 MHz, CDCl3) δ 173.0, 156.3 (q, J=31.6 Hz), 154.6, 
147.5, 147.2, 144.5, 131.0, 129.2, 123.9, 123.4, 115.9 (q, J=288.3 Hz), 113.3, 110.3, 
81.4, 55.6, 46.3, 35.3, 35.2; 
19
F NMR (376 MHz, CDCl3) δ -72.8; HR-MS: m/z Calcd. for 
C18H14ClF3N2O4 [M+H]
+
: 415.0594, Found 415.0663 (+6.9 ppm). 
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N-(2-(5-Bromo-1H-indol-3-yl)ethyl)-2,2,2-
trifluoroacetamide S10: 5-Bromo N-TFA tryptamine S10 was prepared in a similar 
fashion to 5-Me N-TFA tryptamine S6.
15 
5-Bromotryptamine hydrochloride (170 mg, 
0.62 mmol, 1.0 equiv) was added to an oven dried 10 mL round bottom flask containing 
methanol (2.8 mL, 0.20 M) and NEt3 (0.17 mL, 1.2 mmol, 2.0 equiv) under an 
atmosphere of argon. The mixture was then cooled to 0 °C and ethyl trifluoroacetate 
(0.15 mL, 1.3 mmol, 2.0 equiv) was added dropwise. The mixture was allowed to warm 
to room temperature and stir for a further 90 minutes. After quenching with 5 mL of 
aqueous sodium bicarbonate, the product was extracted from the aqueous layer with 3x 
10 mL of CH2Cl2 and dried over sodium sulfate. The crude product was then purified by 
flash chromatography using hexanes/EtOAc (3:1) to obtain pure product S10 (180 mg, 
0.54 mmol, 87%). White solid; Rf = 0.44 (hexanes/EtOAc 7:3); m.p. 98-100 
o
C; IR νmax 
3361, 1702, 1640, 1461, 1160, 1096, 795 cm
-1
; 
1
H NMR (500 MHz, CD3OD) δ 7.70 (dd, 
J=2.0, 0.5, 1H), 7.24 (dd, J=8.5, 0.5 Hz, 1H), 7.16 (dd, J=8.5, 2.0 Hz, 1H), 7.07 (s, 1H), 
3.51 (o, 2H), 2.94 (o, 2H); 
13
C NMR (125 MHz, CD3OD) δ 157.7 (q, J=36.7 Hz), 135.3, 
129.1, 123.8, 123.7, 120.4, 116.3 (q, J=288.2 Hz),  112.5, 111.6, 111.0, 40.3, 24.0; 
19
F 
NMR (376 MHz, CD3OD) δ -77.3; HR-MS: m/z Calcd. for C12H10BrF3N2O [M+H]
+
: 
334.9929, Found 335.0001 (+7.2 ppm). 
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2-(5-Bromo-1-(2,2,2-trifluoroacetyl)-2,3,8,8a-
tetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-3-hydroxy-4H-pyran-4-one 84: 
Pyrroloindoline 84 was prepared according to the general procedure using 5-Br N-TFA 
tryptamine S10 (61.0 mg, 0.18 mmol, 1.0 equiv) and 3-siloxy-4-pyrone 44 (87.0 mg, 0.27 
mmol, 1.5 equiv) in CH3CN (1.5 mL, 0.1 M). 0.10 mL (0.40 mmol, 2.2 equiv) of 4.0 M 
HCl in dioxane was added. The reaction was quenched after 15 minutes using 3 mL of 
aqueous sodium bicarbonate. The crude product was purified by flash chromatography 
using a gradient of CH2Cl2/MeOH (99:1 to 95:5) to obtain pure product 84 (29 mg, 0.063 
mmol, 35%). Yellowish solid; Rf = 0.41 (CH2Cl2/MeOH 95:5); m.p. 85-88 
o
C; IR νmax 
3327, 2925, 1684, 1622, 1459, 1261, 1154, 732 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.78 
(d, J=6.0 Hz, 1H), 7.38 (s, 1H), 7.32 (d, J=8.0 Hz, 1H), 6.60 (d, J=8.0 Hz, 1H), 6.54 (d, 
J=6.0 Hz, 1H), 5.69 (s, 1H), 5.37 (s, 1H), 4.02 (dd, J=8.0, 8.0 Hz, 1H), 3.42 (m, 1H), 3.28 
(d, J=14.0 Hz, 1H), 3.23 (d, J=14.0 Hz, 1H), 2.53 (o, 2H); 
13
C NMR (125 MHz, CDCl3) δ 
172.9, 156.2 (q, J=37.8 Hz), 154.7, 147.5, 147.0, 144.4, 132.1, 129.0, 128.2, 126.3, 115.7 
(q, J=286.9 Hz), 113.1, 110.9, 81.2, 55.6, 46.3, 35.3, 35.2; 
19
F NMR (376 MHz, CDCl3) δ 
-72.8; HR-MS: m/z Calcd. for C18H14BrF3N2O4 [M+H]
+
: 459.0089, Found 459.0171 
(+8.2 ppm). 
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N-(2-(4-Bromo-1H-indol-3-yl)ethyl)-2,2,2-trifluoroacetamide 
21: 4-Bromo N-TFA tryptamine S11 was prepared in a similar fashion to 5-Me N-TFA 
tryptamine S6.
15 
4-Bromotryptamine (330.0 mg, 1.38 mmol, 1.0 equiv) was added to an 
oven dried 25 mL round bottom flask containing methanol (10.0 mL, 0.13 M) and NEt3 
(0.38 mL, 2.8 mmol, 2.0 equiv) under an atmosphere of argon. The mixture was then 
cooled to 0 °C and ethyl trifluoroacetate (0.34 mL, 2.8 mmol, 2.0 equiv) was added 
dropwise. The mixture was allowed to warm to room temperature and stir for a further 90 
minutes. After quenching with 5 mL of aqueous sodium bicarbonate, the product was 
extracted from the aqueous layer with 3x 10 mL of CH2Cl2 and dried over sodium sulfate. 
The crude product was then purified by flash chromatography using hexanes/EtOAc (3:1) 
to obtain pure product S11 (300 mg, 0.90 mmol, 65%). White oil; Rf = 0.48 
(hexanes/EtOAc 7:3); IR νmax  3334, 1706, 1560, 1334, 1160, 740 cm
-1
; 
1
H NMR (500 
MHz, CD3OD) δ 7.31 (d, J=7.9 Hz, 1H), 7.16 (d, J=7.7 Hz, 1H), 7.11 (s, 1H), 6.92 (dd, 
J=7.9, 7.7 Hz, 1H), 3.61 (o, 2H), 3.23 (o, 2H); 
13
C NMR (125 MHz, CD3OD) δ 157.6 (q, 
J=36.5 Hz), 138.2, 125.0, 124.7, 122.8, 121.8, 116.2 (q, J=287.3 Hz), 113.1, 111.8, 110.5, 
41.5, 25.0; 
19
F NMR (376 MHz, CD3OD) δ -77.2; HR-MS: m/z Calcd. for 
C12H10BrF3N2O [M+H]
+
: 334.9929, Found  334.9881 (-4.8 ppm). 
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2-(4-Bromo-1-(2,2,2-trifluoroacetyl)-2,3,8,8a-
tetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-3-hydroxy-4H-pyran-4-one 85: 
Pyrroloindoline 85 was prepared according to the general procedure using 4-Br N-TFA 
tryptamine S11 (61.0 mg, 0.18 mmol, 1.0 equiv) and 3-siloxy-4-pyrone 44 (87.0 mg, 0.27 
mmol, 1.5 equiv) in CH3CN (1.5 mL, 0.1 M). 0.10 mL (0.40 mmol, 2.2 equiv) of 4.0 M 
HCl in dioxane was added. The reaction was quenched after 15 minutes using 3 mL of 
aqueous sodium bicarbonate. The crude product was purified by flash chromatography 
using a gradient of CH2Cl2/MeOH (99:1 to 95:5) to obtain pure product 85 (36 mg, 0.077 
mmol, 43%). Red oil; Rf = 0.36 (CH2Cl2/MeOH 95:5); IR νmax  3376, 1683, 1627, 1454, 
1205, 1143, 737 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.55 (d, J=4.9 Hz, 1H), 6.93 (o, 
2H), 6.75 (br. s, 1H), 6.47 (d, J=7.9 Hz, 1H), 6.36 (d, J=4.9 Hz, 1H), 5.62 (br.s, 1H), 5.34 
(br. s, 1H), 3.91 (dd, J=8.7, 8.3 Hz, 1H), 3.33 (o, 4H), 2.18 (dd, J=11.7, 8.3 Hz, 1H); 
13
C 
NMR (125 MHz, CDCl3) δ 172.9, 155.7 (q, J=35.2 Hz), 154.6, 150.8, 147.2, 144.4, 
131.0, 125.4, 123.4, 119.4, 115.5 (q, J=286.2 Hz), 112.9, 108.3, 80.7, 57.5, 46.2, 33.2, 
33.1; 
19
F NMR (376 MHz, CDCl3) δ -72.8; HR-MS: m/z Calcd. for C18H14BrF3N2O4 
[M+H]
+
: 459.0089, Found 459.0162 (+7.3 ppm). 
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3-Hydroxy-2-((-8-methyl-1-(2,2,2-trifluoroacetyl)-2,3,8,8a-
tetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-4H-pyran-4-one 86: 
Pyrroloindoline 86 was prepared according to the general procedure using 1-Me N-TFA 
tryptamine (40.0 mg, 0.14 mmol, 1.0 equiv) and 3-siloxy-4-pyrone 44 (89.0 mg, 0.28 
mmol, 2.0 equiv) in CH3CN (1.0 mL, 0.14 M). 0.1 mL (0.40 mmol, 2.9 equiv) of 4.0 M 
HCl in dioxane was added. The reaction was quenched after 30 minutes using 3 mL of 
aqueous sodium bicarbonate. The crude product was purified by flash chromatography 
using a gradient of CH2Cl2/MeOH (99:1 to 95:5) to obtain pure product 86 (26.5 mg, 
0.067 mmol, 48%). Orange oil; Rf = 0.42 (CH2Cl2/MeOH 95:5); IR νmax  3428, 1726, 
1615, 1448, 71259, 1208 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.62 (d, J= 5.2 Hz, 1H), 
7.12 (dd, J= 7.8, 7.4 Hz, 1H), 7.00 (d, J= 7.4 Hz, 1H), 6.69 (dd, J= 7.6, 7.4 Hz, 1H), 6.39 
(o, 2H), 6.41 (s, 1H), 5.82 (s, 1H), 3.88 (dd, J= 9.4, 9.0 Hz, 1H), 3.22 (o, 3H), 2.97 (s, 
3H), 2.30 (o, 2H); 
13
C NMR (100 MHz, CDCl3) δ 172.9, 156.1 (q, J= 37.2 Hz), 154.3, 
150.5, 148.0, 144.3, 129.8, 129.3, 122.8, 118.2, 113.3 (q, J= 288.2 Hz), 113.1, 106.3, 
86.0, 54.9, 46.0, 37.0, 36.2, 33.4; 
19
F NMR (376 MHz, CDCl3) δ -71.8; HR-MS: m/z 
Calcd. for C19H17F3N2O4 [M+H]
+
: 395.1140, Found 395.1224 (+8.4 ppm). 
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5-Bromo-3-hydroxy-2-(1-(2,2,2-trifluoroacetyl)-2,3,8,8a-
tetrahydropyrrolo[2,3-b]indol-3a(1H)-yl)methyl)-4H-pyran-4-one 87: 
Pyrroloindoline 87 was prepared according to the general procedure using N-TFA 
tryptamine 77e (45.0 mg, 0.17 mmol, 1.0 equiv) and bromo siloxypyrone S2 (139 mg, 
0.35 mmol, 2.0 equiv) in CH3CN (1.5 mL, 0.11 M). 0.15 mL (0.60 mmol, 3.5 equiv) of 
4.0 M HCl in dioxane was added. The reaction was quenched after 30 minutes using 3 
mL of aqueous sodium bicarbonate. The crude product was purified by flash 
chromatography using a gradient of CH2Cl2/MeOH (99:1 to 95:5) to obtain pure product 
87 (55 mg, 0.12 mmol, 69%). White solid; Rf = 0.43 (CH2Cl2/MeOH 95:5); m.p. 55-60 
o
C; IR νmax 3359, 1684, 1611, 1467, 1257, 1143, 751 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 
7.95 (s, 1H), 7.26 (d, J= 2.1 Hz, 1H), 7.11 (dd, J= 7.9, 7.2 Hz, 1H), 7.03 (d, J= 7.2 Hz, 
1H), 6.77 (dd, J= 7.9, 6.2 Hz, 1H), 6.60 (d, J= 7.9 Hz, 1H), 6.41 (s, 1H), 5.53 (s, 1H), 
5.18 (s, 1H), 3.90 (dd, J= 8.8, 8.8 Hz, 1H), 3.28 (m, 1H), 3.18 (d, J= 14.1 Hz, 1H), 3.12 
(d, J= 14.1 Hz, 1H), 2.46 (m, 1H), 2.35 (dd, J= 11.2, 8.8 Hz, 1H); 
13
C NMR (125 MHz, 
CDCl3) δ 168.8, 156.4 (q, J= 32.3 Hz), 153.1, 148.4, 147.9, 142.7, 129.5, 128.5, 123.0, 
119.6, 115.5 (q, J= 290.3 Hz), 110.5, 109.6, 81.2, 55.4, 46.4, 35.5, 35.3; 
19
F NMR (376 
MHz, CDCl3) δ -72.8; HR-MS: m/z Calcd. for C18H14BrF3N2O6 [M+H]
+
: 459.0089, 
Found 459.0163 (+7.4 ppm). 
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Benzyl (2,2,2-trifluoroacetyl)-L-tryptophanate 88: Bn L-
tryptophan N-TFA tryptamine 88 was prepared in a similar fashion to 5-Me N-TFA 
tryptamine S6.
15 
Benzyl ester L-tryptophan hydrochloride (400.0 mg, 1.22 mmol, 1.0 
equiv) was added to an oven dried 25 mL round bottom flask containing methanol (8.0 
mL, 0.15 M) and NEt3 (0.34 mL, 2.4 mmol, 2.0 equiv) under an atmosphere of argon. 
The mixture was then cooled to 0 °C and ethyl trifluoroacetate (0.35 mL, 2.4 mmol, 2.0 
equiv) was added dropwise. The mixture was allowed to warm to room temperature and 
stir for a further 90 minutes. After quenching with 5 mL of aqueous sodium bicarbonate, 
the product was extracted from the aqueous layer with 3x 10 mL of CH2Cl2 and dried 
over sodium sulfate. The crude product was then purified by flash chromatography using 
hexanes/EtOAc (3:1) to obtain pure product 88 (356 mg, 0.91 mmol, 75%). White oil; Rf 
= 0.28 (hexanes/EtOAc 7:3); IR νmax  3418, 1820, 1713, 1555, 1456, 1178 cm
-1
; 
1
H NMR 
(400 MHz, CD3OD) δ 7.52 (d, J= 8.0 Hz, 1H), 7.31 (o, 4H), 7.19 (o, 2H), 7.09 (m, 1H), 
7.01 (o, 2H), 5.10 (s, 2H), 4.78 (dd, J= 8.6, 6.2 Hz, 1H), 3.40 (dd, J= 14.6, 6.2 Hz, 1H), 
3.24 (dd, J= 14.6, 8.6 Hz, 1H); 
13
C NMR (100 MHz, (CD3)2SO) δ 170.6, 136.4, 136.0, 
128.8, 128.5, 128.1, 127.3, 126.0, 124.5, 124.0, 121.5, 119.0, 118.4, 111.9, 109.5, 66.9, 
54.2, 26.4; 
19
F NMR (376 MHz, CD3OD) δ -77.1; HR-MS: m/z Calcd. for C20H17F3N2O3 
[M+H]
+
: 391.1191, Found  391.1277 (+ 8.6 ppm). 
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Benzyl (2S,3aS,8aR)-3a-((3-hydroxy-4-oxo-4H-pyran-2-
yl)methyl)-1-(2,2,2-trifluoroacetyl)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-
carboxylate 89: Pyrroloindoline 89 was prepared according to the general procedure 
using Bn L-tryptophan N-TFA tryptamine 88 (100.0 mg, 0.25 mmol, 1.0 equiv) and 
siloxypyrone 44 (150 mg, 0.47 mmol, 1.9 equiv) in CH3CN (3.0 mL, 0.082 M). 0.10 mL 
(0.40 mmol, 1.6 equiv) of 4.0 M HCl in dioxane was added. The reaction was quenched 
after 30 minutes using 3 mL of aqueous sodium bicarbonate. The crude product was 
purified by flash chromatography using a gradient of CH2Cl2/MeOH (99:1 to 95:5) to 
obtain pure product 89 (72 mg, 0.14 mmol, 57%). White solid; Rf = 0.43 (CH2Cl2/MeOH 
95:5); m.p. 55-60 
o
C; IR νmax 3016, 1657, 1247, 1152 cm
-1
; 
1
H NMR (500 MHz, CDCl3) 
δ 7.66 (d, J= 5.5 Hz, 1H), 7.62 (d, J= 5.6 Hz, 1H), 7.33 (o, 2H), 7.19 (d, J= 5.2 Hz, 1H), 
7.10 (o, 3H), 7.05 (d, J= 6.0 Hz, 1H), 6.40 (m, 1H), 6.34 (d, J= 5.5 Hz, 1H), 5.57 (o, 2H), 
3.11 (d, J= 18 Hz, 1H), 2.98 (o, 2H), 2.74 (m, 1H), 2.32 (m, 1H); 
13
C NMR (125 MHz, 
CDCl3) δ 189.4, 184.8, 171.5, 162.2, 159.2, 153.0, 146.6, 140.7, 128.5, 116.8, 104.0, 
91.7, 80.8, 50.2, 32.6, 21.5; HR-MS: m/z Calcd. for C26H21F3N2O6 [M+H]
+
: 515.1352, 
Found 515.1442 (+9.0 ppm). 
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3-Hydroxy-2-((8-methyl-2,3,8,8a-tetrahydrobenzo[b]pyrrolo[3,2-
d]pyrrol-3a(1H)-yl)methyl)-4H-pyran-4-one 98: N-H Pyrroloindoline 98 was prepared 
using N-TFA N-Me pyrroloindoline 87 (45 mg, 0.18 mmol, 1.0 equiv) The crude product 
was purified by flash chromatography using a gradient of CH2Cl2/MeOH (99:1 to 95:5) 
to obtain pure product 98 (47 mg, 0.12 mmol, 71%). Light orange solid; Rf = 
(CH2Cl2/MeOH 95:5); m.p. 
o
C; IR (thin film) νmax  cm
-1
; 
1
H NMR (500 MHz, (CD3)2CO 
δ 7.92 (d, J= 4.9 Hz, 1H), 7.09 (o, 2H), 6.68 (dd, J= 7.4, 6.9 Hz, 1H), 6.54 (d, J= 7.4 Hz, 
1H), 6.33 (d, J= 4.9 Hz, 1H), 3.43 (d, J= 10.0 Hz, 1H), 3.24 (d, J= 10.0 Hz, 1H), 2.99 (d, 
J= 14.2 Hz, 1H), 2.74 (s, 3H), 2.05 (o, 4H); 
13
C NMR (125 MHz, (CD3)2CO) δ 172.4, 
155.0, 152.6, 148.4, 144.3, 133.7, 128.3, 122.8, 117.8, 110.0, 107.6, 66.0, 47.1, 36.3, 
36.1, 35.0, 28.5. 
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X-Ray Crystallographic Information for 49 
         Crystals of compound 49 suitable for x-ray analysis were obtained by slow 
evaporation from iso-propanol. Crystallographic data have been deposited with the 
Cambridge Crystallographic Data Centre (CCDC #837345). Copies of the data can be 
obtained free of charge on application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)- 1223-336-033; e-mail: deposit@ccdc.cam.ac.uk. 
 
 
Crystal data 
  C19H19NO3 F(000) = 2624 
Mr = 309.35 Dx = 1.366 Mg m
-3 
Orthorhombic, Fdd2 Cu K radiation,  = 1.54178 Å 
Hall symbol:  F 2 -2d Cell parameters from 9941 reflections 
a = 11.6618 (4) Å  = 3.0–66.0° 
b = 58.9414 (17) Å  = 0.75 mm-1 
c = 8.7546 (3) Å T = 100 K 
V = 6017.6 (3)  Å3 Plate, colorless 
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Z = 16 0.10 × 0.05 × 0.04 mm 
 
    
Data collection 
  Bruker Proteum-R  
diffractometer 
2639 independent reflections 
Radiation source: rotating anode 2612 reflections with I > 2(I) 
multilayer Rint = 0.053 
 &  scans max = 66.4°, min = 3.0° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -1313 
Tmin = 0.661, Tmax = 0.753 k = -7070 
60407 measured reflections l = -1010 
 
    
Refinement 
  Refinement on F2 Secondary atom site location: difference Fourier 
map 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2 > 2(F2)] = 0.024 H-atom parameters constrained 
wR(F2) = 0.060 w = 1/[2(Fo
2) + (0.031P)2 + 5.8135P]   
where P = (Fo
2 + 2Fc
2)/3 
S = 1.05 (/)max < 0.001 
2639 reflections max = 0.16 e Å
-3 
209 parameters min = -0.14 e Å
-3 
1 restraint Absolute structure:  Flack H D (1983), Acta 
Cryst. A39, 876-881 
Primary atom site location: structure-invariant 
direct methods 
Flack parameter: 0.01 (14) 
 
     
Special details 
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 Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)   
are estimated using the full covariance matrix.  The cell esds are taken   into 
account individually in the estimation of esds in distances, angles   and torsion 
angles; correlations between esds in cell parameters are only   used when they are 
defined by crystal symmetry.  An approximate (isotropic)   treatment of cell esds 
is used for estimating esds involving l.s. planes. 
 
Refinement. Refinement of F2 against ALL reflections.  The weighted R-factor 
wR and   goodness of fit S are based on F2, conventional R-factors R are based   
on F, with F set to zero for negative F2. The threshold expression of   F2 > 
2sigma(F2) is used only for calculating R-factors(gt) etc. and is   not relevant to 
the choice of reflections for refinement.  R-factors based   on F2 are statistically 
about twice as large as those based on F, and R-   factors based on ALL data will 
be even larger. 
 
 
      
Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters (Å2) 
 x y z Uiso*/Ueq  
O1 -0.18159 (8) 0.220187 (15) 0.49589 (11) 0.0229 (2)  
O2 0.01478 (8) 0.195194 (14) 0.49835 (11) 0.0204 (2)  
O3 0.10431 (8) 0.245624 (14) 0.29160 (10) 0.0210 (2)  
N1 0.09756 (9) 0.159459 (17) 0.49995 (12) 0.0182 (2)  
C1 0.13986 (12) 0.15315 (2) 0.03014 (15) 0.0214 (3)  
H1 0.1544 0.1520 -0.0763 0.026*  
C2 0.18743 (11) 0.17106 (2) 0.11386 (15) 0.0195 (3)  
H2 0.2336 0.1822 0.0652 0.023*  
C3 0.16576 (11) 0.17218 (2) 0.26849 (15) 0.0183 (3)  
C4 0.21164 (11) 0.18796 (2) 0.39011 (14) 0.0179 (3)  
64 
 
C5 0.21830 (11) 0.21307 (2) 0.34581 (15) 0.0193 (3)  
H5A 0.2740 0.2208 0.4134 0.023*  
H5B 0.2468 0.2143 0.2396 0.023*  
C6 0.10603 (11) 0.22460 (2) 0.35749 (15) 0.0183 (3)  
C7 0.01390 (11) 0.21591 (2) 0.43046 (15) 0.0185 (3)  
C8 -0.09398 (11) 0.22835 (2) 0.43832 (15) 0.0193 (3)  
C9 0.33303 (11) 0.17961 (2) 0.43549 (15) 0.0198 (3)  
H9A 0.3338 0.1628 0.4334 0.024*  
H9B 0.3886 0.1850 0.3582 0.024*  
C10 0.37244 (12) 0.18755 (2) 0.59257 (16) 0.0225 (3)  
H10A 0.3786 0.2043 0.5937 0.027*  
H10B 0.4490 0.1811 0.6155 0.027*  
C11 0.28658 (12) 0.17985 (2) 0.71348 (15) 0.0235 (3)  
H11A 0.2825 0.1631 0.7146 0.028*  
H11B 0.3124 0.1850 0.8155 0.028*  
C12 0.16837 (11) 0.18958 (2) 0.67964 (16) 0.0209 (3)  
H12A 0.1134 0.1839 0.7570 0.025*  
H12B 0.1715 0.2063 0.6883 0.025*  
C13 0.12516 (11) 0.18326 (2) 0.52128 (15) 0.0177 (3)  
C14 0.09939 (11) 0.15548 (2) 0.34069 (15) 0.0184 (3)  
C15 0.05006 (11) 0.13794 (2) 0.25863 (16) 0.0216 (3)  
H15 0.0032 0.1269 0.3073 0.026*  
C16 0.07158 (11) 0.13703 (2) 0.10146 (16) 0.0222 (3)  
H16 0.0388 0.1252 0.0425 0.027*  
C17 0.00720 (12) 0.14896 (2) 0.58982 (16) 0.0236 (3)  
H17A -0.0676 0.1544 0.5543 0.035*  
H17B 0.0172 0.1529 0.6977 0.035*  
H17C 0.0110 0.1324 0.5781 0.035*  
C18 0.00792 (12) 0.25820 (2) 0.30470 (16) 0.0228 (3)  
H18 0.0080 0.2730 0.2624 0.027*  
C19 -0.08739 (12) 0.25098 (2) 0.37364 (15) 0.0228 (3)  
H19 -0.1518 0.2608 0.3805 0.027*  
 
   
Atomic displacement parameters (Å2) 
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 U11 U22 U33 U12 U13 U23 
O1 0.0208 (5) 0.0225 (5) 0.0254 (5) 0.0003 (4) 0.0036 (4) 0.0021 (4) 
O2 0.0202 (5) 0.0161 (4) 0.0250 (5) 0.0020 (4) 0.0033 (4) 0.0052 (4) 
O3 0.0227 (5) 0.0156 (4) 0.0246 (5) -0.0002 (4) 0.0017 (4) 0.0038 (4) 
N1 0.0209 (5) 0.0148 (5) 0.0187 (6) -0.0017 (4) 0.0027 (5) 0.0012 (4) 
C1 0.0244 (7) 0.0223 (7) 0.0173 (6) 0.0045 (5) -0.0009 (5) -0.0021 (5) 
C2 0.0198 (6) 0.0182 (6) 0.0205 (6) 0.0010 (5) 0.0012 (5) 0.0011 (5) 
C3 0.0181 (6) 0.0156 (6) 0.0212 (6) 0.0024 (5) -0.0008 (5) 0.0011 (5) 
C4 0.0197 (6) 0.0154 (6) 0.0186 (6) 0.0003 (5) 0.0017 (5) 0.0003 (5) 
C5 0.0207 (6) 0.0163 (6) 0.0209 (7) -0.0012 (5) 0.0016 (5) 0.0009 (5) 
C6 0.0238 (7) 0.0135 (6) 0.0177 (6) -0.0010 (5) -0.0006 (5) -0.0006 (5) 
C7 0.0234 (7) 0.0153 (6) 0.0168 (6) -0.0003 (5) -0.0004 (5) -0.0003 (5) 
C8 0.0223 (7) 0.0195 (6) 0.0160 (6) -0.0006 (5) -0.0017 (5) -0.0017 (5) 
C9 0.0190 (6) 0.0178 (6) 0.0228 (7) 0.0011 (5) 0.0024 (5) -0.0003 (5) 
C10 0.0219 (7) 0.0227 (6) 0.0231 (7) 0.0010 (6) -0.0017 (6) -0.0011 (6) 
C11 0.0264 (7) 0.0242 (7) 0.0199 (7) 0.0006 (6) -0.0018 (6) -0.0011 (5) 
C12 0.0252 (7) 0.0187 (6) 0.0187 (6) 0.0003 (5) 0.0024 (6) -0.0002 (5) 
C13 0.0189 (6) 0.0144 (6) 0.0198 (6) 0.0017 (5) 0.0017 (5) 0.0012 (5) 
C14 0.0179 (6) 0.0170 (6) 0.0204 (7) 0.0032 (5) -0.0002 (5) 0.0019 (5) 
C15 0.0208 (6) 0.0170 (6) 0.0271 (7) 0.0005 (5) 0.0000 (6) 0.0024 (5) 
C16 0.0231 (7) 0.0180 (6) 0.0256 (7) 0.0020 (5) -0.0044 (6) -0.0024 (5) 
C17 0.0270 (7) 0.0212 (6) 0.0227 (7) -0.0031 (5) 0.0040 (6) 0.0025 (5) 
C18 0.0241 (7) 0.0174 (6) 0.0269 (7) 0.0024 (5) -0.0020 (6) 0.0033 (5) 
C19 0.0235 (7) 0.0191 (6) 0.0258 (7) 0.0032 (5) -0.0011 (6) 0.0011 (5) 
 
   
Geometric parameters (Å, º) 
  O1—C8 1.2368 (16) C8—C19 1.4510 (19) 
O2—C7 1.3581 (16) C9—C10 1.5236 (19) 
O2—C13 1.4807 (15) C9—H9A 0.9900 
O3—C18 1.3513 (16) C9—H9B 0.9900 
O3—C6 1.3672 (15) C10—C11 1.5262 (19) 
N1—C14 1.4140 (16) C10—H10A 0.9900 
N1—C13 1.4512 (15) C10—H10B 0.9900 
N1—C17 1.4533 (17) C11—C12 1.5224 (19) 
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C1—C16 1.388 (2) C11—H11A 0.9900 
C1—C2 1.3997 (19) C11—H11B 0.9900 
C1—H1 0.9500 C12—C13 1.5215 (18) 
C2—C3 1.3787 (19) C12—H12A 0.9900 
C2—H2 0.9500 C12—H12B 0.9900 
C3—C14 1.4027 (18) C14—C15 1.3842 (19) 
C3—C4 1.5115 (18) C15—C16 1.3997 (19) 
C4—C5 1.5321 (16) C15—H15 0.9500 
C4—C9 1.5506 (18) C16—H16 0.9500 
C4—C13 1.5532 (18) C17—H17A 0.9800 
C5—C6 1.4784 (18) C17—H17B 0.9800 
C5—H5A 0.9900 C17—H17C 0.9800 
C5—H5B 0.9900 C18—C19 1.335 (2) 
C6—C7 1.3507 (18) C18—H18 0.9500 
C7—C8 1.4577 (18) C19—H19 0.9500 
    
C7—O2—C13 119.55 (9) C11—C10—H10A 109.7 
C18—O3—C6 118.27 (10) C9—C10—H10B 109.7 
C14—N1—C13 106.48 (10) C11—C10—H10B 109.7 
C14—N1—C17 118.31 (11) H10A—C10—H10B 108.2 
C13—N1—C17 120.17 (10) C12—C11—C10 110.30 (11) 
C16—C1—C2 120.53 (13) C12—C11—H11A 109.6 
C16—C1—H1 119.7 C10—C11—H11A 109.6 
C2—C1—H1 119.7 C12—C11—H11B 109.6 
C3—C2—C1 118.54 (12) C10—C11—H11B 109.6 
C3—C2—H2 120.7 H11A—C11—H11B 108.1 
C1—C2—H2 120.7 C13—C12—C11 112.63 (11) 
C2—C3—C14 120.65 (12) C13—C12—H12A 109.1 
C2—C3—C4 131.03 (12) C11—C12—H12A 109.1 
C14—C3—C4 108.03 (11) C13—C12—H12B 109.1 
C3—C4—C5 115.72 (11) C11—C12—H12B 109.1 
C3—C4—C9 107.95 (10) H12A—C12—H12B 107.8 
C5—C4—C9 108.99 (10) N1—C13—O2 104.42 (9) 
C3—C4—C13 100.44 (10) N1—C13—C12 115.32 (10) 
C5—C4—C13 113.11 (10) O2—C13—C12 107.15 (10) 
C9—C4—C13 110.28 (10) N1—C13—C4 102.80 (10) 
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C6—C5—C4 112.42 (10) O2—C13—C4 112.29 (10) 
C6—C5—H5A 109.1 C12—C13—C4 114.51 (11) 
C4—C5—H5A 109.1 C15—C14—C3 121.31 (12) 
C6—C5—H5B 109.1 C15—C14—N1 129.00 (12) 
C4—C5—H5B 109.1 C3—C14—N1 109.66 (11) 
H5A—C5—H5B 107.9 C14—C15—C16 117.66 (12) 
C7—C6—O3 122.10 (12) C14—C15—H15 121.2 
C7—C6—C5 124.27 (11) C16—C15—H15 121.2 
O3—C6—C5 113.60 (11) C1—C16—C15 121.26 (13) 
C6—C7—O2 122.80 (12) C1—C16—H16 119.4 
C6—C7—C8 121.22 (12) C15—C16—H16 119.4 
O2—C7—C8 115.98 (11) N1—C17—H17A 109.5 
O1—C8—C19 124.08 (12) N1—C17—H17B 109.5 
O1—C8—C7 122.45 (11) H17A—C17—H17B 109.5 
C19—C8—C7 113.47 (11) N1—C17—H17C 109.5 
C10—C9—C4 114.14 (11) H17A—C17—H17C 109.5 
C10—C9—H9A 108.7 H17B—C17—H17C 109.5 
C4—C9—H9A 108.7 C19—C18—O3 123.80 (12) 
C10—C9—H9B 108.7 C19—C18—H18 118.1 
C4—C9—H9B 108.7 O3—C18—H18 118.1 
H9A—C9—H9B 107.6 C18—C19—C8 120.91 (13) 
C9—C10—C11 109.67 (11) C18—C19—H19 119.5 
C9—C10—H10A 109.7 C8—C19—H19 119.5 
 
 
X-Ray Crystallographic Information for 77e 
         Crystals of compound 77e suitable for x-ray analysis were obtained by slow 
evaporation from dichloromethane/isooctane. Crystallographic data have been deposited 
with the Cambridge Crystallographic Data Centre (CCDC #993626). Copies of the data 
can be obtained free of charge on application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)- 1223-336-033; e-mail: deposit@ccdc.cam.ac.uk. 
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Crystal data 
  C18H15F3N2O4 Z = 8 
Mr = 380.32 Cu K radiation,  = 1.54178 Å 
Tetragonal, I¯4  = 1.15 mm-1 
a = 22.0537 (9) Å T = 100 K 
c = 6.7214 (3) Å 0.13 × 0.05 × 0.03 mm 
V = 3269.1 (3)  Å
3
  
 
    
Data collection 
  Bruker Proteum-R  
diffractometer 
2861 independent reflections 
Absorption correction: multi-scan  
SADABS2012/1 (Bruker,2012) was used for 
absorption correction. wR2(int) was 0.0878 
before and 0.0434 after correction. The Ratio of 
minimum to maximum transmission is 0.9024. 
The /2 correction factor is 0.0015. 
2840 reflections with I > 2(I) 
Tmin = 0.679, Tmax = 0.753 Rint = 0.032 
51689 measured reflections  
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Refinement 
  R[F2 > 2(F2)] = 0.037 H-atom parameters constrained 
wR(F
2
) = 0.097 max = 0.35 e Å
-3
 
S = 1.10 min = -0.21 e Å
-3
 
2861 reflections Absolute structure:  Flack x determined using 
1277 quotients [(I+)-(I-)]/[(I+)+(I-)]  (Parsons 
and Flack (2004), Acta Cryst. A60, s61). 
245 parameters Flack parameter: 0.48 (2) 
0 restraints  
 
Data collection: APEX2 (Bruker, 2013); cell refinement: SAINT v8.34A (Bruker, 
2013); data reduction: SAINT v8.34A (Bruker, 2013); program(s) used to solve structure: 
XS (Sheldrick, 2008); program(s) used to refine structure: XL (Sheldrick, 2008); 
molecular graphics: Olex2 (Dolomanov et al., 2009); software used to prepare material 
for publication: Olex2 (Dolomanov et al., 2009). 
 References   
Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. 
(2009). J. Appl. Cryst. 42, 339–341. 
Sheldrick, G. M. (2008). Acta Cryst. A64, 112–122. 
   
Crystal data 
  C18H15F3N2O4 Dx = 1.546 Mg m
-3
 
Mr = 380.32 Cu K radiation,  = 1.54178 Å 
Tetragonal, I¯4 Cell parameters from 9743 reflections 
a = 22.0537 (9) Å  = 2.8–66.7° 
c = 6.7214 (3) Å  = 1.15 mm-1 
V = 3269.1 (3)  Å
3
 T = 100 K 
Z = 8 Bar, colorless 
F(000) = 1568 0.13 × 0.05 × 0.03 mm 
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Data collection 
  Bruker Proteum-R  
diffractometer 
2861 independent reflections 
Radiation source: rotating anode 2840 reflections with I > 2(I) 
Montel Rint = 0.032 
 &  scans max = 66.7°, min = 2.8° 
Absorption correction: multi-scan  
SADABS2012/1 (Bruker,2012) was used for 
absorption correction. wR2(int) was 0.0878 
before and 0.0434 after correction. The Ratio of 
minimum to maximum transmission is 0.9024. 
The /2 correction factor is 0.0015. 
h = -2626 
Tmin = 0.679, Tmax = 0.753 k = -2423 
51689 measured reflections l = -77 
 
    
Refinement 
  Refinement on F2 Secondary atom site location: difference Fourier 
map 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F
2
 > 2(F2)] = 0.037 H-atom parameters constrained 
wR(F
2
) = 0.097  w = 1/[2(Fo
2
) + (0.0664P)
2
 + 2.5938P]   
where P = (Fo
2
 + 2Fc
2
)/3 
S = 1.10 (/)max = 0.001 
2861 reflections max = 0.35 e Å
-3
 
245 parameters min = -0.21 e Å
-3
 
0 restraints Absolute structure:  Flack x determined using 
1277 quotients [(I+)-(I-)]/[(I+)+(I-)]  (Parsons 
and Flack (2004), Acta Cryst. A60, s61). 
Primary atom site location: structure-invariant 
direct methods 
Flack parameter: 0.48 (2) 
 
     
Special details 
 Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)  
are estimated using the full covariance matrix.  The cell esds are taken  into account 
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individually in the estimation of esds in distances, angles  and torsion angles; correlations 
between esds in cell parameters are only  used when they are defined by crystal 
symmetry.  An approximate (isotropic)  treatment of cell esds is used for estimating esds 
involving l.s. planes. 
 
Refinement. CheckCIF Alerts and Discussion: 
 STRVA01_ALERT_4_C Flack test results are ambiguous.  From the CIF: 
_refine_ls_abs_structure_Flack 0.480  From the CIF: _refine_ls_abs_structure_Flack_su 
0.020 
 Discussion:  The crystal is racemic, with the two enanti-omers related by the 4 bar 
symmetry operator.  In such a crystal the two possible absolute structures  are equivalent, 
as indicated by the Flack test result of 0.5 within  experimental error. 
 PLAT089_ALERT_3_C Poor Data / Parameter Ratio (Zmax < 18) .. 6.41 Note  
PLAT340_ALERT_3_C Low Bond Precision on  C-C Bonds .. 0.0042 Ang.   
 Discussion:  The instrument used for the structure determination has collision  limits 
preventing the acquisition of most data below 0.84 Angstroms resolution.  This resolution 
limit often results in a low data to parameter ratio for  bicyclic and polycyclic compounds 
despite the nearly complete data  collection to 0.84 Angstroms.  Polycylics exhibit a 
higher number of atoms per  cubic Angstrom in the crystal form (15.1 cubic Angstroms 
per nonhydrogen atom  in this case) than acyclic compounds, and thus have more 
parameters to be  refined per data point than a typical organic residue.  For this study the  
donor D-H hydrogens were refined with a riding model in order to reduce the  number of 
parameters, but despite this step the data to parameter ratio is  still low and the C-C bond 
precision is slightly high.   
 PLAT415_ALERT_2_C Short Inter D-H..H-X  H1 .. H12 .. 2.14 Ang.  
PLAT420_ALERT_2_C D-H Without Acceptor  N1 - H1 ··· Please Check  
 Discussion:  Adjacent inter-molecular hydrogen bonds O3-H3 – O2 and C3-H3A –  
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O1 form a tight network which directs the residues to an orientation  precluding a 
hydrogen bond to N1-H1.  The tight network also results in the  short D-H – H-X 
distance at this site. 
 
 
      
Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters (Å2) 
 x y z Uiso*/Ueq  
F1 1.03941 (8) 0.06063 (8) 0.1649 (3) 0.0278 (4)  
F2 1.11146 (8) 0.12180 (8) 0.2465 (3) 0.0251 (4)  
F3 1.10306 (8) 0.09146 (8) -0.0558 (3) 0.0289 (5)  
O1 0.74840 (9) 0.13856 (9) -0.0455 (3) 0.0193 (5)  
O2 0.80034 (8) 0.20649 (9) 0.4886 (3) 0.0147 (4)  
O3 0.82860 (9) 0.23030 (9) -0.0348 (3) 0.0184 (4)  
H3 0.8143 0.2108 -0.1313 0.028*  
C2 0.74036 (13) 0.13559 (13) 0.3089 (5) 0.0181 (6)  
H2 0.7118 0.1033 0.3120 0.022*  
C3 0.75951 (12) 0.16043 (12) 0.4798 (5) 0.0162 (6)  
H3A 0.7437 0.1450 0.6011 0.019*  
C4 0.82358 (12) 0.22992 (12) 0.3148 (4) 0.0145 (6)  
C6 0.86847 (12) 0.27989 (12) 0.3509 (5) 0.0153 (6)  
H6A 0.8576 0.3008 0.4764 0.018*  
H6B 0.8651 0.3098 0.2418 0.018*  
C7 0.93531 (12) 0.25855 (12) 0.3649 (4) 0.0125 (5)  
C8 0.96390 (11) 0.24299 (12) 0.1597 (4) 0.0124 (6)  
H8 0.9321 0.2319 0.0599 0.015*  
N2 1.00395 (10) 0.19063 (10) 0.2054 (4) 0.0130 (5)  
C17 1.03090 (12) 0.16329 (12) 0.0526 (4) 0.0135 (6)  
C18 1.07129 (13) 0.10815 (13) 0.1034 (5) 0.0188 (6)  
C1 0.76267 (12) 0.15742 (12) 0.1208 (4) 0.0142 (6)  
C5 0.80611 (12) 0.20749 (12) 0.1379 (5) 0.0154 (6)  
C10 0.94441 (12) 0.20103 (12) 0.4898 (4) 0.0139 (6)  
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H10A 0.9458 0.2109 0.6334 0.017*  
H10B 0.9112 0.1717 0.4660 0.017*  
C9 1.00472 (13) 0.17561 (13) 0.4199 (4) 0.0154 (6)  
H9A 1.0391 0.1954 0.4885 0.018*  
H9B 1.0070 0.1313 0.4414 0.018*  
C11 0.97534 (12) 0.31179 (12) 0.4289 (5) 0.0139 (6)  
C16 1.01101 (13) 0.33029 (13) 0.2687 (5) 0.0153 (6)  
C15 1.05104 (13) 0.37835 (13) 0.2868 (5) 0.0204 (6)  
H15 1.0749 0.3914 0.1770 0.024*  
C14 1.05531 (13) 0.40709 (14) 0.4712 (5) 0.0221 (6)  
H14 1.0834 0.4394 0.4880 0.026*  
C13 1.01912 (13) 0.38937 (14) 0.6318 (5) 0.0212 (6)  
H13 1.0219 0.4102 0.7550 0.025*  
C12 0.97889 (12) 0.34090 (13) 0.6105 (4) 0.0167 (6)  
H12 0.9544 0.3282 0.7190 0.020*  
N1 0.99729 (11) 0.29662 (11) 0.0985 (4) 0.0169 (5)  
H1 1.0072 0.3062 -0.0244 0.020*  
O4 1.02532 (9) 0.17823 (9) -0.1220 (3) 0.0183 (4)  
 
   
Atomic displacement parameters (Å2) 
 U
11
 U
22
 U
33
 U
12
 U
13
 U
23
 
F1 0.0277 (9) 0.0145 (8) 0.0413 (11) 0.0010 (7) 0.0018 (8) 0.0021 (8) 
F2 0.0176 (9) 0.0279 (9) 0.0298 (10) 0.0057 (7) -0.0086 (7) 0.0006 (8) 
F3 0.0284 (9) 0.0289 (10) 0.0293 (10) 0.0136 (8) 0.0075 (8) -0.0055 (8) 
O1 0.0187 (10) 0.0199 (11) 0.0192 (11) 0.0018 (8) -0.0050 (9) -0.0022 (9) 
O2 0.0112 (9) 0.0164 (9) 0.0166 (11) -0.0014 (7) 0.0012 (8) -0.0014 (8) 
O3 0.0171 (10) 0.0209 (10) 0.0172 (10) -0.0006 (8) 0.0006 (8) 0.0023 (8) 
C2 0.0166 (13) 0.0161 (13) 0.0216 (15) 0.0000 (10) -0.0006 (12) 0.0016 (12) 
C3 0.0126 (12) 0.0137 (13) 0.0222 (15) 0.0002 (10) 0.0037 (11) 0.0002 (11) 
C4 0.0090 (12) 0.0155 (13) 0.0190 (14) 0.0037 (10) -0.0004 (11) -0.0009 (11) 
C6 0.0125 (13) 0.0136 (12) 0.0198 (14) 0.0004 (10) -0.0006 (11) -0.0024 (11) 
C7 0.0111 (12) 0.0150 (13) 0.0114 (13) -0.0001 (10) 0.0009 (10) 0.0001 (11) 
C8 0.0115 (12) 0.0126 (12) 0.0132 (14) 0.0023 (10) -0.0021 (11) -0.0003 (10) 
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N2 0.0132 (11) 0.0125 (10) 0.0135 (12) 0.0013 (9) -0.0026 (9) 0.0012 (9) 
C17 0.0089 (12) 0.0122 (12) 0.0193 (15) -0.0018 (10) -0.0007 (11) -0.0013 (11) 
C18 0.0201 (14) 0.0175 (14) 0.0189 (15) 0.0014 (11) 0.0011 (12) -0.0008 (12) 
C1 0.0104 (12) 0.0121 (13) 0.0199 (15) 0.0035 (10) -0.0030 (11) -0.0003 (11) 
C5 0.0122 (12) 0.0148 (13) 0.0191 (14) 0.0047 (10) 0.0022 (12) 0.0021 (11) 
C10 0.0131 (13) 0.0147 (13) 0.0139 (13) -0.0011 (10) -0.0002 (10) 0.0022 (10) 
C9 0.0159 (13) 0.0164 (13) 0.0140 (14) -0.0003 (10) -0.0019 (11) 0.0037 (11) 
C11 0.0091 (12) 0.0144 (13) 0.0181 (15) 0.0017 (10) -0.0001 (11) 0.0000 (11) 
C16 0.0154 (13) 0.0129 (13) 0.0176 (15) 0.0041 (10) -0.0002 (11) 0.0018 (11) 
C15 0.0176 (14) 0.0181 (14) 0.0255 (17) -0.0014 (11) 0.0042 (13) 0.0025 (12) 
C14 0.0183 (14) 0.0171 (14) 0.0307 (17) -0.0060 (11) -0.0009 (13) -0.0023 (13) 
C13 0.0214 (14) 0.0217 (15) 0.0206 (16) 0.0002 (11) -0.0015 (12) -0.0068 (12) 
C12 0.0147 (12) 0.0197 (14) 0.0156 (13) 0.0000 (10) -0.0004 (11) -0.0010 (11) 
N1 0.0220 (12) 0.0159 (11) 0.0129 (12) -0.0004 (9) 0.0031 (9) 0.0028 (9) 
O4 0.0171 (10) 0.0229 (10) 0.0148 (10) 0.0014 (8) 0.0003 (8) -0.0027 (8) 
 
   
Geometric parameters (Å, º) 
  F1—C18 1.328 (4) N2—C17 1.331 (4) 
F2—C18 1.342 (4) N2—C9 1.479 (4) 
F3—C18 1.331 (4) C17—C18 1.545 (4) 
O1—C1 1.234 (4) C17—O4 1.226 (4) 
O2—C3 1.359 (3) C1—C5 1.466 (4) 
O2—C4 1.377 (3) C10—H10A 0.9900 
O3—H3 0.8400 C10—H10B 0.9900 
O3—C5 1.359 (4) C10—C9 1.518 (4) 
C2—H2 0.9500 C9—H9A 0.9900 
C2—C3 1.341 (4) C9—H9B 0.9900 
C2—C1 1.439 (4) C11—C16 1.394 (4) 
C3—H3A 0.9500 C11—C12 1.381 (4) 
C4—C6 1.501 (4) C16—C15 1.385 (4) 
C4—C5 1.344 (4) C16—N1 1.397 (4) 
C6—H6A 0.9900 C15—H15 0.9500 
C6—H6B 0.9900 C15—C14 1.395 (5) 
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C6—C7 1.550 (3) C14—H14 0.9500 
C7—C8 1.555 (4) C14—C13 1.398 (5) 
C7—C10 1.534 (4) C13—H13 0.9500 
C7—C11 1.531 (4) C13—C12 1.396 (4) 
C8—H8 1.0000 C12—H12 0.9500 
C8—N2 1.486 (3) N1—H1 0.8800 
C8—N1 1.453 (4)   
    
C3—O2—C4 119.3 (2) F3—C18—C17 110.1 (2) 
C5—O3—H3 109.5 O1—C1—C2 126.6 (2) 
C3—C2—H2 119.7 O1—C1—C5 119.4 (3) 
C3—C2—C1 120.5 (2) C2—C1—C5 114.0 (3) 
C1—C2—H2 119.7 O3—C5—C1 116.8 (3) 
O2—C3—H3A 118.3 C4—C5—O3 121.0 (2) 
C2—C3—O2 123.5 (3) C4—C5—C1 122.2 (3) 
C2—C3—H3A 118.3 C7—C10—H10A 110.8 
O2—C4—C6 112.6 (2) C7—C10—H10B 110.8 
C5—C4—O2 120.4 (2) H10A—C10—H10B 108.9 
C5—C4—C6 127.1 (3) C9—C10—C7 104.5 (2) 
C4—C6—H6A 108.6 C9—C10—H10A 110.8 
C4—C6—H6B 108.6 C9—C10—H10B 110.8 
C4—C6—C7 114.5 (2) N2—C9—C10 102.1 (2) 
H6A—C6—H6B 107.6 N2—C9—H9A 111.4 
C7—C6—H6A 108.6 N2—C9—H9B 111.4 
C7—C6—H6B 108.6 C10—C9—H9A 111.4 
C6—C7—C8 113.5 (2) C10—C9—H9B 111.4 
C10—C7—C6 114.1 (2) H9A—C9—H9B 109.2 
C10—C7—C8 104.5 (2) C16—C11—C7 109.4 (2) 
C11—C7—C6 109.4 (2) C12—C11—C7 129.6 (3) 
C11—C7—C8 100.7 (2) C12—C11—C16 120.9 (3) 
C11—C7—C10 113.9 (2) C11—C16—N1 110.8 (2) 
C7—C8—H8 111.4 C15—C16—C11 121.1 (3) 
N2—C8—C7 103.2 (2) C15—C16—N1 128.1 (3) 
N2—C8—H8 111.4 C16—C15—H15 121.0 
N1—C8—C7 106.1 (2) C16—C15—C14 117.9 (3) 
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N1—C8—H8 111.4 C14—C15—H15 121.0 
N1—C8—N2 112.9 (2) C15—C14—H14 119.3 
C17—N2—C8 117.3 (2) C15—C14—C13 121.3 (3) 
C17—N2—C9 130.2 (2) C13—C14—H14 119.3 
C9—N2—C8 112.5 (2) C14—C13—H13 120.1 
N2—C17—C18 116.3 (3) C12—C13—C14 119.8 (3) 
O4—C17—N2 124.9 (2) C12—C13—H13 120.1 
O4—C17—C18 118.8 (3) C11—C12—C13 118.8 (3) 
F1—C18—F2 107.7 (2) C11—C12—H12 120.6 
F1—C18—F3 108.1 (2) C13—C12—H12 120.6 
F1—C18—C17 112.6 (2) C8—N1—H1 125.9 
F2—C18—C17 111.2 (2) C16—N1—C8 108.1 (2) 
F3—C18—F2 106.9 (2) C16—N1—H1 125.9 
    
O1—C1—C5—O3 -0.3 (4) C8—N2—C17—O4 0.3 (4) 
O1—C1—C5—C4 -179.8 (2) C8—N2—C9—C10 24.3 (3) 
O2—C4—C6—C7 92.0 (3) N2—C8—N1—C16 -89.6 (3) 
O2—C4—C5—O3 179.8 (2) N2—C17—C18—F1 69.5 (3) 
O2—C4—C5—C1 -0.6 (4) N2—C17—C18—F2 -51.5 (3) 
C2—C1—C5—O3 -179.7 (2) N2—C17—C18—F3 -169.8 (2) 
C2—C1—C5—C4 0.8 (4) C17—N2—C9—C10 -152.5 (3) 
C3—O2—C4—C6 -179.3 (2) C1—C2—C3—O2 -0.3 (4) 
C3—O2—C4—C5 0.0 (4) C5—C4—C6—C7 -87.2 (3) 
C3—C2—C1—O1 -179.7 (3) C10—C7—C8—N2 -19.1 (2) 
C3—C2—C1—C5 -0.3 (4) C10—C7—C8—N1 -138.1 (2) 
C4—O2—C3—C2 0.5 (4) C10—C7—C11—C16 121.9 (2) 
C4—C6—C7—C8 75.9 (3) C10—C7—C11—C12 -58.8 (4) 
C4—C6—C7—C10 -43.7 (3) C9—N2—C17—C18 -2.1 (4) 
C4—C6—C7—C11 -172.6 (2) C9—N2—C17—O4 177.0 (3) 
C6—C4—C5—O3 -0.9 (4) C11—C7—C8—N2 99.2 (2) 
C6—C4—C5—C1 178.6 (2) C11—C7—C8—N1 -19.8 (2) 
C6—C7—C8—N2 -144.0 (2) C11—C7—C10—C9 -74.5 (3) 
C6—C7—C8—N1 97.0 (2) C11—C16—C15—
C14 
1.0 (4) 
C6—C7—C10—C9 158.9 (2) C11—C16—N1—C8 -16.3 (3) 
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C6—C7—C11—C16 -109.0 (3) C16—C11—C12—
C13 
-0.2 (4) 
C6—C7—C11—C12 70.2 (4) C16—C15—C14—
C13 
-1.9 (4) 
C7—C8—N2—C17 174.0 (2) C15—C16—N1—C8 167.3 (3) 
C7—C8—N2—C9 -3.2 (3) C15—C14—C13—
C12 
1.8 (5) 
C7—C8—N1—C16 22.8 (3) C14—C13—C12—
C11 
-0.7 (4) 
C7—C10—C9—N2 -35.3 (3) C12—C11—C16—
C15 
0.0 (4) 
C7—C11—C16—C15 179.3 (2) C12—C11—C16—N1 -176.7 (2) 
C7—C11—C16—N1 2.7 (3) N1—C8—N2—C17 -71.9 (3) 
C7—C11—C12—C13 -179.4 (3) N1—C8—N2—C9 110.9 (3) 
C8—C7—C10—C9 34.3 (3) N1—C16—C15—C14 177.1 (3) 
C8—C7—C11—C16 10.7 (3) O4—C17—C18—F1 -109.7 (3) 
C8—C7—C11—C12 -170.0 (3) O4—C17—C18—F2 129.4 (3) 
C8—N2—C17—C18 -178.8 (2) O4—C17—C18—F3 11.1 (4) 
 
      
 
 
 
Energy (kJ/mol)      Rel. Energy 
-1303100.90               0.000000000 
-1303073.02               27.8803607 
 
Conformational searches (AM1) were carried out with Spartan 10. DFT optimizations 
were conducted with the Lee-Yang-Parr correction function (B3LYP) employing a 6- 
31G* basis set. 
The minimum energy conformation of (E)-2-ethylidene-4-hydroxy-3-oxo-2,3-
dihydropyrylium is shown below: 
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SPARTAN '10 Quantum Mechanics Program: (PC/x86) Release 1.0.1v4  
Job type: Single point. 
Method: RB3LYP 
Basis set: 6-31G(D) 
Number of shells: 54 
Number of basis functions: 164 
Charge : +1Multiplicity: 1 
SCF model: 
A restricted hybrid HF-DFT SCF calculation will be 
performed using Pulay DIIS + Geometric Direct Minimization 
SCF total energy: -496.3245053 hartrees 
Reason for exit: Successful completion  
Quantum Calculation CPU Time : 47.48 
Quantum Calculation Wall Time: 45.28 
SPARTAN '10 Semi-Empirical Program: (WIN) Release 1.0.1  
Semi-empirical Property Calculation  
M0001  
Guess from Archive 
Energy Due to Solvation 
Solvation Energy SM5.4/A -221.527 
Memory Used: 902.86 Kb 
Reason for exit: Successful completion 
Semi-Empirical Program CPU Time : .08 
Semi-Empirical Program Wall Time: .10 
SPARTAN '10 Properties Program: (PC/x86) Release 1.0.1  
Reason for exit: Successful completion  
Properties CPU Time : .56 
Properties Wall Time: .58 
 
Cartesian Coordinates (Angstroms) 
Atom     X         Y         Z 
C(1) 2.3650 0.7040 0.0010 
C(2) -0.4580 0.4960 -0.0020 
C(3) 1.5200 1.8110 -0.0010 
C(4) -1.8200 0.5810 0.0010 
C(5) -2.6950 -0.5920 0.0020 
C(6) 0.3180 -0.7320 -0.0030 
C(7) 1.8100 -0.5700 0.0000 
H(8) -2.5120 -1.2220 -0.9120 
H(9) -3.7740 -0.2960 0.0280 
H(10) -2.4750 -1.2520 0.8870 
H(11) -2.2940 1.5840 0.0010 
H(12) 3.4620 0.8430 0.0030 
H(13) 1.8710 2.8700 -0.0020 
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O(14) -0.1670 -1.8690 -0.0050 
O(15) 2.6000 -1.6380 0.0010 
O(16) 0.1920 1.7520 -0.0030 
H(17) 2.0630 -2.4660 0.0000 
 
The minimum energy conformation of (Z)-2-ethylidene-4-hydroxy-3-oxo-2,3-
dihydropyrylium is shown below: 
 
 
 
Energy (kJ/mol) 
-1303108.05 
 
SPARTAN '10 Quantum Mechanics Program: (PC/x86) Release 1.0.1v4  
Job type: Single point. 
Method: RB3LYP 
Basis set: 6-31G(D) 
Number of shells: 54 
Number of basis functions: 164 
Charge : +1Multiplicity: 1 
SCF model: 
A restricted hybrid HF-DFT SCF calculation will be 
performed using Pulay DIIS + Geometric Direct Minimization 
SCF total energy: -496.3272281 hartrees 
Reason for exit: Successful completion  
Quantum Calculation CPU Time : 48.25 
Quantum Calculation Wall Time: 52.84 
SPARTAN '10 Semi-Empirical Program: (WIN) Release 1.0.1  
Semi-empirical Property Calculation  
M0001  
Guess from Archive 
Energy Due to Solvation 
Solvation Energy SM5.4/A -221.884 
Memory Used: 902.86 Kb 
Reason for exit: Successful completion 
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Semi-Empirical Program CPU Time : .09 
Semi-Empirical Program Wall Time: -3.46 
SPARTAN '10 Properties Program: (PC/x86) Release 1.0.1  
Reason for exit: Successful completion  
Properties CPU Time : .56 
Properties Wall Time: 4.22 
 
Cartesian Coordinates (Angstroms) 
Atom        X            Y         Z 
C(1) -1.5980 -0.8800 0.0000 
C(2) 1.9950 1.2720 0.0000 
C(3) 2.1160 -0.1130 0.0000 
C(4) 0.8820 -0.9680 0.0000 
C(5) -0.3880 -0.2570 0.0000 
C(6) 0.7240 1.8400 0.0000 
C(7) -2.9020 -0.2160 0.0000 
O(8) -0.4160 1.1560 0.0000 
H(9) 0.5280 2.9380 -0.0000 
H(10) 2.8920 1.9180 0.0000 
H(11) 3.2440 -1.6580 0.0000 
O(12) 3.3200 -0.6740 0.0000 
O(13) 0.9980 -2.1970 0.0000 
H(14) -1.5950 -1.9930 0.0000 
H(15) -2.8260 0.8990 0.0000 
H(16) -3.4860 -0.5370 0.9050 
H(17) -3.4860 -0.5370 -0.9050 
 
A comparison of the computed energies of (E)-65 and (Z)-65 shows that (Z)-65 is lower 
in energy by 7.15 kJ/mol or 1.71 kcal/mol 
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1.6 Select Spectra 
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Chapter 2 
 
Asymmetric Synthesis of Alkaloid-Pyrone Adducts via Thiourea Catalysis 
 
2.1 Asymmetric Counterion-Directed Catalysis 
 The enantioselective construction of molecules is important; for example, 
pharmaceutical drugs are often only active as single enantiomer and there are some cases 
where the inactive enantiomer can lead to deleterious side effects.
39
 Organic chemists 
have been interested in chirality for over a century, yet a relatively recent trend is using 
organocatalysis (no metals) to control enantioselectivity.
40
 Asymmetric counterion-
directed catalysis (ACDC) was formally proposed by Professor List in 2006.
41
 This mode 
of catalysis takes advantage of an ionic intermediate by using a suitable counterion as a 
catalyst to tightly bind and effectively block one face of the molecule. Thioureas have 
found use as neutral hydrogen bond donors in a wide variety of reactions involving 
cationic intermediates (Figure 2.1).
42
 The unique ability of thioureas is due in part to 
their low pKa (~11) combined with an anion recognition that mimics enzymatic reactions. 
Figure 2.1 Thioureas as Anion Binding Catalysts 
 
104 
 
2.2 Previous Examples of Asymmetric Reactions of Quinone Methides 
 o-Quinone methides are an important class of reactive molecules.
43
 They typically 
cannot be isolated, although there are stabilized versions
44
 that reduce their high 
propensity to accept nucleophiles and rearomatize. It is this feature that is key to the 
biological properties of molecules such as vitamin E and the anthracycline antibiotics. 
Quinone methides have found extensive utility in the synthesis of natural products.
45
 The 
high reactivity of quinone methides has made their asymmetric reactions rare.
46
 However, 
there are several examples, including Lectka’s chiral ammonium fluoride approach 
(Scheme 2.1).
47
 In this formal hetero-Diels-Alder cycloaddition, use of the cinchona 
alkaloid-derived catalyst 4 and stabilized o-quinone methide 1 afforded [4+2] adducts 
such as 3 in up to 90% ee. 
Scheme 2.1 Lectka’s Enantioselective Synthesis of Lactones 
 
Ye and coworkers achieved a (4+3) annulation of the same stabilized quinone methide 1 
with enals (Scheme 2.2).
48
 The NHC catalyst 7 derived from L-pyroglutamic acid  
Scheme 2.2 Ye’s (4+3) Annulation 
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effected a highly enantioselective transformation through presumed hydrogen bonding 
between the hydroxyl of the catalyst and carbonyl of quinone methide. High yields and 
ee’s were obtained with good diastereoselectivity for the cis ε-lactone 6. 
Scheidt and coworkers developed a complementary method with in situ generated 
quinone methides (Scheme 2.3).
49
 Benzylic bromide 8 was found to be a useful surrogate 
for a quinone methide, which was generated in situ by treatment CsF in combination with 
18-crown-6 and the weak base n-Bu4N·OAc. The azolium salt 10 imparted 
enantioselectivity by blocking one face of the enal leading to the production of lactone 9 
in high ee.  
Scheme 2.3 Scheidt’s Fluoride-induced Approach 
  
Schaus and Luan were also able to generate o-quinone methides in situ and add alkenyl 
groups in an enantioselective fashion via boronates such as 12 (Scheme 2.4).
50
 Bromo 
BINOL 14 was an effective hydrogen bonding catalyst to afford diaryl vinyl methanes 13 
in up to 96% ee. The enantioselectivity was attained through boronate exchange to the  
Scheme 2.4 Schaus’ Addition of Boronates 
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BINOL followed by hydrogen bonding to the carbonyl to deliver the aryl group 
selectively to one face.  
Further studies related to our work include Shi and coworker’s addition of 2-vinyl 
indoles to in situ-generated quinone methides (Scheme 2.5).
51
 Chiral phosphoric acid 18 
was able to promote elimination of the benzylic alcohol 15 and impart asymmetry for 
[4+2] cycloadditions between the generated enone and 2-vinyl indole 16.  
Scheme 2.5 Shi’s Addition of Indoles 
 
Chromenes could be made enantioselectively by both the Schneider
52
 and 
Rueping
53
 groups (Scheme 2.6). Both investigators used in situ-generated quinone 
methides from benzylic alcohol 19 catalyzed by chiral phosphoric acids and cyclic 
diketones such as 1,3-cyclohexanedione 20. The Schneider group needed two steps and  
Scheme 2.6 Enantioselective Synthesis of Chromenes 
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achieved higher yields (eq. 1), while the Rueping group employed milder conditions to 
attained higher ee (eq. 2). 
Finally, the Sigman group has developed enantioselective methods to 
functionalize styrenes (Scheme 2.7).
54
 Compound 24 was dearomatized to an o-quinone 
methide employing a Pd(II) Quinox 28 catalyst system which imparted enantioselectivity 
when the alcoholic solvent attacked. Dimethoxy compound 27 was isolated in up to 92% 
ee. The mechanism is believed to proceed through an interesting nucleopalladation step. 
Initial addition of methanol to form 25 would be enantioselective by virtue of catalyst 28  
Scheme 2.7 Sigman’s Use of Pd(II) Catalysis for Enantioselective Dihydroxylation 
 
and then the second methanol addition would occur syn through the intermediacy of the 
palladium ligated o-quinone methide 26. Deuterium labeling experiments support the 
overall proposal. 
2.3 Previous Examples Using Thiourea Catalysis 
 There have been a few examples of oxocarbenium ions used in highly 
enantioselective transformations. Jacobsen and coworkers took advantage of an 
oxidopyrylium intermediate in a (5+2) cycloaddition (Scheme 2.8).
55
 The reaction 
featured a two catalyst system where both the achiral simple thiourea 31 and chiral 
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primary amine thiourea 32 were needed to attain the best ee. They believe that 31 binds 
the acetate anion and 32 condenses onto the enone to make a chiral enamine. A range of 
intramolecular substrates worked to give useful bicycloether ring systems 
Scheme 2.8 Jacobsen’s Enantioselective (5+2) Cycloaddition 
 
such as 30. Recently, they were able to extend the reaction to an intermolecular variant.
56
 
The Jacobsen group was also able to achieve enantioselective additions to 
chloroisochromans (Scheme 2.9).
57
 The use of newly developed 2-arylpyrrolidino 
thiourea 36 catalyzed the highly enantioselective addition of silyl ketene acetal 34 to 33 
through an oxocarbenium intermediate. Product 35 was isolated in high yield and good ee.   
Scheme 2.9 Enantioselective Addition to Isochromans 
 
 The counterion can have a substantial effect on the enantioselectivity of thiourea 
catalyzed transformations. Jacobsen and coworkers showed that increasing the size of the 
halogen had a deleterious effect on enantioselectivity for a Pictet-Spengler reaction 
(Scheme 2.10).
58
 Use of a chloride counterion led to very high ee while iodide gave 
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essentially racemic product 38 when hemiaminal lactam 37 was treated with a TMS 
source and thiourea catalyst 39.  
Scheme 2.10 Role of the Counterion in Enantioselective Pictet-Spengler Reaction 
 
The use of the 2-arylpyrrolidino thioureas also necessitates further mention. After 
the initial disclosure in the oxocarbenium example (Scheme 2.9), a systematic study on 
the size of the aryl ring was carried out in a cationic cyclization study (Scheme 2.11).
59
  
Scheme 2.11 Role of Aryl Group in Cationic Cyclization 
 
The Jacobsen group found that increasing the aromatic bulk led to an increase in ee of 
product 41, with 4-pyrenyl substituted catalyst 42 being the optimal with 95% ee attained. 
Along these lines, the Jacobsen group later developed an addition of indole 43 to  
Scheme 2.12 Jacobsen’s Addition of Indoles to Episulfoniums  
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episulfonium 44 under acid catalysis (Scheme 2.12). They proposed that the phenanthryl 
ring of catalyst 46 efficiently stabilized carbocation intermediates as well as blocked one 
face due to its size. They undertook mechanistic studies and found that presence of the N-
H was key; when N-Me was used no enantioinduction was observed. A similar finding 
was also made in the work reported by the Ma,
60
 Barbas
61
 and Jørgensen
62
 labs.  
2.4 Results 
 When considering the asymmetric addition of carbazoles and hydroxypyrones, we 
sought to take advantage of the proposed oxocarbenium 48 through an anionic binding 
mechanism (Scheme 2.13).
6
 Acidic activation of siloxypyrone 47 would generate the 
counterion pair which would then guide a substituted indole or carbazole to one face of 
Scheme 2.13 Proposed Enantioselective Addition of Indoles to Pyrone 47 
 
the oxocarbenium. Either the cycloadduct 49 or the ring-opened indolenine 50 may be 
obtained in enantioenriched form. 
Initially, we focused on use of chiral phosphoric acid catalysts as it would 
combine the proton source and asymmetric elements together (Table 2.1). However, we 
observed no detectable enantiomeric excess when siloxypyrone 47 and N-Me 
tetrahydrocarbazole 51 were used. We also had chiral thioureas in hand and were able to 
evaluate N-Bn catalyst 54 as well as the more elaborate 2-naphthyl catalyst 55. In these 
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cases, we saw <5% ee in combination with HCl. At this point, we decided to switch to 
use of N-H tetrahydrocarbazole 56 as substrate (Scheme 2.14).  
Table 2.1 Initial Attempts at Enantioselective Additions 
 
Gratifyingly, we were able to observe some enantioselectivity using N-Bn thiourea 54 in 
combination with HCl. We were able to obtain an X-ray crystal structure on a 93% ee 
sample that confirmed the absolute stereochemistry as (R). Use of 56 with chiral 
phosphoric acids led to no ee; we hypothesize that the phosphate anion desilylated the 
pyrone and was thus not active in the catalytic cycle.  
Scheme 2.14 Use of an N-H Carbazole with Thiourea 54 
  
We then set out to optimize the asymmetric reaction and entered into 
collaboration with the Jacobsen group at Harvard University to survey a wide range of 
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chiral thiourea catalyst motifs. Some of the less successful ones are shown in Figure 2.2. 
Presumably, the thioureas with basic amines (e.g. 60 and 61) were involved in side  
Figure 2.2 Optimization of Enantioselective Reaction 
 
reactions with the pyrone intermediate which led to deactivation of the catalyst. Thiourea 
proved to be the best dual hydrogen bond donor with urea 64 and squaramide 65 catalysts 
giving lower ee. Benzhydryl-derived catalysts 66 showed promise which led us to focus 
on sidechains with multiple aryl rings.  
We next screened a large number of 2-arylpyrrolidino thioureas with substituents varying 
in both size and electronics (Figure 2.3). There was a similar observation to the prior 
studies (Scheme 2.11) that larger aryl systems gave higher ee, increasing from 1-naphthyl 
68 to 3-anthracenyl 46 to 4-pyrenyl 42 and triphenylene 69. However, 2-naphthyl 55 
gave a 91% ee suggesting a specific window where the aryl group blocks one face and 
offers cation-pi stabilization (Figure 2.4). A model showed this effect as well as the N-H 
coordinated to the bromide anion which may increase the nucleophilicity of the indole 
and subsequently attack the pyrone from the α face. 
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Figure 2.3 Evaluation of 2-Arylpyrrolidino Thiourea Catalysts 
  
Figure 2.4 Gaussian Model of Transition State with Catalyst 55 
 
114 
 
We next explored substituted aryl rings and found m-terphenyl catalyst 76 to be very 
effective, providing a 68% yield and 95% ee. The ee could be further bumped up to 96% 
ee by using the corresponding β-naphthyl catalyst 77. Bromo, t-butyl, and trifluoromethyl 
substituents all failed to give comparable ee’s. 
The synthesis of the most promising thiourea 77 catalyst is shown in Scheme 2.15. 
Starting from 2,4-dibromobenzaldehyde 81, Suzuki-Miyaura coupling with boronic acid  
Scheme 2.15 Synthesis of Catalyst 77 
 
82 installed the naphthyl appendages. Condensation of Ellman’s chiral sulfonamide 
auxiliary
63
 84 allowed for a highly diastereoselective addition of Grignard reagent 86. 
Deprotection of the acetal under acidic conditions was then accompanied by imine 
formation and subsequent reduction to pyrrolidine 88. Amide coupling with 89, Boc 
deprotection, and addition of isothiocyanate 91 completed the synthesis of thiourea 
catalyst 77.  
 We were able to apply the methodology to a wide range of substituted carbazoles 
(Figure 2.5). Both electron-withdrawing (93-95) and electron-donating (96-98, 100) 
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substituents on the indole ring were well tolerated, indicating that the nucleophilicity of 
the reactive 3-position of the indole is not critical for high enantioselectivity. Variation of   
Figure 2.5 Substrate Scope of Enantioselective Method 
 
both the 2- and 3- substituents on the indole was also possible (101-103), although 
substitution at the 3-position was necessary to avoid rearomatization to an achiral product. 
We were also able to obtain the interesting chromenoindole
64
 adduct 104 in high yield 
and 96% ee. These substrates were easily made through Fischer indole synthesis.
65
 
There were limitations to the methodology that were observed (Figure 2.6). 4,6-
disubstituted carbazoles gave only moderate ee regardless of whether the substituents 
were electron-donating (112) or withdrawing (108). This may be due to blocking an 
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important interaction of a C-H bond on the aryl ring. Variation of the carbocycle ring size 
annulated to the indole also failed to give high ee (109-111). A 7-substituted ring gave 
poor ee (105) while 4-substitution failed to give product under the reaction conditions.  
Figure 2.6 Substrates with Moderate Enantioselectivity 
 
 We also examined other pyrones with little success (Scheme 2.16). Bromo pyrone 
113 showed little reactivity under the conditions with mostly starting material obtained 
(eq. 1). Ethyl maltol derivative 115 reacted, but in this case underwent N-alkylation 
instead of the desired C-3 attack. Interestingly no ee was observed which lends support to 
our proposed mechanism involving a hydrogen bonded transition state (Figure 2.9). 
Finally, chromone siloxypyrone 117 failed to give any desired product 118 with mostly 
decomposition observed. We also tested the enantioselective method using a 
pyrroloindoline scaffold (Chapter 1) and found that product 120 could be obtained in  
117 
 
 
Scheme 2.16 Enantioselective Method Applied to Other Pyrones  
 
moderate ee (Scheme 2.17). The absolute configurations of adducts were assigned by 
comparison to the parent indolenine 58. 
Scheme 2.17 Enantioselective Synthesis of Pyrroloindolines 
   
To further probe the reaction mechanism, we undertook a systematic study of the 
Brønsted acid co-catalyst (Figure 2.7). Changing the Brønsted acid co-catalyst had only a 
little effect on reaction outcome. The more acidic HCl and TsOH gave lower 
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enantioselectivities but not by enough to suggest there may be significant background 
reaction. With carboxylic acids, there was no background reaction at all with 1 equiv  
Figure 2.7 Variation of Brønsted Acid 
 
giving the same ee as 9 mol% acid. This suggests that the acid does not participate 
directly in the enantiodetermining step. 
We also wanted to determine the anion that was binding to the thiourea and 
coordinating the oxocarbenium. We were able to synthesize the corresponding chloro and 
benzoyl pyrone substrates to test the reaction (Figure 2.8). The chloro pyrone 121 gave 
Figure 2.8 Variation of Pyrone Leaving Group 
 
noticeably lower ee than the bromo pyrone 47 which suggests that the halide is the anion 
binding to the thiourea rather than the benzoate. Benzoyl pyrone 122 failed to react under 
the enantioselective conditions. 
119 
 
These aggregate results led us to propose the following mechanism: bromosiloxy 
pyrone 47 undergoes desilylation in the presence of the Brønsted acid. The protonated 
quinone methide-like intermediate 48 then interacts with the thiourea which is hydrogen 
bonded to the bromide anion (Figure 2.9). The tetrahydrocarbazole 56 can then add in a 
1,4 fashion to the electrophile through the ordered transition state shown. Interactions 
such as π-π or C–H-π between the cationic electrophile and the catalyst pyrrolidine 
Figure 2.9 Proposed Mechanism for Enantioselective Addition 
 
substituent are suggested by the dependence of the reaction enantioselectivity on the 
nature of that aromatic group (c.f. Figure 2.3).
66
 The long reach of the m-terphenyl 
system may be able to shift from initially stabilizing the oxocarbenium to stabilizing the 
incipient charge developing on the nitrogen of the carbazole/indole reaction partner. The 
N-H may be coordinated to the bromide anion as suggested by the model in Figure 2.4 
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since it is presumed that the amide of the thiourea is hydrogen bonded to intermediate 48. 
Taken together, these findings are most consistent with an enantiodetermining step 
involving specific interactions between the catalyst and both the pyrone leaving group 
and the indole N-H moiety. 
2.5 Future Directions 
 We plan on exploring the m-terphenyl effect in more detail. This group has shown 
utility as a stabilizing group, including a range of unusual main group elements.
67
 The 
Siegel group has used this effect to synthesize a stable silylium ion (Scheme 2.18).
68
 
Reaction of 123 with a trityl borane salt efficiently generated the cation 124. 
Scheme 2.18 Use of a Terphenyl to Synthesize a Silylium Ion 
 
The Deng group has also taken advantage of the π-π stabilizing effect of a 
terphenyl group.
69
 They used catalyst 128 to promote a highly enantioselective addition 
of imine 125 to enal 126 under anionic conditions (Scheme 2.19). 
Scheme 2.19 Umpolung Reaction of Imines 
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 To further probe the mechanism and transition state of our enantioselective 
addition, we also plan to synthesize a stable surrogate for the protonated quinone 
methide-like intermediate 48. It may be possible to prepare the dimethyl analogue 130 
from known compound 129 and then treat it with acid (Scheme 2.20). We would then try 
to grow a crystal of the thiourea catalyst 74 complexed to intermediate 131 to evaluate 
interactions (e.g. π-π, C–H-π) that are present. 
Scheme 2.20 Plan to Synthesize a Stable Surrogate 
 
2.6 Conclusion 
 In summary, we have extended our alkaloid-pyrone methodology (Chapter 1) to 
an asymmetric variant using chiral thiourea catalysis. A range of substituted indoles and 
carbazoles can be used and the corresponding indolenines with a 3-quaternary center are 
obtained in good to high ee. We also developed a new thiourea catalyst bearing an m-
terphenyl motif that should find greater use in asymmetric catalysis.  
2.7 Experimental Section 
Methods:  
All reactions were performed in round bottom flasks under air unless otherwise noted. 
Catalytic experiments were performed in oven-dried 2-dram vials under a nitrogen 
atmosphere. Stainless steel syringes were used to transfer air- and moisture-sensitive 
liquids. Reactions were monitored by thin-layer chromatography (TLC) on Silica Gel 60 
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F254 plates (EMD) under UV light (254 nm) or visualized with KMnO4 upon heating. 
Flash chromatography was performed using Silica Gel 60 (230-400 mesh, EM Science), 
SiliaFlash P60 (230-400 mesh, SiliCycle), or 200-400 mesh silica gel (Sorbent 
Technologies). Flash column chromatography was conducted on a Biotage Isolera 
automated chromatography system or manually in a glass column or 3 mL pipette. 
Preparative TLC was performed on Silica Gel 60 F254 plates (EMD) or PLC Silica Gel 60 
F254 plates (Merck). Organic solutions were concentrated under reduced pressure on a 
Büchi or Heidolph rotary evaporator. 
Materials and reagents:  
Commercial reagents were purchased from Sigma-Aldrich, Alfa Aesar, Strem, Oakwood, 
Matrix Scientific, or TCI and used without purification. Where specified, MeCN, CH2Cl2, 
toluene, THF, TBME, and 1,4-dioxane (PURE SOLV) were dried by passing through 
columns of activated alumina. Deuterated solvent CDCl3 (Cambridge Isotope 
Laboratories) was treated with and stored over anhydrous K2CO3 prior to use. Deuterated 
solvents CD3OD and DMSO-d6 (Cambridge Isotope Laboratories) were used without 
purification. Extraction and chromatography solvents were reagent grade and used 
without purification (VWR or Clean Harbors). Molecular sieves (4Å) were activated by 
heating in vacuo and stored in a vial in a dessicator. Anhydrous diethylamine was used 
without purification (Aldrich). HPLC solvents were used without purification (VWR). 
Instrumentation:  
Proton nuclear magnetic resonance (
1
H NMR) spectra and proton-decoupled carbon 
nuclear magnetic resonance (
13
C{
1
H} NMR) spectra were recorded on a Varian Mercury 
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400 (400 MHz), Inova 500 (500 MHz), or Inova 600 (600 MHz) spectrometer at ambient 
temperature. All chemical shifts (δ) are reported in parts per million (ppm) downfield 
from tetramethylsilane. Proton resonances are referenced to residual protium in the NMR 
solvent or tetramethylsilane. Carbon resonances are referenced to the carbon resonances 
of the NMR solvent. Data are represented as follows: chemical shift, multiplicity (br = 
broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants 
(J) in Hertz (Hz), integration.  
Infrared (IR) spectra were obtained using a Bruker Optics Tensor 27 FTIR spectrometer 
or Bruker Alpha FTIR spectrometer equipped with an attenuated total reflectance (ATR) 
single reflection unit or Nicolet Nexus 670 FT-IR spectrometer.  
Optical rotations ([α]) were measured using a 1 mL cell with a 0.5 dm path length on a 
Jasco DIP 370 digital polarimeter at 589 nm (sodium D line) at ambient temperature. 
Mass spectral (MS) data were obtained on a Waters Q-TOF API-US spectrometer 
(Boston University Chemical Instrumentation Center) or an Agilent 6210 TOF LC/MS 
spectrometer (Harvard FAS Division of Science Small Molecule Mass Spectrometry). 
High-performance liquid chromatography (HPLC) analysis was performed using an 
Agilent 1200 series quaternary HPLC system with commercially available ChiralPak and 
ChiralCel columns. The sulfonylated indole-pyrone adducts exhibit high polarity and are 
mildly basic. Elution and separation can depend heavily on prior use (commonly referred 
to as a memory effect). A basic wash (0.01% diethylamine in 20% iPrOH in hexanes) 
followed by an adequate equilibration is recommended prior to chiral analysis. 
Enantioenriched and racemic samples were injected as iPrOH solutions. 
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Melting points (m.p.) were recorded on a Mel-Temp or Mel-Temp II (Laboratory 
Devices). 
 
3,5-Di(naphthalen-2-yl)benzaldehyde 83: According to a modified literature procedure, 
a 200 mL round-bottom flask was charged with 3,5-dibromobenzaldehyde 81 (2.64 g, 
10.0 mmol), 2-naphthylboronic acid 82 (3.61 g, 21.0 mmol, 2.1 equiv.), Pd(PPh3)4 (173 
mg, 0.15 mmol, 1.5 mol%), and THF (50 mL). To the resulting solution was added 
K2CO3 (2 M in H2O, 25 mL, 50 mmol, 5 equiv.). The biphasic mixture was heated to 
reflux under a nitrogen atmosphere for 19 h. The reaction mixture was cooled to rt and 
the organic and aqueous layers were separated. The aqueous layer was extracted with 4 x 
25 mL EtOAc, and the combined organic fractions were washed with 25 mL brine, dried 
over MgSO4, filtered, and concentrated in vacuo. The crude residue was purified by 
column chromatography (eluent: 50-80% CH2Cl2/hexanes, v/v) to give 3.47 g (97% 
yield) of the desired product. White solid. Rf = 0.36 (50% CH2Cl2/hexanes, v/v). m.p. 
151–154 ºC. IR (thin film) 3056, 1697, 1595, 1167, 881, 816, 695 cm–1. 1H NMR (600 
MHz, CDCl3) δ 10.18 (s, 1H), 8.30 – 8.28 (m, 1H), 8.20 (d, J = 1.7 Hz, 2H), 8.15 (s, 2H), 
7.98 (d, J = 8.5 Hz, 2H), 7.96 – 7.93 (m, 2H), 7.93 – 7.89 (m, 2H), 7.83 (dd, J = 8.5, 1.7 
Hz, 2H), 7.58 – 7.52 (m, 4H). 13C{1H} NMR (126 MHz, CDCl3) δ 192.4, 142.8, 137.7, 
137.0, 133.7, 133.1, 132.2, 129.0, 128.4, 127.8, 127.5, 126.7, 126.6, 126.3, 125.3. MS 
(ESI) m/z calc’d for C27H19O (M+H): 359.1430, found: 359.1436; m/z calc’d for 
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C27H22NO (M+NH4): 376.1696, found: 376.1702; m/z calc’d for C27H18NaO (M+Na): 
381.1250, found: 381.1249. 
 
(RS,ES)-N-3,5-Di(naphthalen-2-yl)benzaldimine-2-methylpropanesulfinamide 85: 
According to a modified literature procedure, a 250 mL round-bottom flask was charged 
with 3,5-di(naphthalen-2-yl)benzaldehyde 83 (3.37 g, 9.40 mmol), (R)-(+)-2-methyl-2-
propanesulfinamide 84 (1.25 g, 10.3 mmol, 1.1 equiv.), activated molecular sieves (4Å, 
9.4 g, 1 g/mmol), and anhydrous THF (40 mL). To the resulting suspension was added 
pyrrolidine (157 μL, 1.88 mmol, 0.2 equiv.). The suspension was heated to 60 ºC under a 
nitrogen atmosphere for 14 h. The reaction mixture was cooled to rt and filtered through a 
plug of celite, washing the residue with copious amounts of CH2Cl2. The filtrate was 
concentrated in vacuo. The crude residue was purified by column chromatography 
(eluent: 0-5% EtOAc/CH2Cl2, v/v) to give 3.22 g (74% yield) of the desired product. Off-
white solid. Rf = 0.28 (CH2Cl2). m.p. 181–183 ºC. IR (thin film) 3056, 2960, 1609, 1585, 
1364, 1179, 854, 816 cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 8.82 (s, 1H), 8.21 (s, 3H), 8.17 
(s, 2H), 7.99 (d, J = 8.4 Hz, 2H), 7.96 (d, J = 7.9 Hz, 2H), 7.92 (d, J = 7.6 Hz, 2H), 7.85 
(dd, J = 8.4, 1.5 Hz, 2H), 7.59 – 7.52 (m, 4H), 1.35 (s, 9H). 13C{1H} NMR (126 MHz, 
CDCl3) δ 162.9, 142.8, 137.5, 135.3, 133.7, 133.0, 130.5, 128.9, 128.4, 127.8, 127.3, 
126.7, 126.5, 126.3, 125.4, 58.1, 22.8. MS (ESI) m/z calc’d for C31H28NOS (M+H): 
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462.1886, found: 462.1891; m/z calc’d for C31H27NNaOS (M+Na): 484.1706, found: 
484.1690. [α]D
24
 +23º (c = 0.72, CHCl3). 
 
(RS,ES)-N-((R)-1-(3,5-Di(naphthalen-2-yl)phenyl)-3-(1,3-dioxan-2-yl)propanyl)-2-
methylpropanesulfinamide 87: According to a modified literature procedure, an oven-
dried 100 mL round-bottom flask was charged with (RS,ES)-N-3,5-di(naphthalen-2-
yl)benzaldimine-2-methylpropanesulfinamide 85 (3.02 g, 6.40 mmol) and anhydrous 
THF (27 mL) and cooled to –78 ºC in a dry ice/acetone bath under a nitrogen atmosphere. 
To the resulting suspension was added dropwise a solution of (1,3-dioxan-2-
ylethyl)magnesium bromide 86 (0.5 M in THF, 14.7 mL, 7.35 mmol, 1.15 equiv.). The 
suspension was stirred at –78 ºC for 30 min and the reaction vessel was sealed and 
transferred to a –50 ºC cryocool and stirred for 13 h. The reaction mixture was warmed to 
rt and partitioned between 25 mL sat’d NH4Cl and 15 mL EtOAc, and the organic and 
aqueous layers were separated. The aqueous layer was extracted with 3 x 15 mL EtOAc 
and the combined organic fractions were washed with 15 mL brine, dried over MgSO4, 
filtered, and concentrated in vacuo. The crude residue was purified by column 
chromatography (eluent: 15-35% EtOAc/CH2Cl2, v/v) to give 3.57 g (97% yield) of the 
desired product. White solid. Rf = 0.26 (20% EtOAc/CH2Cl2, v/v). m.p. 160–162 ºC. IR 
(thin film) 2957, 2854, 1139, 1089, 855, 816 cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 8.13 (s, 
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2H), 7.99 – 7.96 (m, 2H), 7.96 (s, 2H), 7.94 (s, 1H), 7.90 (d, J = 7.8 Hz, 2H), 7.83 (dd, J 
= 8.5, 1.8 Hz, 2H), 7.69 (d, J = 1.6 Hz, 2H), 7.56 – 7.49 (m, 4H), 4.59 – 4.55 (m, 1H), 
4.54 (t, J = 5.0 Hz, 1H), 4.11 – 4.07 (m, 2H), 3.76 – 3.70 (m, 2H), 3.65 (d, J = 4.0 Hz, 
1H), 2.31 – 2.23 (m, 1H), 2.10 – 2.00 (m, 2H), 1.76 – 1.70 (m, 1H), 1.66 – 1.59 (m, 1H), 
1.34 – 1.30 (m, 1H), 1.28 (s, 9H). 13C{1H} NMR (126 MHz, CDCl3) δ 143.7, 142.4, 
138.4, 133.8, 132.9, 128.7, 128.4, 127.8, 126.5, 126.4, 126.2, 125.8, 125.5, 101.9, 67.0, 
59.5, 56.0, 31.8, 31.2, 25.9, 22.8. One carbon resonance is missing due to overlapping 
signals. MS (ESI) m/z calc’d for C37H40NO3S (M+H): 578.2723, found: 578.2737; m/z 
calc’d for C37H39NNaO3S (M+Na): 600.2543, found: 600.2544; m/z calc’d for 
C37H39KNO3S: 616.2282, found: 616.2293. [α]D
24
 –15º (c = 0.72, CHCl3). 
 
(R)-2-(3,5-Di(naphthalen-2-yl)phenyl)pyrrolidine 88: According to a modified 
literature procedure, a 250 mL round bottom flask is charged with (RS,ES)-N-((R)-1-(3,5-
di(naphthalen-2-yl)phenyl)-3-(1,3-dioxan-2-yl)propanyl)-2-methylpropanesulfinamide 87 
(3.05 g, 5.28 mmol), trifluoroacetic acid (47 mL) and water (4.7 mL). The resulting 
solution was stirred for 1.5 h, at which point triethylsilane was added (8.5 mL, 53.2 
mmol, 10.1 equiv.). The solution was stirred for 16 h and concentrated in vacuo. The 
crude residue was purified by column chromatography (eluent: CH2Cl2, followed by 2% 
MeOH/1% NH4OH/CH2Cl2, v/v, and finally 8% MeOH/2% NH4OH/CH2Cl2, v/v). All 
fractions containing the desired product were combined and concentrated in vacuo. 
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Residual ammonia and MeOH were removed by addition of EtOAc and concentration in 
vacuo. The purified product was re-dissolved in 100 mL CH2Cl2 and washed with 25 mL 
sat’d NaHCO3. The aqueous layer was washed with 3 x 25 mL CH2Cl2, and the combined 
organic fractions were dried over MgSO4, filtered, and concentrated in vacuo to give 1.58 
g (75% yield) of the desired product. Red-brown foam. Rf = 0.17 (1% NH4OH and 3% 
MeOH in CH2Cl2, v/v). m.p. 68 ºC (dec). IR (thin film) 3056, 1679, 1594, 1508, 1201, 
1131, 855, 817 cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 8.13 (s, J = 15.0 Hz, 2H), 7.96 – 
7.92 (m, 5H), 7.89 (d, J = 7.6 Hz, 2H), 7.83 (dd, J = 8.5, 1.5 Hz, 2H), 7.75 (d, J = 1.1 Hz, 
2H), 7.55 – 7.49 (m, 4H), 4.36 (t, J = 7.7 Hz, 1H), 4.03 (br. s, 1H), 3.34 – 3.28 (m, 1H), 
3.14 – 3.08 (m, 1H), 2.37 – 2.31 (m, 1H), 2.07 – 2.00 (m, 1H), 1.98 – 1.88 (m, 2H). 
13
C{
1
H} NMR (126 MHz, CDCl3) δ 144.2, 142.1, 138.4, 133.8, 132.9, 128.6, 128.4, 
127.8, 126.5, 126.13, 126.10, 125.8, 125.7, 125.0, 63.1, 46.8, 34.2, 25.3. MS (ESI) m/z 
calc’d for C30H26N (M+H): 400.2060, found: 400.2072; m/z calc’d for C30H25NNa 
(M+Na): 422.1879, found: 422.1871. [α]D
24
 +18º (c = 0.76, CHCl3). 
 
tert-Butyl ((S)-1-((R)-2-(3,5-di(naphthalen-2-yl)phenyl)pyrrolidin-1-yl)-3,3-dimethyl-
1-oxobutan-2-yl)carbamate 90: According to a modified literature procedure,
2
 a 100 
mL round-bottom flask was charged with (R)-2-(3,5-di(naphthalen-2-
yl)phenyl)pyrrolidine 88 (1.45 g, 3.64 mmol), Boc-L-tert-leucine 89 (926 mg, 4.00 mmol, 
1.1 equiv.), PyAOP (2.28 g, 4.37 mmol, 1.2 equiv.), and anhydrous CH2Cl2 (25 mL) and 
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immersed in a water bath. To the resulting solution was added dropwise N,N-
diisopropylethylamine (1.91 mL, 10.9 mmol, 3 equiv.). The solution was stirred at rt for 3 
days. The reaction mixture was diluted with 100 mL CH2Cl2 and washed sequentially 
with 15 mL sat’d NH4Cl, 15 mL sat’d NaHCO3, and 15 mL brine, dried over MgSO4, and 
concentrated in vacuo. The crude residue was purified by column chromatography 
(eluent: 10-30% EtOAc/hexanes, v/v) to give 1.79 g (80% yield) of the desired product. 
Beige solid. Rf = 0.22 (20% EtOAc/hexanes, v/v).  m.p. 193 ºC (dec). IR (thin film) 3440, 
2975, 1708, 1614, 1499, 1430, 1393, 1238, 1168, 1063, 1007, 855, 819 cm
–1
. This 
compound is a mixture of amide rotamers (3.7:1 in DMSO-d6). One of the proton 
resonances corresponding to the major rotamer was integrated to 1H (denoted with *) and 
all other integration data are reported relative to it. 
1
H NMR (600 MHz, DMSO-d6) δ 
8.36 (s, 0.27H), 8.29 (s, 1H, *), 8.12 (s, 0.19H), 8.06 – 7.90 (m, 6.0H), 7.70 (s, 0.29H), 
7.58 – 7.49 (m, 3.7H), 6.91 (d, J = 10.3 Hz, 0.24H), 6.62 – 6.55 (m, 0.60H), 5.44 (d, J = 
8.0 Hz, 0.23H), 5.24 (d, J = 7.8 Hz, 0.62H), 4.26 (d, J = 8.4 Hz, 0.62H), 4.18 – 4.08 (m, 
0.79H), 3.80 (dd, J = 17.3, 9.3 Hz, 0.72H), 3.76 – 3.63 (m, 0.54H), 2.35 – 2.25 (m, 
0.71H), 2.06 (d, J = 1.5 Hz, 2.6H), 2.04 – 1.87 (m, 2.3H), 1.44 (s, 1.2H), 1.35 (s, 0.55H), 
1.32 – 1.18 (m, 1.2H), 0.96 (s, J = 21.0 Hz, 8.3H), 0.90 (s, 0.56H), 0.61 (s, 1.3H). All 
observed carbon resonances are reported. 
13
C{
1
H} NMR (126 MHz, DMSO-d6) δ 206.4, 
169.5, 155.7, 145.7, 141.0, 140.8, 137.8, 137.4, 133.3, 132.4, 132.3, 128.5, 128.4, 128.2, 
127.5, 127.4, 126.5, 126.3, 126.1, 125.6, 125.5, 125.3, 124.5, 124.0, 123.4, 78.3, 77.7, 
60.3, 58.6, 47.9, 35.6, 34.1, 34.0, 30.7, 28.2, 27.7, 26.4, 26.3, 23.1. MS (ESI) m/z calc’d 
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for C41H45N2O3 (M+H): 613.3425, found: 613.3440; m/z calc’d for C41H44N2NaO3 
(M+Na): 635.3244, found: 635.3245. [α]D
24
 +48º (c = 0.78, CHCl3). 
 
1-(3,5-Bis(trifluoromethyl)phenyl)-3-((S)-1-((R)-2-(3,5-di(naphthalen-2-
yl)phenyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)thiourea 77: According to a 
modified literature procedure, a 200 mL round-bottom flask was charged with tert-butyl 
((S)-1-((R)-2-(3,5-di(naphthalen-2-yl)phenyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate 90 (1.51 g, 2.47 mmol) and anhydrous CH2Cl2 (10 mL) and cooled to 0 ºC 
in an ice water bath. To the resulting solution was added dropwise trifluoroacetic acid (5 
mL). The reaction vessel was warmed to rt and the solution was stirred for 1 h, at which 
point the reaction mixture was cooled to 0 ºC, diluted with 20 mL CH2Cl2, and quenched 
carefully with 4 N NaOH (20 mL). The organic and aqueous layers were separated. The 
aqueous layer was extracted with 3 x 15 mL CH2Cl2 and the combined organic fractions 
were dried over MgSO4, filtered, and concentrated in vacuo in a 250 mL pear-shaped 
flask. MS (ESI) m/z calc’d for C36H37N2O (M+H): 513.2900, found: 513.2916; m/z calc’d 
for C36H36N2NaO (M+Na): 535.2720, found: 535.2724. The crude residue was re-
dissolved in anhydrous CH2Cl2 (12 mL) and 3,5-bis(trifluoromethyl)phenyl 
isothiocyanate 91 (495 μL, 2.71 mmol, 1.1 equiv.) was added. The resulting solution was 
stirred at rt for 16 h, at which point the reaction mixture was concentrated in vacuo. The 
131 
 
crude residue was purified by column chromatography (eluent: 10-30% EtOAc/hexanes, 
v/v) to give 1.69 g (87% yield) of the desired product. Beige solid. Rf = 0.082 and 0.19 
for the two rotamers (20% EtOAc/hexanes, v/v). m.p. 117 ºC (dec). IR (thin film) 1691, 
1530, 1475, 1446, 1385, 1278, 1177, 1136, 1001, 885, 854 cm
–1
. This compound is a 
mixture of amide rotamers (5.3:1 in DMSO-d6). One of the proton resonances 
corresponding to the major rotamer was integrated to 1H (denoted with *) and all other 
integration data are reported relative to it. 
1
H NMR (600 MHz, DMSO-d6) δ 10.43 (s, 1H, 
*), 10.33 (s, 0.19H), 8.40 – 8.36 (m, 0.63H), 8.32 (s, 1.8H), 8.28 (s, 1.9H), 8.24 (d, J = 
9.2 Hz, 1.0H), 8.15 (s, 0.18H), 8.06 – 8.02 (m, 0.51H), 8.01 (s, 1.0H), 7.99 – 7.93 (m, 
0.68H), 7.92 – 7.85 (3.8H), 7.83 (s, 0.35H), 7.77 (s, 0.23H), 7.77 – 7.73 (m, 2.8H), 7.71 
(d, J = 8.6 Hz, 2.0H), 7.55 (d, J = 1.2 Hz, 2.2H), 7.47 – 7.42 (m, 1.9H), 7.37 (dd, J = 
11.4, 4.4 Hz, 2.0H), 5.92 (d, J = 0.28H), 5.41 (d, J = 9.2 Hz, 1.1H), 5.29 (d, J = 8.8 Hz, 
1.1H), 5.25 (d, J = 9.8 Hz, 0.23H), 4.53 – 4.45 (m, 1.1H), 3.88 (dd, J = 16.8, 8.7 Hz, 
1.1H), 3.82 – 3.70 (m, 0.54H), 2.40 – 2.30 (m, 1.2H), 1.95 – 1.89 (m, 2.4H), 1.08 (s, 
8.3H), 0.65 (s, 1.1H). All observed carbon resonances are reported. 
13
C{
1
H} NMR (126 
MHz, DMSO-d6) δ 180.2, 168.7, 145.9, 145.1, 141.7, 141.1, 140.5, 137.3, 137.2, 133.3, 
133.2, 132.4, 132.2, 130.1 (q, J = 32.8 Hz), 128.6, 128.2, 128.1, 128.0, 127.5, 127.2, 
126.5, 126.1, 126.0, 125.6, 125.3, 125.2, 124.7, 123.7, 123.16 (q, J = 272.7 Hz), 123.15, 
121.0, 116.2, 61.3, 60.4, 48.2, 35.7, 35.1, 34.1, 26.4, 23.0, 14.1. 
19
F NMR (471 MHz, 
DMSO-d6) δ –61.61. MS (ESI) m/z calc’d for C45H40F6N3OS (M+H): 784.2791, found: 
784.2789; m/z calc’d for C45H39F6N3NaOS (M+Na): 806.2610, found: 806.2608; m/z 
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calc’d for C45H39F6KN3OS (M+K): 822.2350, found: 822.2325. [α]D
24
 +83º (c = 0.60, 
CHCl3). 
Chloro pyrone precursor 121 was synthesized via known procedures. 
 
 
3-((tert-Butyldimethylsilyl)oxy)-2-(chloromethyl)-4H-pyran-4-one 121: According to 
a modified literature procedure, to an oven-dried 5 mL round-bottom flask was charged 
3-((tert-butyldimethylsilyl)oxy)-2-methyl-4H-pyran-4-one S2 (50.0 mg, 0.21 mmol) and 
anhydrous THF (1.5 mL) and cooled to –78 ºC under an argon atmosphere. To the 
resulting solution was added a solution of LiHMDS (1.0 M in THF, 0.41 mL, 0.41 mmol, 
2.0 equiv.). The solution was warmed to 0 ºC slowly and stirred for 45 mins. The solution 
was then added to a solution of TsCl (89.2 mg, 0.47 mmol, 2.3 equiv.) in anhydrous THF 
(0.5 mL) that was already pre-cooled to -78 ºC. The solution was slowly warmed to rt and 
stirred for 4h. The reaction mixture was quenched with NaHCO3, and the organic and 
aqueous layers were separated. The aqueous layer was extracted with EtOAc and the 
combined organic fractions were dried, filtered, and concentrated in vacuo. The crude 
residue was purified by column chromatography (eluent: 5-20% EtOAc/hexanes, v/v) to 
give 20.5 mg (36% yield) of the desired product. Colorless oil. Rf = 0.36 (20% 
EtOAc/hexanes, v/v). IR (thin film) 2932, 1649, 1283, 1232, 895, 788 cm
–1
. 
1
H NMR 
(400 MHz, CDCl3) δ 7.68 (d, J = 5.6 Hz, 1H), 6.35 (d, J = 5.6 Hz, 1H), 4.57 (s, 2H), 0.99 
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(s, 9H), 0.30 (s, 6H). 
13
C{
1
H} NMR (125 MHz, CDCl3) δ 174.4, 153.5, 150.6, 143.6, 
115.8, 37.2, 25.9, 18.8, -3.7. MS (ESI) m/z calc’d for C12H20ClO3Si (M+H): 275.0865, 
found: 275.0873. 
Benzoyl pyrone precursor 122 was synthesized via known procedures. 
 
 
(3-((tert-Butyldimethylsilyl)oxy)-4-oxo-4H-pyran-2-yl)methyl benzoate 122: 
According to a modified literature procedure, to an oven-dried 5 mL round-bottom flask 
was charged (3-hydroxy-4-oxo-4H-pyran-2-yl)methyl benzoate S5 (75.0 mg, 0.30 mmol), 
TBSCl (55.0 mg, 0.37 mmol, 1.2 equiv.), and anhydrous DMF (1.5 mL) under an argon 
atmosphere. The resulting solution was stirred for 5 min, and imidazole (41.5 mg, 0.61 
mmol, 2.0 equiv.) was added. The solution was stirred for 12 h. The reaction mixture was 
quenched with aqueous NaHCO3, and the organic and aqueous layers were separated. 
The aqueous layer was extracted with EtOAc and the combined organic fractions were 
dried, filtered, and concentrated in vacuo. The crude residue was purified by column 
chromatography (eluent: 25% EtOAc/hexanes, v/v) to give 80.0 mg (73% yield) of the 
desired product. Colorless oil. Rf = 0.24 (20% EtOAc/hexanes, v/v). IR (thin film) 2953, 
2929, 2857, 1724, 1644, 1451, 1250, 1204, 1106, 1096, 1066, 1026, 891, 824, 786, 710 
cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 8.05 – 8.03 (m, 2H), 7.67 (d, J = 5.6 Hz, 1H), 7.58 – 
7.55 (m, 1H), 7.43 (t, J = 7.8 Hz, 2H), 6.36 (d, J = 5.6 Hz, 1H), 5.36 (s, 2H), 0.95 (s, 9H), 
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0.29 (s, 6H). 
13
C{
1
H} NMR (126 MHz, CDCl3) δ 174.6, 166.1, 153.7, 150.0, 144.8, 
133.5, 129.9, 129.45, 128.6, 115.9, 110.1, 58.6, 25.9, 18.9, –3.6. MS (ESI) m/z calc’d for 
C19H25O5Si (M+H): 361.1466, found: 361.1463; m/z calc’d for C19H24NaO5Si (M+Na): 
383.1285, found: 383.1288.  
 
General procedure: In an oven-dried 2-dram vial was mixed bromopyrone precursor 47 
(32.0 mg, 0.10 mmol) and TBME (0.50 mL). The resulting suspension was cooled to –78 
ºC in a dry ice/acetone bath. In a separate oven-dried 0.5-dram vial was added catalyst 77 
(7.8 mg, 0.01 mmol, 10 mol%), indole (0.15 mmol, 1.5 equiv.), and TBME (0.45 mL). 
To this mixture was added 50 μL of a 0.2 M solution of benzoic acid in TBME (0.009 
mmol, 9 mol%). The resulting solution was transferred to the 2-dram vial by syringe and 
the 0.5-dram vial was rinsed twice with 0.50 mL TBME. The reaction mixture was stirred 
in an oil bath heated to 30 ºC and stirred for 3 days. The reaction was quenched by 
sequential addition of MsCl (23 μL, 0.30 mmol, 3 equiv.) or TsCl (57.2 mg, 0.30 mmol, 3 
equiv.), NEt3 (84 μL, 0.50 mmol, 5 equiv.), and CH2Cl2 (1 mL). The resulting suspension 
was stirred overnight, at which point it was partitioned between CH2Cl2 (3 mL) and water 
(2 mL). The organic layer was separated and the aqueous layer was extracted with 
CH2Cl2 (2 x 3 mL). The combined organic fractions were dried over Na2SO4, filtered, 
and concentrated to afford the crude sulfonylated indole-pyrone adduct. The crude 
material was purified by preparative TLC (eluent: 3% MeOH/CH2Cl2) to provide the pure 
135 
 
sulfonylated indole-pyrone adducts. Note: Prior to sulfonylation, the indole-pyrone 
adducts are susceptible to decomposition by elimination, leading to deterioration in 
enantioenrichment, especially in protic solvents such as MeOH or iPrOH and in the 
presence of bases such as Cs2CO3. These products can be isolated in their pure form by 
column chromatography (eluent: 0-8% MeOH/EtOAc, v/v) and stored in the refrigerator 
if desired. 
For initial catalyst optimization studies, the same procedure was followed at half scale 
(0.05 mmol of 47). Each indole-pyrone adduct was isolated prior to sulfonylation by 
column chromatography (eluent: 0-8% MeOH/EtOAc). The purified products were 
sulfonylated by treatment with excess MsCl or TsCl (~13 equiv.) and NEt3 (~8 equiv.) in 
CH2Cl2 (1 mL) and worked-up in an analogous fashion. The crude sulfonylated indole-
pyrone adducts are passed through a plug of silica gel (eluent: 5% MeOH/CH2Cl2, v/v) 
and can be subsequently analyzed by chiral HPLC.    
 
(R)-3-Hydroxy-2-((1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4H-pyran-4-one 
58: 
1
H NMR (500 MHz, CD3OD) δ 7.55 (d, J = 4.8 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 
7.40 (d, J = 7.6 Hz, 1H), 7.29 (dd, J = 7.6, 6.9 Hz, 1H), 7.20 (dd, J = 7.6, 6.9 Hz, 1H), 
6.15 (d, J = 4.8 Hz, 1H), 3.58 (d, J = 14.7 Hz, 1H), 3.47 (d, J = 14.7 Hz, 1H), 3.08 (m, 
1H), 2.87 (d, J = 15.2 Hz, 1H), 2.63 (d, J = 13.8 Hz, 1H), 2.33 (m, 1H), 2.05 (m, 1H), 
1.80 (d, J = 13.4 Hz, 1H), 1.47 (m, 1H), 1.22 (m, 1H). 
13
C{
1
H} NMR (125 MHz, CDCl3) 
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δ 187.8, 172.7, 154.5, 154.2, 147.7, 143.3, 143.0, 128.0, 124.7, 122.2, 120.0, 112.6, 57.4, 
38.8, 31.9, 30.0, 29.0, 21.3. All spectral data were in agreement with reported values.
7 
The enantiomeric excess was determined to be 96% ee by chiral HPLC analysis of the 
mesylated product 58. Crystals suitable for X-ray diffraction were obtained from an 
enantioenriched sample (92% ee) from iPrOH/hexanes, and allowed us to assign the 
absolute configuration of this product as R. The absolute configuration of all other indole-
pyrone adducts are assigned by analogy. Prior to sulfonylation, 58 is susceptible to 
decomposition by elimination, leading to deterioration in enantioenrichment, especially 
in protic solvents such as MeOH or iPrOH and in the presence of bases such as Cs2CO3. 
These products can be isolated in their pure form by column chromatography (eluent: 0-
8% MeOH/EtOAc, v/v) and stored in the refrigerator if desired. 
 
(R)-4-Oxo-2-((1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4H-pyran-3-yl 
methanesulfonate 58-Ms: Yellow oil. Rf = 0.13 (3% MeOH/CH2Cl2, v/v). IR (thin film) 
2939, 1656, 1583, 1366, 1245, 1189, 1140, 975, 867, 837, 793, 678 cm
–1
. 
1
H NMR (600 
MHz, CDCl3) δ 7.48 (d, J = 7.7 Hz, 1H), 7.32 (d, J = 7.4 Hz, 1H), 7.29 – 7.26 (m, 2H), 
7.15 (t, J = 7.4 Hz, 1H), 6.14 (d, J = 5.8 Hz, 1H), 3.49 (s, 3H), 3.45 (s, 2H), 3.00 – 2.93 
(m, 1H), 2.80 (ddd, J = 13.3, 5.7 Hz, 1H), 2.48 (dd, J = 13.7, 2.5 Hz, 1H), 2.30 – 2.23 (m, 
1H), 1.91 – 1.80 (m, 1H), 1.77 (d, J = 13.3 Hz, 1H), 1.46 (qt, J = 13.3, 4.3 Hz, 1H), 1.24 
(td, J = 13.7, 4.1 Hz, 1H). 
13
C{
1
H} NMR (126 MHz, CDCl3) δ 187.2, 172.2, 162.0, 
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154.5, 154.1, 142.2, 138.6, 128.5, 125.2, 122.3, 120.3, 117.3, 57.1, 40.9, 39.7, 32.9, 30.2, 
29.3, 21.5. MS (ESI) m/z calc’d for C19H20NO5S (M+H): 374.1057, found: 374.1068; m/z 
calc’d for C19H19NNaO5S (M+Na): 396.0876, found: 396.0880. The enantiomeric excess 
was determined to be 96% ee by chiral HPLC analysis (ChiralCel OD-H, 20% iPrOH in 
hexanes, 1 mL/min, 254 nm): tR (major) = 16.5 min, tR (minor) = 19.5 min. [α]D
24
 –7º (c 
= 0.84, CHCl3). 
 
(R)-4-Oxo-2-((1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4H-pyran-3-yl 4-
methylbenzenesulfonate 58-Ts: Orange oil. Rf = 0.091 (3% MeOH/CH2Cl2, v/v). IR 
(thin film) 2939, 1660, 1583, 1373, 1244, 1193, 1178, 1139, 1091, 861, 757, 683 cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 7.95 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 7.7 Hz, 1H), 7.35 (d, 
J = 8.2 Hz, 2H), 7.31 (d, J = 7.4 Hz, 1H), 7.26 – 7.22 (m, 2H), 7.11 (td, J = 7.4, 0.7 Hz, 
1H), 6.05 (d, J = 5.7 Hz, 1H), 3.53 (dd, J = 53.6, 15.0 Hz, 2H), 2.98 – 2.92 (m, 1H), 2.79 
(td, J = 13.3, 5.7 Hz, 1H), 2.48 (dd, J = 13.6, 2.4 Hz, 1H), 2.44 (s, 3H), 2.27 (ddd, J = 
7.9, 4.2, 2.1 Hz, 1H), 1.88 (ddt, J = 27.5, 13.7, 3.5 Hz, 1H), 1.80 – 1.74 (m, 1H), 1.51 – 
1.41 (m, 1H), 1.22 (td, J = 13.7, 4.0 Hz, 1H).
 13
C{
1
H} NMR (126 MHz, CDCl3) δ 187.4, 
171.5, 162.0, 154.5, 153.8, 145.9, 142.3, 138.2, 133.3, 129.7, 128.9, 128.4, 125.2, 122.2, 
120.3, 117.2, 57.1, 39.7, 33.0, 30.1, 29.3, 21.9, 21.5. MS (ESI) m/z calc’d for 
C25H24NO5S (M+H): 450.1370, found: 450.1383; m/z calc’d for C25H23NNaO5S (M+Na): 
472.1189, found: 472.1193. The enantiomeric excess was determined to be 92% ee by 
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chiral HPLC analysis (ChiralPak AD-H, 15% iPrOH in hexanes, 1 mL/min, 220 nm): tR 
(minor) = 16.2 min, tR (major) = 18.8 min. [α]D
24
 –39º (c = 1.09, CHCl3). 
 
(R)-2-((6-Fluoro-1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4-oxo-4H-pyran-3-
yl 4-methylbenzenesulfonate 92-Ts: Orange oil. Rf = 0.16 (3% MeOH/CH2Cl2, v/v). IR 
(thin film) 2940, 1658, 1597, 1463, 1372, 1242, 1178, 1147, 1091, 863, 814, 759, 682 
cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 7.95 (d, J = 8.3 Hz, 2H), 7.38 (dd, J = 8.5, 4.6 Hz, 
1H), 7.35 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 5.7 Hz, 1H), 7.06 (dd, J = 7.9, 2.5 Hz, 1H), 
6.94 (td, J = 8.8, 2.5 Hz, 1H), 6.09 (d, J = 5.7 Hz, 1H), 3.57 – 3.48 (m, 2H), 2.93 – 2.88 
(m, 1H), 2.78 (td, J = 13.3, 5.7 Hz, 1H), 2.48 – 2.45 (m, 1H), 2.44 (s, 3H), 2.29 – 2.23 
(m, 1H), 1.92 – 1.82 (m, 1H), 1.78 (d, J = 13.3 Hz, 1H), 1.50 – 1.40 (m, 1H), 1.23 (td, J = 
13.6, 4.1 Hz, 1H). 
13
C{
1
H} NMR (126 MHz, CDCl3) δ 187.2 (d, J = 3.5 Hz), 171.5, 
161.9, 161.4, 160.0, 153.8, 150.5, 145.9, 144.3 (d, J = 8.6 Hz), 138.3, 133.2, 129.3 (d, J = 
107.4 Hz), 120.9 (d, J = 8.8 Hz), 117.3, 115.1 (d, J = 23.6 Hz), 110.2 (d, J = 24.7 Hz), 
57.6, 39.5, 33.0, 30.1, 29.2, 21.9, 21.4. 
19
F NMR (471 MHz, CDCl3) δ –116.9 (m). MS 
(ESI) m/z calc’d for C25H23FNO5S (M+H): 468.1275, found: 468.1291; m/z calc’d for 
C25H22FNNaO5S (M+Na): 490.1095, found: 490.1097; m/z calc’d for C25H22FKNO5S 
(M+K): 506.0834, found: 506.0856. The enantiomeric excess was determined to be 92% 
ee by chiral HPLC analysis (ChiralCel OD-H, 25% iPrOH in hexanes, 1 mL/min, 220 
nm): tR (minor) = 17.4 min, tR (major) = 21.2 min. [α]D
24
 –29º (c = 1.21, CHCl3). 
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(R)-2-((6-Chloro-1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4-oxo-4H-pyran-3-
yl methanesulfonate 93-Ms: Yellow oil. Rf = 0.14 (3% MeOH/CH2Cl2, v/v). IR (thin 
film) 2940, 1657, 1582, 1451, 1367, 1245, 1188, 1140, 973, 865, 834, 680 cm
–1
. 
1
H NMR 
(600 MHz, CDCl3) δ 7.39 (d, J = 8.2 Hz, 1H), 7.32 (s, 1H), 7.31 (d, J = 3.6 Hz, 1H), 7.25 
(dd, J = 6.2, 2.0 Hz, 1H), 6.18 (d, J = 5.7 Hz, 1H), 3.51 (s, 3H), 3.43 (dd, J = 32.9, 14.9 
Hz, 2H), 2.96 – 2.91 (m, 1H), 2.79 (td, J = 13.4, 5.7 Hz, 1H), 2.45 (dd, J = 13.7, 2.3 Hz, 
1H), 2.30 – 2.24 (m, 1H), 1.90 – 1.75 (m, 2H), 1.45 (qt, J = 13.2, 4.3 Hz, 1H), 1.24 (td, J 
= 13.6, 4.2 Hz, 1H). 
13
C{
1
H} NMR (126 MHz, CDCl3) δ 187.7, 172.2, 161.3, 154.1, 
153.1, 144.0, 138.7, 131.1, 128.7, 123.1, 121.1, 117.4, 57.5, 40.9, 39.4, 32.8, 30.2, 29.2, 
21.4. MS (ESI) m/z calc’d for C19H19ClNO5S (M+H): 408.0667, found: 408.0686; m/z 
calc’d for C19H18ClNNaO5S (M+Na): 430.0486, found: 430.0494. The enantiomeric 
excess was determined to be 92% ee by chiral HPLC analysis (ChiralPak AD-H, 20% 
iPrOH in hexanes, 1 mL/min, 210 nm): tR (major) = 17.8 min, tR (minor) = 20.3 min. 
[α]D
24
 +55º (c = 0.90, CHCl3). 
 
(R)-2-((6-Bromo-1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4-oxo-4H-pyran-3-
yl methanesulfonate 94-Ms: Yellow oil. Rf = 0.18 (3% MeOH/CH2Cl2, v/v). IR (thin 
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film) 2939, 1656, 1581, 1448, 1366, 1245, 1189, 1140, 974, 863, 836, 792, 678 cm
–1
. 
1
H 
NMR (600 MHz, cdcl3) δ 7.47 (d, J = 1.7 Hz, 1H), 7.41 (dd, J = 8.2, 1.8 Hz, 1H), 7.33 
(dd, J = 13.9, 7.0 Hz, 2H), 6.19 (d, J = 5.7 Hz, 1H), 3.52 (s, 3H), 3.42 (q, J = 14.9 Hz, 
2H), 2.93 (d, J = 13.1 Hz, 1H), 2.78 (td, J = 13.4, 5.7 Hz, 1H), 2.45 (dd, J = 13.7, 2.1 Hz, 
1H), 2.30 – 2.23 (m, 1H), 1.89 – 1.75 (m, 2H), 1.50 – 1.40 (m, 1H), 1.24 (td, J = 13.6, 4.2 
Hz, 1H).
 13
C{
1
H} NMR (126 MHz, CDCl3) δ 187.7, 172.1, 161.2, 154.1, 153.5, 144.4, 
138.7, 131.6, 126.0, 121.6, 118.9, 117.4, 57.6, 40.9, 39.3, 32.9, 30.2, 29.2, 21.4. MS 
(ESI) m/z calc’d for C19H19BrNO5S (M+H): 452.0162, found: 452.0176; m/z calc’d for 
C19H18BrNNaO5S (M+Na): 473.9981, found: 473.9978. The enantiomeric excess was 
determined to be 92% ee by chiral HPLC analysis (ChiralPak AD-H, 20% iPrOH in 
hexanes, 1 mL/min, 210 nm): tR (major) = 20.1 min, tR (minor) = 22.7 min. [α]D
24
 +74º (c 
= 1.08, CHCl3). 
 
(R)-4-Oxo-2-((6-(trifluoromethoxy)-1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-
4H-pyran-3-yl methanesulfonate 95-Ms: Light yellow oil. Rf = 0.18 (3% 
MeOH/CH2Cl2, v/v). IR (thin film) 2941, 1658, 1585, 1463, 1416, 1368, 1331, 1258, 
1218, 1173, 975, 865, 838, 792, 678 cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 7.47 (d, J = 8.4 
Hz, 1H), 7.29 (d, J = 5.7 Hz, 1H), 7.22 (d, J = 1.2 Hz, 1H), 7.15 (dd, J = 8.4, 1.6 Hz, 1H), 
6.17 (d, J = 5.7 Hz, 1H), 3.50 (s, 3H), 3.43 (dd, J = 31.5, 14.7 Hz, 2H), 2.98 – 2.93 (m, 
1H), 2.83 (td, J = 13.4, 5.7 Hz, 1H), 2.48 (dd, J = 13.7, 2.4 Hz, 1H), 2.32 – 2.26 (m, 1H), 
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1.91 – 1.77 (m, 2H), 1.46 (qt, J = 13.2, 4.3 Hz, 1H), 1.28 (td, J = 13.6, 4.2 Hz, 1H). 
13
C{
1
H} NMR (126 MHz, CDCl3) δ 188.7, 172.1, 161.1, 154.1, 153.0, 146.8, 143.8, 
138.8, 121.7, 120.9, 120.7 (q, J = 256.8 Hz), 117.4, 116.2, 57.8, 40.8, 39.3, 33.0, 30.2, 
29.2, 21.4. 
19
F NMR (471 MHz, CDCl3) δ –58.0. MS (ESI) m/z calc’d for C20H19F3NO6S 
(M+H): 458.0880, found: 458.0899; m/z calc’d for C20H18F3NO6S (M+Na): 480.0699, 
found: 480.0709; m/z calc’d for C20H18F3KNO6S (M+K): 496.0439, found: 496.0457. 
The enantiomeric excess was determined to be 91% ee by chiral HPLC analysis 
(ChiralPak AD-H, 20% iPrOH in hexanes, 1 mL/min, 254 nm): tR (minor) = 11.7 min, tR 
(major) = 13.6 min. [α]D
24
 +14º (c = 0.91, CHCl3). 
 
(R)-2-((6-Cyano-1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4-oxo-4H-pyran-3-
yl methanesulfonate 99-Ms: Light yellow oil. Rf = 0.11 (3% MeOH/CH2Cl2, v/v). IR 
(thin film) 2937, 2227, 1658, 1578, 1463, 1367, 1245, 1181, 1146, 976, 865, 843, 792, 
678, 617 cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 7.67 – 7.66 (m, 1H), 7.63 (dd, J = 8.0, 1.6 
Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.32 (d, J = 5.7 Hz, 1H), 6.20 (d, J = 5.7 Hz, 1H), 3.53 
(s, J = 5.1 Hz, 3H), 3.49 (q, J = 15.0 Hz, 2H), 3.03 – 2.99 (m, 1H), 2.87 (td, J = 13.4, 5.9 
Hz, 1H), 2.55 – 2.51 (m, 1H), 2.36 – 2.31 (m, 1H), 1.93 – 1.80 (m, 2H), 1.53 – 1.44 (m, 
1H), 1.29 – 1.22 (m, 1H). 13C{1H} NMR (126 MHz, CDCl3) δ 191.8, 172.0, 160.8, 158.1, 
154.1, 143.3, 138.8, 133.6, 126.4, 121.2, 119.2, 117.6, 108.7, 57.7, 41.0, 39.5, 32.8, 30.5, 
29.3, 21.3. MS (ESI) m/z calc’d for C20H19N2O5S (M+H): 399.1009, found: 399.1022; 
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m/z calc’d for C20H18N2NaO5S (M+Na): 421.0829, found: 421.0836. The enantiomeric 
excess was determined to be 86% ee by chiral HPLC analysis (ChiralPak AD-H, 30% 
iPrOH in hexanes, 1 mL/min, 210 nm): tR (major) = 16.5 min, tR (minor) = 19.4 min. 
[α]D
24
 +23º (c = 0.74, CHCl3).  
 
(R)-2-((6-Methyl-1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4-oxo-4H-pyran-3-
yl methanesulfonate 96-Ms: Yellow oil. Rf = 0.17 (3% MeOH/CH2Cl2, v/v). IR (thin 
film) 2940, 1658, 1584, 1368, 1245, 1182, 1146, 974, 865, 826, 793, 678 cm
–1
. 
1
H NMR 
(600 MHz, CDCl3) δ 7.36 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 5.7 Hz, 1H), 7.14 (s, 1H), 7.07 
(d, J = 7.8 Hz, 1H), 6.16 (d, J = 5.7 Hz, 1H), 3.50 (s, 3H), 3.48 – 3.41 (m, 2H), 2.98 – 
2.92 (m, 1H), 2.77 (td, J = 13.3, 5.7 Hz, 1H), 2.47 – 2.42 (m, 1H), 2.36 (s, 3H), 2.28 – 
2.23 (m, 1H), 1.89 – 1.80 (m, 1H), 1.79 – 1.74 (m, 1H), 1.51 – 1.42 (m, 1H), 1.24 (td, J = 
13.6, 4.1 Hz, 1H).
 13
C{
1
H} NMR (126 MHz, CDCl3) δ 186.2, 172.3, 162.1, 154.2, 152.3, 
142.3, 138.7, 135.0, 129.1, 123.2, 119.8, 117.3, 56.8, 40.9, 39.7, 32.9, 30.2, 29.3, 21.6, 
21.5. MS (ESI) m/z calc’d for C20H22NO5S (M+H): 388.1213, found: 388.1231; m/z 
calc’d for C20H21NNaO5S (M+Na): 410.1033, found: 410.1038. The enantiomeric excess 
was determined to be 91% ee by chiral HPLC analysis (ChiralPak AD-H, 20% iPrOH in 
hexanes, 1 mL/min, 230 nm): tR (minor) = 13.4 min, tR (major) = 15.2 min. [α]D
24
 +22º (c 
= 0.51, CHCl3). 
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(R)-2-((6-Isopropyl-1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4-oxo-4H-pyran-
3-yl methanesulfonate 97-Ms: Orange oil. Rf = 0.16 (3% MeOH/CH2Cl2). IR (thin film) 
2958, 1658, 1584, 1368, 1245, 1184, 1141, 974, 865, 835, 793, 679 cm
–1
. 
1
H NMR (600 
MHz, CDCl3) δ 7.36 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 5.7 Hz, 1H), 7.19 (d, J = 1.6 Hz, 
1H), 7.11 (dd, J = 7.9, 1.7 Hz, 1H), 6.13 (d, J = 5.7 Hz, 1H), 3.47 (s, J = 14.7 Hz, 3H), 
3.47 – 3.36 (m, 2H), 2.96 – 2.92 (m, 1H), 2.91 (quintet, J = 6.9 Hz, 1H), 2.78 (td, J = 
13.4, 5.7 Hz, 1H), 2.49 – 2.44 (m, 1H), 2.28 – 2.22 (m, 1H), 1.84 (ddt, J = 27.3, 13.5, 3.5 
Hz, 1H), 1.79 – 1.74 (m, 1H), 1.50 – 1.41 (m, 1H), 1.30 – 1.24 (m, 1H), 1.22 
(overlapping d, J = 6.7, 6.2 Hz, 6H). 
13
C{
1
H} NMR (126 MHz, CDCl3) δ 186.4, 172.2, 
162.1, 154.1, 152.5, 146.1, 142.1, 138.6, 126.7, 120.4, 119.8, 117.2, 57.0, 40.9, 39.5, 
34.2, 33.1, 30.1, 29.2, 24.5, 24.0, 21.5. MS (ESI) m/z calc’d for C22H26NO5S (M+H): 
416.1526, found: 416.1546; m/z calc’d for C22H25NNaO5S (M+Na): 438.1346, found: 
438.1348. The enantiomeric excess was determined to be 90% ee by chiral HPLC 
analysis (ChiralPak AD-H, 20% iPrOH in hexanes, 1 mL/min, 210 nm): tR (minor) = 10.4 
min, tR (major) = 15.0 min. [α]D
24
 +22º (c = 0.80, CHCl3). 
(R)-2-((6-(tert-Butyl)-1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-
4-oxo-4H-pyran-3-yl methanesulfonate 98-Ms: Yellow oil. Rf = 0.16 (3% 
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MeOH/CH2Cl2, v/v). IR (thin film) 2954, 1658, 1584, 1367, 1245, 1191, 1178, 1140, 
973, 866, 834, 793, 682 cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 7.37 – 7.35 (m, 2H), 7.30 
(d, J = 5.7 Hz, 1H), 7.28 (dd, J = 8.1, 2.0 Hz, 1H), 6.13 (d, J = 5.7 Hz, 1H), 3.47 (s, J = 
13.9 Hz, 3H), 3.50 – 3.35 (m, 2H), 2.96 – 2.91 (m, 1H), 2.78 (td, J = 13.4, 5.7 Hz, 1H), 
2.48 (dd, J = 13.7, 2.4 Hz, 1H), 2.28 – 2.22 (m, 1H), 1.88 – 1.74 (m, 2H), 1.50 – 1.41 (m, 
1H), 1.30 (s, J = 12.3 Hz, 9H), 1.29 – 1.22 (m, 1H). 13C{1H} NMR (126 MHz, CDCl3) δ 
186.6, 172.2, 162.2, 154.1, 152.1, 148.3, 141.7, 138.6, 125.3, 119.6, 119.4, 117.2, 57.2, 
40.9, 39.5, 34.9, 33.2, 31.7, 30.1, 29.2, 21.5. MS (ESI) m/z calc’d for C23H28NO5S 
(M+H): 430.1683, found: 430.1695; m/z calc’d for C23H27NNaO5S (M+Na): 452.1502, 
found: 452.1502. The enantiomeric excess was determined to be 84% ee by chiral HPLC 
analysis (ChiralPak AD-H, 15% iPrOH in hexanes, 1 mL/min, 254 nm): tR (minor) = 13.6 
min, tR (major) = 17.9 min. [α]D
24
 +16º (c = 0.99, CHCl3). 
 
(R)-2-((6-Methoxy-1,2,3,4-tetrahydro-4aH-carbazol-4a-yl)methyl)-4-oxo-4H-pyran-
3-yl methanesulfonate 100-Ms: Yellow oil. Rf = 0.16 (3% MeOH/CH2Cl2, v/v). IR (thin 
film) 2939, 1656, 1586, 1473, 1366, 1244, 1180, 1148, 1030, 976, 866, 841, 794, 678 
cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 7.37 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 5.7 Hz, 1H), 
6.90 (d, J = 2.5 Hz, 1H), 6.81 (dd, J = 8.4, 2.5 Hz, 1H), 6.18 (d, J = 5.7 Hz, 1H), 3.81 (s, 
3H), 3.50 (s, J = 7.6 Hz, 3H), 3.44 (s, 2H), 2.95 – 2.90 (m, 1H), 2.76 (td, J = 13.3, 5.6 Hz, 
1H), 2.46 – 2.42 (m, 1H), 2.28 – 2.22 (m, 1H), 1.89 – 1.75 (m, 2H), 1.51 – 1.42 (m, 1H), 
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1.25 (td, J = 13.5, 4.2 Hz, 1H).
 13
C{
1
H} NMR (126 MHz, CDCl3) δ 185.0, 172.3, 162.1, 
157.9, 154.2, 148.1, 143.8, 138.7, 120.6, 117.4, 113.9, 108.5, 57.2, 55.8, 41.0, 39.8, 33.0, 
30.1, 29.3, 21.6. MS (ESI) m/z calc’d for C20H22NO6S (M+H): 404.1162, found: 
404.1178; m/z calc’d for C20H21NNaO6S (M+Na): 426.0982, found: 426.0988. The 
enantiomeric excess was determined to be 91% ee by chiral HPLC analysis (ChiralPak 
AD-H, 10% iPrOH in hexanes, 1 mL/min, 254 nm): tR (minor) = 51.6 min, tR (major) = 
56.4 min. [α]D
24
 +38º (c = 0.74, CHCl3). 
 
(R)-2-((2,3-Dimethyl-3H-indol-3-yl)methyl)-4-oxo-4H-pyran-3-yl methanesulfonate 
101-Ms: Orange oil. Rf = 0.091 (3% MeOH/CH2Cl2, v/v). IR (thin film) 2931, 1656, 
1581, 1416, 1365, 1246, 1191, 1177, 1143, 974, 865, 836, 794, 683 cm
–1
. 
1
H NMR (600 
MHz, CDCl3) δ 7.43 (d, J = 7.7 Hz, 1H), 7.33 – 7.29 (m, 1H), 7.27 (t, J = 7.5 Hz, 1H), 
7.17 (t, J = 7.4 Hz, 1H), 6.18 (d, J = 5.7 Hz, 1H), 3.50 (s, J = 16.8 Hz, 3H), 3.52 – 3.14 
(m, 2H), 2.39 (s, 3H), 1.42 (s, 3H).
 13
C{
1
H} NMR (126 MHz, CDCl3) δ 185.1, 172.3, 
161.5, 154.2, 153.9, 141.2, 138.7, 128.6, 125.6, 122.3, 120.1, 117.4, 56.8, 40.9, 35.1, 
23.4, 15.9. MS (ESI) m/z calc’d for C17H18NO5S (M+H): 348.0900, found: 348.0915; m/z 
calc’d for C17H17NNaO5S (M+Na): 370.0720, found: 370.0726. The enantiomeric excess 
was determined to be 92% ee by chiral HPLC analysis (ChiralCel OD-H, 15% iPrOH in 
hexanes, 1 mL/min, 230 nm): tR (major) = 21.7 min, tR (minor) = 24.7 min. [α]D
22
 +39º (c 
= 0.99, CHCl3). 
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(R)-2-((3-Methyl-2-phenyl-3H-indol-3-yl)methyl)-4-oxo-4H-pyran-3-yl 4-
methylbenzenesulfonate 102-Ts: Orange oil. Rf = 0.17 (3% MeOH/CH2Cl2, v/v). IR 
(thin film) 2937, 1661, 1524, 1375, 1244, 1194, 1179, 1150, 1092, 861, 755, 694 cm
–1
. 
1
H NMR (600 MHz, CDCl3) δ 8.15 (dd, J = 6.4, 2.8 Hz, 2H), 7.92 (d, J = 8.2 Hz, 2H), 
7.59 (d, J = 7.7 Hz, 1H), 7.53 – 7.49 (m, 3H), 7.35 (t, J = 7.1 Hz, 3H), 7.31 (t, J = 7.6 Hz, 
1H), 7.21 (t, J = 7.4 Hz, 1H), 7.13 (d, J = 5.7 Hz, 1H), 6.04 (d, J = 5.7 Hz, 1H), 3.88 (d, J 
= 15.4 Hz, 1H), 3.62 (d, J = 15.4 Hz, 1H), 2.45 (s, 3H), 1.75 (s, 3H). 
13
C{
1
H} NMR (126 
MHz, CDCl3) δ 180.9, 171.6, 161.7, 153.7, 153.3, 145.8, 143.3, 138.2, 133.3, 133.2, 
131.0, 129.7, 129.0, 128.9, 128.7, 128.3, 126.3, 121.8, 121.1, 117.3, 110.1, 56.5, 36.7, 
25.3, 21.9. MS (ESI) m/z calc’d for C28H24NO5S (M+H): 486.1370, found: 486.1382; m/z 
calc’d for C28H23NNaO5S (M+Na): 508.1189, found: 508.1192; m/z calc’d for 
C28H23KNO5S (M+K): 524.0929, found: 524.0952. The enantiomeric excess was 
determined to be 93% ee by chiral HPLC analysis (ChiralPak AD-H, 15% iPrOH in 
hexanes, 1 mL/min): tR (minor) = 16.7 min, tR (major) = 21.1 min. [α]D
23
 –9º (c = 0.61, 
CHCl3).  
(R)-2-((3-Ethyl-2-phenyl-3H-indol-3-yl)methyl)-4-oxo-4H-pyran-3-yl 
methanesulfonate 103-Ms: Light yellow oil. Rf = 0.22 (3% MeOH/CH2Cl2, v/v). IR 
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(thin film) 2930, 1656, 1525, 1369, 1330, 1248, 1184, 1146, 973, 865, 834, 794, 649 cm
–
1
. 
1
H NMR (600 MHz, CDCl3) δ 8.13 – 8.09 (m, 2H), 7.59 (d, J = 7.6 Hz, 1H), 7.52 – 
7.49 (m, 3H), 7.36 – 7.30 (m, 2H), 7.24 (td, J = 7.6, 1.0 Hz, 1H), 7.16 (d, J = 5.7 Hz, 1H), 
6.11 (d, J = 5.7 Hz, 1H), 3.76 (d, J = 15.2 Hz, 1H), 3.53 (d, J = 15.2 Hz, 1H), 3.44 (s, J = 
5.2 Hz, 3H), 2.51 – 2.42 (m, 1H), 2.25 (dq, J = 14.7, 7.4 Hz, 1H), 0.38 (t, J = 7.4 Hz, 
3H). 
13
C{
1
H} NMR (126 MHz, CDCl3) δ 179.6, 172.3, 161.7, 154.3, 154.0, 141.1, 138.5, 
133.6, 131.0, 129.0, 128.8, 128.0, 126.3, 121.9, 120.8, 117.2, 61.6, 40.8, 36.3, 32.0, 8.0. 
MS (ESI) m/z calc’d for C23H22NO5S (M+H): 424.1213, found: 424.1232; m/z calc’d for 
C23H21NNaO5S (M+Na): 446.1033, found: 446.1042; m/z calc’d for C23H21KNO5S 
(M+K): 462.0772, found: 462.0779. The enantiomeric excess was determined to be 88% 
ee by chiral HPLC analysis (ChiralCel OD-H, 15% iPrOH in hexanes, 1 mL/min, 254 
nm): tR (major) = 20.7 min, tR (minor) = 23.5 min. [α]D
24
 –5º (c = 0.81, CHCl3). 
 
(S)-2-(Chromeno[4,3-b]indol-6a(6H)-ylmethyl)-4-oxo-4H-pyran-3-yl 
methanesulfonate 104-Ms: Thick pale yellow oil. Rf = 0.22 (3% MeOH/CH2Cl2, v/v). 
IR (thin film) 2928, 1654, 1468, 1454, 1365, 1243, 1187, 1148, 1129, 754, 731 cm
–1
. 
1
H 
NMR (600 MHz, CDCl3) δ 7.98 (dd, J = 7.7, 1.6 Hz, 1H), 7.60 (dd, J = 7.1, 1.3 Hz, 1H), 
7.44 (ddd, J = 8.7, 7.3, 1.7 Hz, 1H), 7.41 – 7.37 (m, 2H), 7.33 (d, J = 5.7 Hz, 1H), 7.24 – 
7.21 (m, 1H), 7.14 – 7.11 (m, 1H), 7.05 (dd, J = 8.4, 0.6 Hz, 1H), 6.18 (d, J = 5.7 Hz, 
1H), 4.80 (d, J = 11.3 Hz, 1H), 4.00 (d, J = 11.3 Hz, 1H), 3.52 (dd, J = 54.9, 14.8 Hz, 
148 
 
2H), 3.40 (s, 3H). 
13
C{
1
H} NMR (126 MHz, CDCl3) δ 175.8, 172.2, 161.2, 156.56, 
156.53, 154.1, 139.2, 135.3, 133.8, 130.0, 126.01, 125.95, 123.7, 122.4, 121.0, 118.0, 
117.5, 117.4, 73.7, 53.5, 40.7, 32.3. MS (ESI) m/z calc’d for C22H18NO6S (M+H): 
424.0849, found: 424.0868; m/z calc’d for C22H17NNaO6S (M+Na): 446.0669, found: 
446.0679; m/z calc’d for C22H17KNO6S (M+K): 462.0408, found: 462.0404. The 
enantiomeric excess was determined to be 96% ee by chiral HPLC analysis (ChiralPak 
AD-H, 20% iPrOH in hexanes, 1 mL/min, 254 nm): tR (major) = 24.8 min, tR (minor) = 
21.4 min. [α]D
24
 –215º (c = 0.91, CHCl3). 
3-Hydroxy-2-(1-(1,2,3,4-tetrahydro-9H-carbazol-9-yl)ethyl)-4H-pyran-4-
one 116: Red solid; Rf = 0.57 (CH2Cl2/MeOH 95:5); m.p. 58-62 
o
C; IR νmax 3246, 2931, 
2840, 1622, 1461, 1266, 1196, 831, 738 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 7.81 (d, 
J=6.2 Hz, 1H), 7.49 (d, J=8.0 Hz, 1H), 7.47 (d, J=8.0 Hz, 1H), 7.10 (o, 2H), 6.79 (br. s, 
N-H), 6.44 (d, J=6.2 Hz, 1H), 5.88 (q, J=7.1 Hz, 1H), 2.96 (m, 1H), 2.77 (m, 1H), 2.73 (o, 
2H), 1.98 (o, 2H), 1.95 (d, J=7.1 Hz, 3H), 1.87 (o, 2H);
 13
C NMR (125 MHz, CDCl3) δ 
173.4, 154.6, 148.2, 142.6, 135.4, 135.2, 128.2, 120.8, 119.0, 117.9, 112.9, 110.3, 110.3, 
47.7, 23.5, 22.9, 22.8, 21.1, 16.7; HR-MS: m/z Calcd. for C19H20NO3 [M+H
+
]: 310.1443, 
Found 310.1470 (+2.7 ppm). 
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(±)-(5aR,10bR)-6-Methyl-6H-5a,10b-butanopyrano[2',3':5,6]pyrano[2,3-b]indol-
4(11H)-one 52: The indole-pyrone adduct was isolated prior to sulfonylation by column 
chromatography (eluent: 0-8% MeOH/EtOAc). 
1
H NMR (400 MHz, CDCl3) δ 7.52 (d, J 
= 5.8 Hz, 1H), 7.13 (ddd, J = 7.6, 7.6, 0.8 Hz, 1H), 7.00 (dd, J = 7.2, 0.8 Hz, 1H), 6.76 
(dd, J = 7.6, 7.2 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 6.24 (d, J = 5.8 Hz, 1H), 2.98 (m, 2H), 
2.94 (s, 3H), 2.23 (ddd, J = 6.0, 4.3, 2.3 Hz, 1H), 1.73 (m, 3H), 1.53 (m, 4H). 
13
C{
1
H} 
NMR (100 MHz, CDCl3) δ 172.1, 152.6, 149.1, 147.9, 142.3, 134.3, 128.3, 120.1, 119.0, 
115.9, 108.7, 101.8, 45.9, 37.5, 28.6, 27.8, 27.5, 22.9, 21.3. All spectral data were in 
agreement with reported values.
7 
The enantiomeric excess was determined to be <5% ee 
by chiral HPLC analysis (ChiralPak IB, 20% MeOH in iPrOH, 1 mL/min, 254 nm): t1 = 
12.6 min, t2 = 14.5 min. 
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Chiral HPLC Analyses 
58-Ms (96% ee, ChiralCel OD-H, 20% iPrOH in hexanes, 1 mL/min) 
 
 
 
 
 
 
 
58-Ts (92% ee, ChiralPak AD-H, 15% iPrOH in hexanes, 1 mL/min) 
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92-Ts (92% ee, ChiralCel OD-H, 25% iPrOH in hexanes, 1 mL/min) 
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93-Ms (92% ee, ChiralPak AD-H, 20% iPrOH in hexanes, 1 mL/min) 
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94-Ms (92% ee, ChiralPak AD-H, 20% iPrOH in hexanes, 1 mL/min) 
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95-Ms (91% ee, ChiralPak AD-H, 20% iPrOH in hexanes, 1 mL/min) 
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96-Ms (86% ee, ChiralPak AD-H, 30% iPrOH in hexanes, 1 mL/min) 
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97-Ms (91% ee, ChiralPak AD-H, 20% iPrOH in hexanes, 1 mL/min) 
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98-Ms (90% ee, ChiralPak AD-H, 20% iPrOH in hexanes, 1 mL/min) 
 
 
 
 
 
 
 
 
 
 
99-Ms (84% ee, ChiralPak AD-H, 15% iPrOH in hexanes, 1 mL/min) 
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100-Ms (91% ee, ChiralPak AD-H, 10% iPrOH in hexanes, 1 mL/min) 
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101-Ms (92% ee, ChiralCel OD-H, 15% iPrOH in hexanes, 1 mL/min) 
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102-Ts (93% ee, ChiralPak AD-H, 15% iPrOH in hexanes, 1 mL/min) 
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103-Ms (88% ee, ChiralCel OD-H, 15% iPrOH in hexanes, 1 mL/min) 
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104-Ms (96% ee, ChiralPak AD-H, 20% iPrOH in hexanes, 1 mL/min) 
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X-Ray crystallographic data for (R)-58  
 
A crystal mounted on a diffractometer was collected data at 100 K. The intensities of the 
reflections were collected by means of a Bruker APEX II DUO CCD diffractometer 
(CuK radiation, =1.54178 Å), and equipped with an Oxford Cryosystems nitrogen flow 
apparatus. The collection method involved 1.0 scans in  at 30, 55, 80 and 115 in 
2. Data integration down to 0.84 Å resolution was carried out using SAINT V7.46 A 
with reflection spot size optimisation. Absorption corrections were made with the 
program SADABS. The structure was solved by the direct methods procedure and refined 
by least-squares methods again F
2
 using SHELXS-97 and SHELXL-97. Non-hydrogen 
atoms were refined anisotropically, and hydrogen atoms were allowed to ride on the 
respective atoms. Crystal data as well as details of data collection and refinement are 
summarized in Table S1, geometric parameters are shown in Table S2 and hydrogen-
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bond parameters are listed in Table S3. The Ortep plots produced with SHELXL-97 
program, and the other drawings were produced with Accelrys DS Visualizer 2.0. 
 
Table S1. Experimental details 
Crystal data 
Chemical formula C18H17NO3 
Mr 295.33 
Crystal system, space group Orthorhombic, P212121 
Temperature (K) 100 
a, b, c (Å) 7.2422 (1), 9.7575 (1), 20.2541 (3) 
V (Å
3
) 1431.27 (3) 
Z 4 
Radiation type Cu K 
 (mm-1) 0.76 
Crystal size (mm) 0.20 × 0.18 × 0.14 
Data collection 
Diffractometer Bruker D8 goniometer with CCD area detector diffractometer 
Absorption correction Multi-scan  
SADABS 
 Tmin, Tmax 0.863, 0.901 
No. of measured, independent and 
observed [I > 2(I)] reflections 
34017, 2501, 2444   
Rint 0.035 
(sin /)max (Å
-1
) 0.594 
Refinement 
R[F
2
 > 2(F2)], wR(F2), S 0.023,  0.054,  1.06 
No. of reflections 2501 
No. of parameters 203 
No. of restraints 0 
H-atom treatment H atoms treated by a mixture of independent and constrained 
refinement 
max, min (e Å
-3
) 0.14, -0.14 
Absolute structure Flack H D (1983), Acta Cryst. A39, 876-881 
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Flack parameter 0.09 (15) 
 
Computer programs: APEX2 v2009.3.0, SAINT 7.46A, SHELXS97, SHELXL97, Bruker 
SHELXTL.
 
Table S2. Geometric parameters (Å, º) 
C1—C2 1.3365 (19) C10—C11 1.3889 (19) 
C1—O1 1.3447 (16) C10—H10 0.9500 
C1—H1 0.9500 C11—C12 1.3911 (18) 
C2—C3 1.4461 (17) C11—H11 0.9500 
C2—H2 0.9500 C12—C13 1.3798 (18) 
C3—O2 1.2375 (15) C12—H12 0.9500 
C3—C4 1.4598 (17) C13—N1 1.4288 (15) 
C4—O3 1.3491 (15) C14—N1 1.2872 (15) 
C4—C5 1.3546 (18) C14—C15 1.4841 (17) 
C5—O1 1.3763 (14) C15—C16 1.5396 (17) 
C5—C6 1.4933 (17) C15—H15A 0.9900 
C6—C7 1.5611 (16) C15—H15B 0.9900 
C6—H6A 0.9900 C16—C17 1.5251 (18) 
C6—H6B 0.9900 C16—H16A 0.9900 
C7—C8 1.5098 (17) C16—H16B 0.9900 
C7—C14 1.5281 (16) C17—C18 1.5295 (18) 
C7—C18 1.5528 (17) C17—H17A 0.9900 
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C8—C9 1.3875 (17) C17—H17B 0.9900 
C8—C13 1.3958 (17) C18—H18A 0.9900 
C9—C10 1.3942 (18) C18—H18B 0.9900 
C9—H9 0.9500 O3—H3 0.911 (19) 
 
C2—C1—O1 123.58 (11) C12—C11—H11 119.8 
C2—C1—H1 118.2 C13—C12—C11 117.68 (12) 
O1—C1—H1 118.2 C13—C12—H12 121.2 
C1—C2—C3 120.96 (12) C11—C12—H12 121.2 
C1—C2—H2 119.5 C12—C13—C8 122.52 (11) 
C3—C2—H2 119.5 C12—C13—N1 125.74 (11) 
O2—C3—C2 124.79 (12) C8—C13—N1 111.67 (10) 
O2—C3—C4 121.28 (11) N1—C14—C15 124.76 (11) 
C2—C3—C4 113.92 (11) N1—C14—C7 114.80 (10) 
O3—C4—C5 119.45 (11) C15—C14—C7 119.73 (10) 
O3—C4—C3 119.31 (11) C14—C15—C16 108.53 (10) 
C5—C4—C3 121.23 (11) C14—C15—H15A 110.0 
C4—C5—O1 121.27 (11) C16—C15—H15A 110.0 
C4—C5—C6 127.02 (11) C14—C15—H15B 110.0 
O1—C5—C6 111.63 (11) C16—C15—H15B 110.0 
C5—C6—C7 115.77 (10) H15A—C15— 108.4 
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H15B 
C5—C6—H6A 108.3 C17—C16—C15 111.34 (10) 
C7—C6—H6A 108.3 C17—C16—H16A 109.4 
C5—C6—H6B 108.3 C15—C16—H16A 109.4 
C7—C6—H6B 108.3 C17—C16—H16B 109.4 
H6A—C6—H6B 107.4 C15—C16—H16B 109.4 
C8—C7—C14 99.42 (9) H16A—C16—
H16B 
108.0 
C8—C7—C18 114.07 (10) C16—C17—C18 111.38 (10) 
C14—C7—C18 106.93 (10) C16—C17—H17A 109.4 
C8—C7—C6 114.16 (10) C18—C17—H17A 109.4 
C14—C7—C6 112.95 (9) C16—C17—H17B 109.4 
C18—C7—C6 108.88 (10) C18—C17—H17B 109.4 
C9—C8—C13 119.61 (11) H17A—C17—
H17B 
108.0 
C9—C8—C7 133.07 (11) C17—C18—C7 112.62 (10) 
C13—C8—C7 107.30 (10) C17—C18—H18A 109.1 
C8—C9—C10 118.21 (12) C7—C18—H18A 109.1 
C8—C9—H9 120.9 C17—C18—H18B 109.1 
C10—C9—H9 120.9 C7—C18—H18B 109.1 
C11—C10—C9 121.54 (12) H18A—C18— 107.8 
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H18B 
C11—C10—H10 119.2 C1—O1—C5 119.03 (10) 
C9—C10—H10 119.2 C4—O3—H3 112.9 (11) 
C10—C11—C12 120.45 (12) C14—N1—C13 106.79 (10) 
C10—C11—H11 119.8   
 
O1—C1—C2—C3 0.30 (19) C11—C12—C13—
C8 
-0.15 (18) 
C1—C2—C3—O2 178.35 (12) C11—C12—C13—
N1 
-176.68 (11) 
C1—C2—C3—C4 -0.77 (16) C9—C8—C13—
C12 
0.03 (18) 
O2—C3—C4—O3 0.60 (17) C7—C8—C13—
C12 
-178.40 (11) 
C2—C3—C4—O3 179.76 (10) C9—C8—C13—N1 177.00 (11) 
O2—C3—C4—C5 -178.48 (11) C7—C8—C13—N1 -1.42 (13) 
C2—C3—C4—C5 0.67 (16) C8—C7—C14—N1 -0.16 (13) 
O3—C4—C5—O1 -179.19 (10) C18—C7—C14—
N1 
-119.02 (11) 
C3—C4—C5—O1 -0.11 (17) C6—C7—C14—N1 121.22 (11) 
O3—C4—C5—C6 -2.62 (18) C8—C7—C14— 170.61 (10) 
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C15 
C3—C4—C5—C6 176.46 (11) C18—C7—C14—
C15 
51.75 (14) 
C4—C5—C6—C7 91.91 (15) C6—C7—C14—
C15 
-68.00 (14) 
O1—C5—C6—C7 -91.24 (12) N1—C14—C15—
C16 
116.20 (13) 
C5—C6—C7—C8 38.10 (14) C7—C14—C15—
C16 
-53.59 (14) 
C5—C6—C7—C14 -74.52 (13) C14—C15—C16—
C17 
53.25 (13) 
C5—C6—C7—C18 166.85 (11) C15—C16—C17—
C18 
-57.51 (14) 
C14—C7—C8—C9 -177.20 (13) C16—C17—C18—
C7 
57.00 (14) 
C18—C7—C8—C9 -63.77 (17) C8—C7—C18—
C17 
-159.33 (10) 
C6—C7—C8—C9 62.30 (17) C14—C7—C18—
C17 
-50.46 (13) 
C14—C7—C8—
C13 
0.93 (12) C6—C7—C18—
C17 
71.88 (12) 
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C18—C7—C8—
C13 
114.35 (11) C2—C1—O1—C5 0.33 (17) 
C6—C7—C8—C13 -119.57 (11) C4—C5—O1—C1 -0.42 (16) 
C13—C8—C9—
C10 
-0.03 (17) C6—C5—O1—C1 -177.47 (10) 
C7—C8—C9—C10 177.91 (12) C15—C14—N1—
C13 
-170.90 (11) 
C8—C9—C10—
C11 
0.15 (18) C7—C14—N1—
C13 
-0.66 (13) 
C9—C10—C11—
C12 
-0.28 (19) C12—C13—N1—
C14 
178.18 (12) 
C10—C11—C12—
C13 
0.26 (18) C8—C13—N1—
C14 
1.32 (13) 
  
Table S3. Hydrogen-bond parameters 
D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (°) 
O3—H3···N1i 0.911 (19) 1.916 (19) 2.7670 (13) 154.8 (16) 
 
Symmetry code(s):  (i) -x+1, y+1/2, -z+1/2. 
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  Figure S1. Perspective views showing 50% probability displacement. 
 
Figure S2. Three-dimensional supramolecular architecture viewed along the b-axis 
direction. 
 
 
c 
a 
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Analysis of the absolute structure using likelihood methods was performed using 
PLATON. The results indicated that the absolute structure had been correctly assigned. 
The method calculated that the probability that the structure is inverted is 0.2E-23. 
 
 
Figure S3. Bijvoet-pair scatter plot. 
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2.8 Select Spectra 
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Chapter 3 
 
Vinylallene-derived Natural Products 
 
3.1 Chloropupukeananin and Related Molecules 
 In 2008, Che and coworkers isolated the natural product chloropupukeananin (1) 
from Pestalotiopsis fici (Figure 3.1).
70
 The compound features the trademark 
pupukeanane skeleton
71
 with a tricyclo-[4.3.1.0
3,7
]-decane core as well as a chlorine at 
the bridgehead position.  The investigators also co-isolated the vinylallene natural 
product iso-A82775C (8), an isomer of the known compound A82775C (11),
72
 and  
Figure 3.1 Natural Products Isolated from Pestalotiopsis fici 
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pestheic acid (9).
73
 A year later, the same group isolated chloropestolide A (5) from the 
same plant fungus.
74
 Chloropestolide A features a highly functionalized spiroketal with a 
unique bicyclo-[2.2.2]-oct-2-en-5-one ring system. Both chloropupukeananin (1) and 
chloropestolide A (5) were unambiguously assigned by X-ray analysis. The chlorine atom 
also allowed for determination of the absolute configuration. In subsequent years,
75
 there 
have been a number of natural products isolated from Pestalotiopsis fici, including the 
interesting endoperoxide chloropupukeanolide A (2).  
Initially, Che and coworkers assigned iso-A82775C as structure 10 based on 
correlation to the known natural product A82775C (11) as well as lack of NOEs observed 
as shown in model A (Figure 3.2). However, analysis of the X-ray structure of 
chloropestolide A (5) shows that the hydrogen on the allene moiety resides in the β-
position, syn to the epoxide moiety.
5
 We have been in correspondence with Professor Che 
over this discrepancy and received a small amount of natural iso-A82775C. Although we 
Figure 3.2 Assignment of iso-A82775C (8) 
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were not able to observe the NOE shown in the model B (Figure 3.2) even after 
deuterium exchange of the hydroxy, Che and coworkers have subsequently changed their 
assignment to structure 8.
74c
 The absolute configuration of iso-A82775C (8) was assigned 
by analogy to the epoxy cyclohexane found in chloropupukeananin (1).
1
 A total synthesis 
of iso-A82775C (8) will be required to fully confirm stereochemistry and structure of this 
interesting vinylallene natural product. 
3.2 Biosynthesis of iso-A82775C 
 Epoxyquinol biosynthesis is believed to proceed as shown in Scheme 3.1.
76
 It 
follows a polyketide pathway wherein four units of acetyl-CoA 12 and malonyl-CoA 13 
condense to form the cyclohexane 15 through an aldol reaction after decarboxylation.  
Scheme 3.1 Proposed Biosynthesis of Epoxyquinol Natural Products 
 
Aromatization through loss of water followed by oxidations would establish the epoxy 
ketone 17. Then, release of the acyl carrier protein would give the product 18. Feeding 
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studies have shown the biosynthesis of compounds such as 18 to proceed along this 
general pathway. In terms of the vinylallene sidechain, less is known about biosynthetic 
pathways. In one case, the vinylallene natural product peridinin (20) has been shown to 
be produced through deprotonation and opening of the epoxide 21.77 The enyne product 23 is 
then produced by deprotonation of the allene and elimination of water. 
3.3 Previous Approaches to Vinylallene Natural Products 
 No total syntheses of vinylallene-derived natural products from Pestalotiopsis fici 
have yet been achieved; however a closely related vinylallene has been made (Scheme 
3.2).
78
 Gordon and Tabacchi were able to synthesize carbocycle 26 through a Diels-Alder 
reaction between diene 24 and dienophile 25. From there, anti-epoxidation and reduction 
provided 27. Jones oxidation and addition of lithium acetylide 28 took place from the α 
face, which set the stage for the key SN2’ reaction to install the vinylallene. The 
transformation 
Scheme 3.2 Synthesis of an Epoxy Vinylallene 
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proceeded to afford compound 31, which has the epoxide anti to the hydroxyls and syn to 
the vinylmethyl group. Silyl deprotection using TBAF finally gave vinylallene 32. 
In 2010, Kobayashi and Suzuki proposed a biosynthesis of chloropupukeananin 
and related molecules.
79
 They proposed that pestheic acid (9) may be oxidized to the 
known natural product maldoxin (4),
80
 which then participated in an inverse demand 
Diels-Alder (IDDA) reaction (Scheme 3.3). o-Benzoquinones have been invoked as 
biosynthetic intermediates in other natural products and find use in total syntheses.
81
 This 
class of molecules can participate in Diels-Alder reactions as a carbodiene, heterodiene, 
dienophile, and heterodienophile. For chloropupukeananin and related [4+2] 
cycloadducts, reaction of the carbodiene in an inverse electron demand sense is desired.  
Scheme 3.3 Proposed Biosynthesis of Chloropupukeananin 
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The reaction can take place either on the carboxylate face of maldoxin (4) or on the ether 
face. When an IDDA occurred on the former in an exo fashion, chloropestolide C (34) 
was formed. This would then undergo a carbonyl-ene reaction to give 
chloropupukeanolide D (35). Finally, compound 35 may undergo trans-esterification of 
the salicylate moiety to produce chloropupukeananin (1). When the reaction takes places 
from the ether face of maldoxin (4), a similar sequence would lead to the natural products 
chloropestolide D (37) and chloropupukeanolide C (38). In the latter case, the molecule is 
not set up to undergo further trans-esterification. Chloropestolide A (5) would be formed 
through an endo cycloaddition on the ether face and chloropestolide B (6) an endo 
reaction on the carboxylate face. In a later study, Che and coworkers were able to isolate 
a dechlorinated version of maldoxin from Pestalotiopsis fici.
74c
 This supports the 
proposal that maldoxin is involved in the biosynthesis and was just too reactive to be 
isolated from the fungus.  
The Snider group has accomplished the total synthesis of (±)-maldoxin (4) (Scheme 
3.4).
82
 They adopted a biomimetic approach and synthesized chloroisosulochrin (42) and 
pestheic acid (9) en route.  Directed lithiation of 40 and addition to benzaldehyde 39 gave 
joined product 41. This compound was transformed to chloroisosulochrin (42) through a 
series of redox and protecting group manipulations. Oxidative spirocyclization through 
furanone 43 followed by hydrolysis of 44 gave the biaryl ether pestheic acid (9). Finally, 
hypervalent iodine in TFE effected oxidative spirocyclization of the carboxylic acid to 
form maldoxin (4). 
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Scheme 3.4 Snider’s Total Synthesis of Maldoxin 
 
 
 
The Snider group then tested maldoxin’s reactivity in IDDA reactions by heating 
it with the model cyclohexane vinylallene 45 (Scheme 3.5).
83
 Diels-Alder cycloaddition 
occurred primarily on the carboxylate face of maldoxin (4) with ~2:1 endo:exo selectivity. 
An appreciable amount of normal demand [4+2] adduct 48 was also isolated (these 
compounds correspond to natural products isolated from Pestalotiopsis fici).
74c
 
Compound 47 underwent carbonyl-ene reaction when further heated to give tricycle 49. 
Scheme 3.5 Model IDDA of Maldoxin with a Vinylallene 
 
 
The Kobayashi group also published model studies towards chloropupukeananin 
(1). In their initial work, they took simple vinylallene 45 and masked o-benzoquinone 52 
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which was synthesized in three steps from known benzoic acid 50 (Scheme 3.6).
84
 
Chlorination and esterification were followed by dearomatization to give ketal 52. High 
pressure conditions were necessary to favor inverse demand over normal demand [4+2] 
cycloaddition; Lewis acids gave much higher yields of normal demand Diels-Alder 
adducts. They believe high pressure forces a tighter transition state and this phenomenon 
has been utilized in other natural product syntheses.
85
 The exo adduct 54 underwent 
carbonyl-ene reaction to 55 when treated with strong acid. Protection and enol ether 
formation followed by deprotection gave model chloropupukeananin 56. 
Scheme 3.6 Kobayashi’s Initial Model Study 
 
Following their 2010 work, Kobayashi and coworkers were able to effect IDDA reaction 
of hydroxy vinylallene 63 with spirodioxanone 60 (Scheme 3.7). The model maldoxin 
substrate was synthesized from chloride 51 by demethylation and MOM protection. SNAr 
reaction with fluoro aryl 58 gave biaryl ether 59 in high yield. From there, standard 
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protecting group manipulations and application of Snider’s spirocyclization conditions 
gave 60. The hydroxy vinylallene 63 was made from known diol 61 in two steps.
86
 
Protection as a carbonate and SN2’ reaction with vinylmethyl Grignard reagent gave 63. 
Application of their previously developed high pressure conditions gave a mixture of 
IDDA adducts 64 and 65 as well as trace normal demand product 66 (eq. 2). The 
intermediate exo [4+2] adduct spontaneously underwent carbonyl-ene reaction to 64 and 
the core of chloropupukeananin 67 could then be made through a base-mediated 
salicylate migration. Interestingly, chiral HPLC separation of the enantiomers of 60 
showed that the (R) enantiomer gave better selectivity for IDDA and was improved to 
7:3:0 for 64:65:66 when used with enantiopure 61. 
Scheme 3.7 Kobayashi’s Advanced Model Study towards Chloropupukeananin 
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3.4 Pestalofones 
 A related set of compounds were isolated in 2009 from the same fungus.
87
 
Pestalofones B and C appear to be dimers of iso-A82275C (8) while the rest of the family 
derives through alternate reactions of the vinylallene (Figure 3.3). Pestalofone B (68) 
may be a heterodimer of vinylallenone 72 and iso-A82775C (8) while pestalofone C (69) 
a homodimer of vinylallenone 72 (Scheme 3.8). Indeed, iso-A82775c (8) was co-isolated 
from the same cultures as the pestalofones.  
Figure 3.3 Pestalofones B-E 
 
 
Scheme 3.8 Proposed Syntheses of Pestalofones 
 
 The structures of pestalofones were determined by HMBC and NOESY studies. 
For example, initial comparison of pestalofone B (68) with known iso-A82775C (8) 
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showed it appeared to be a dimer and further HMBC studies established the epoxy 
cyclohexane and cyclohexanone rings. HMBC correlations from H2-9 to C-10, C-11, and 
C-14’, H-12’ to C-11, C-11’, C-14’, and C-15’, and from H3-15’ to C-12’, C-13’, and C-
14’ indicated that there was a spirocyclic ring joining the two monomeric units.  NOESY 
correlations of H-9a with H-14’a, and H-8 with H-14a set their relative configurations. 
Furthermore, H-12 with H2-9’ and of H-12’ with H3-15’ and H-16’ established the Z-
geometry of the C-11/C-12 olefin and the E-geometry of the C-10’/C-11’ olefin. The 
absolute configuration was assigned by analogy to that of iso-A82775C (8).  
Pestalofones D (70) and E (71) may be derived from the sequence shown in 
Scheme 3.9. Isosulochrin (73), also co-isolated, could be used in a (3+2) reaction with 
iso-A82775C (8). Dehydration to a xanthone and hydration of the allene may provide 71. 
Scheme 3.9 Retrosynthesis of Pestalofones D and E 
 
3.5 Biological Activity of Vinylallene Natural Products 
 The activity of these natural products has been explored and both 1 and 5 were 
shown to have growth inhibitory effects against tumor cells (e.g. HeLa: GI50 = 0.7 μM (1), 
1.4 μM (5)). Chloropestolide A (5) has strong anticancer activity against A549 cells 
(IC50=0.29 µM).
88
 It showed about 5-10 times the potency of 5-fluorouracil against HeLa 
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cells. Chloropupukeananin (1) showed an inhibitory effect against HIV-1 replication in 
C8166 cells with an IC50 value of 14.6 mM. The chloropupukeanolides
6b
 showed 
cytotoxicity and some activity against pathogens of tropical diseases.
89
  
Pestalofone B (68) showed inhibitory effects on HIV-1 replication in C8166 cells, with 
EC50 value of 64.0μM (CC50 value of greater than 200 μM; the positive control indinavir 
sulfate showed an EC50 value of 8.81 nM). They were also evaluated for activities against 
Candida albicans (ATCC 10231), Geotrichum candidum (AS2.498), and A. fumigatus 
(ATCC 10894). Pestalofone C (69) showed significant antifungal activity against A. 
fumigatus, with IC50/MIC values of 1.10/35.3 respectively (fluconazole showed IC50/MIC 
values of 7.35/163.4 μM). 
3.6 Conclusion 
 Natural products from Pestalotiopsis fici possess both interesting structures as 
well as biological activity. The proposed biosynthesis is very compelling and suggests 
oppurtunities to harness a reactive functionality (vinylallene) to undergo cycloadditions 
as well as other tandem complexity-generating reactions. Previous synthetic studies have 
mostly focused on model systems and have been done on synthetic racemic material. 
Accordingly, the monomeric vinylallene natural product iso-A82775C (8) became our 
initial synthetic target and focus in order to gain access to higher order natural products. 
Our studies towards the synthesis of 8 as well as maldoxin (4) will be described in 
Chapter 4.  
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Chapter 4 
 
Synthetic Studies towards Vinylallene Natural Products 
 
4.1 Vinylallenes 
 Allene natural products have been known since the isolation of pyrethrolone by 
Staudinger and Ruzicka in 1924.
90
 The consecutive double carbon bonds of allenes and 
possibility for axial chirality have interested chemists for over a century.
91
 There are now 
numerous methods to synthesize allenes, with special focus on asymmetric reactions.
92
  
A vinylallene was proposed as a biosynthetic intermediate in the production of the 
enediyne natural product esperamicin A (Scheme 4.1).
93
 Enyne 1 could isomerize to 
vinylallene 2 which then undergoes an intramolecular Diels-Alder reaction to make 3.  
Scheme 4.1 Proposed Biosynthesis of Esperamicin 
 
Vinylallenes have an additional double bond conjugated to the allene and 
therefore become ambiphilic in [4+2] reactions. The Danheiser group was able to trap an 
in situ generated vinylallene as a diene with electron deficient alkenes and alkynes as 
dienophiles (Scheme 4.2).
94
 The vinylallene 5 was generated from the bis-alkyne 4 
through a propargylic ene reaction. The investigators observed the vinylallene dimer 
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product 6 when the propargyl group was heated by itself, which showcases how the 
vinylallene can behave as both a diene and dienophile. 
Scheme 4.2 Danheiser’s Observation of a Vinylallene Intermediate 
 
Sterner and coworkers utilized a vinylallene en route to galiellalactone analogues 
(Scheme 4.3).
95
 A tandem Pd-mediated carbonylation and Diels-Alder reaction of enyne 
carbonate 7 was used to access a 5,6 fused system 10. The reaction proceeded through the 
palladated vinylallene intermediate 8 before carboxylation to ester 9 and subsequent 
[4+2] cycloaddition. 
Scheme 4.3 Vinylallene Used in the Synthesis of Galiellalactone 
 
Reich and coworkers were able to generate vinylallenes through SN2’ displacement of 
propargylic acetates 11 with cuprates (Scheme 4.4).
96
 The investigators then treated the 
isolable vinylallene 12 with trans alkene 13 or malonic anhydride 14 and were able to 
obtain either the exo 15 or endo 16 Diels-Alder adduct with good diastereoselectivity.  
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Scheme 4.4 Generation of Vinylallenes through Cuprate Addition 
 
Okamura and coworkers took advantage of a vinylallene intermediate to synthesize the 
natural product sterpurene (22) (Scheme 4.5).
97
 Sonogashira coupling of iodo 
cyclobutene 17 and propargyl alcohol 18 gave enyne 19. Formation of a vinyl sulfenyl 
ester was followed by a [2,3] rearrangement to give vinylallene sulfoxide 20 which then 
underwent a rapid intramolecular Diels-Alder reaction. This led to the formation of the 
hydrindane system 21 which could be advanced to the natural product 22 in two steps.    
Scheme 4.5 Okamura’s Synthesis of Sterpurene 
 
Sherburn and coworkers used a vinylallene in their synthesis of pseudopterosin (28) 
(Scheme 4.6).
98
 Enantioenriched propargylic alcohol 23 was mesylated and eliminated in 
an SN2’ fashion by Ni(II)-mediated addition of Grignard reagent 24 to stereochemically 
defined vinylallene 25. Compound 25 was immediately reacted with the electron poor 
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dienophile 26 to access cyclohexene 27 in good yield and dr as well as in high ee. The 
latter compound was then advanced to pseudopterosin (28) in multiple chemical steps.  
Scheme 4.6 Sherburn’s Synthesis of Pseudopterosin 
 
4.2 Elimination Approach towards Vinylallenes 
 We also identified literature methods to synthesize vinylallenes through 
elimination of activated enols. The Lepore group took acyclic β-keto esters 29 and under 
strongly basic conditions was able to subject to triflation and subsequent elimination to 
form allene 31 and alkyne 32 (Scheme 4.7).
99
 High selectivity for the allene vs. alkyne 
could be obtained by employing α-substituted β-keto esters and ZnCl2. The investigators 
believe that it may be due to a preference for generation of a C-metalated species in situ 
during the course of the reaction.
100
 
Scheme 4.7 Triflate Elimination towards Allenes 
 
The Brummond group was also able to access allenes through elimination of enol 
phosphates (Scheme 4.8).
101
 The investigators could take the multiple isomers formed 
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after phosphate formation of simple alkyl substituted ketone 33 and have them converge 
to the same allene product 36 in moderate yield. 
Scheme 4.8 Elimination of Enol Phosphates to Allenes 
 
We initiated our studies by preparing model diketone 39 through simple acylation 
reaction of cyclohexanone 38 with acid chloride 37 (Scheme 4.9). Treatment with triflic 
anhydride in LiHMDS gave a mixture of what we believe are alkyne 40 and dimer 41.  
Scheme 4.9 Elimination Studies on Model Cyclohexanone 
We were not able to obtain an intermediate enol triflate under any conditions and the 
reaction was somewhat messy, so we explored other options after optimization studies. 
Presumably the desired mechanism goes through intermediate triflate formation of 42 
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followed by γ-deprotonation and immediate dimerization of reactive vinylallene 43 (eq. 
2). We also pursued elimination of an enol phosphate and in this case we could isolate 
intermediate 44. After column chromatography, resubjection to LiHMDS gave the same 
proposed dimer 41 as sole product along with some recovered starting material. We  
Scheme 4.10 Reactions of Enol Phosphates 
 
performed some optimization studies and found that phenyl phosphate substrate 45 was 
more efficient under the reaction conditions. Use of the corresponding dimethyl 
phosphate led to decomposition of the starting material. LiHMDS proved to be the best 
base with LDA giving lower yields, DBU mostly decomposition, and phosphazene bases 
low conversion. Phosphazene bases had previously been shown to be effective for 
elimination of enol nonaflates to synthesize alkynes
102
 and allenes.
103
  
 The 
1
H NMR spectrum of 41 corresponds well to that of pestalofone C (46) (see 
Select Spectra); however, 
13
C as well as 2D NMR studies will be required to fully 
confirm the structure. Additionally, the m/z for a dimeric ion mass has been observed by 
UPLC and HRMS. In order to unambiguously confirm the structure, we are pursuing an 
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X-ray structure by derivatization. Studies are in progress to prepare oxime 47 and 
hydrazone 48 adducts which should be more crystalline (Figure 4.1). Compound 41 is 
acid-sensitive and in initial studies seems to be optimally isolated using chromatography 
with neutral alumina. 
Figure 4.1 Planned Derivatives of Proposed Dimer 
 
We have also collaborated with the Johnson group at UNH to explore the 
transition state for the proposed dimerization event (Figure 4.2). They found that it is 
most likely an asynchronous process which may even have biradical character.
104
 The 
transition state is also a homodimerization where the same enantiomers react with each 
other and results in an endo cycloadduct with respect to the carbonyl. Energy calculations 
on the B3LYP/6-31+G(d,p) level also showed that the cycloaddition is highly exothermic  
Figure 4.2 Spartan DFT Transition State Calculation of Dimerization 
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(-30 to -36 kcal/mol) which may contribute to the apparent instability of vinylallene 43 at 
room temperature. 
We next set out to test substrates with the epoxide intact to more closely mimic 
the natural product (Scheme 4.11). Commercially available 1,3-cyclohexanedione 49 
could be prenylated and methylated to afford 51. Reduction and carbonyl transposition 
with DIBAL-H then provided enone 52. Epoxidation under basic conditions gave the 
known epoxide 53.
105
 We could then attach the alkenyl side chain through the same 
LiHMDS conditions as in Scheme 4.9. However, neither enol triflate conditions on 54 
nor further base treatment of enol phosphate 55 gave desired product. Mostly 
decomposition and some starting material were observed. We therefore decided to pursue 
a different strategy since the strong base may not be compatible with the highly reactive 
epoxy ketone.
106
  
Scheme 4.11 Synthesis of Epoxy Enol Phosphate 55 
  
4.3 Decarboxylation Approach 
 Recently, decarboxylation has been exploited as a useful method to introduce 
previously challenging quaternary centers α to a carbonyl. 107  Both the Stoltz 108  and 
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Tunge
109
 groups have pioneered this area in the last decade. The Stoltz group developed 
an asymmetric protonation method starting from racemic tetralones (Scheme 4.12).
110
 
Allyl ester 56 was treated with Pd(0) and PHOX ligand 59 using Meldrum’s acid 57 as 
allyl scavenger. High yields and ee’s were obtained of the α-methyl product 58. 
Scheme 4.12 Stoltz’s Decarboxylation of Tetralones 
 
Guiry and Doran also utilized PHOX ligands for decarboxylative protonation (Scheme 
4.13).
111
 Cyclic ketones 60 bearing an aryl between the carbonyl groups could be 
smoothly transformed to the enantioenriched products 61.  
Scheme 4.13 Guiry’s Decarboxylation of Cyclopentanones 
 
Finally, Kim and coworkers utilized a γ-keto ester system to protonate the benzylic 
position of 62 (Scheme 4.14).
112
 Treatment of 62 with Pd(0) under heating gave a good 
yield of p-NO2 cyclohexanone 63. 
Scheme 4.14 Decarboxylation at a Benzylic Position 
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Our overall approach is summarized in Scheme 4.15. We envisioned accessing β-
keto ester alkyne 64 which could then be decarboxylated to give anion 65; subsequent 
isomerization and protonation would give the target vinylallenone 66. Vinylallenone 66 
may be further reduced to iso-A82775C (67). Appropriate chiral ligands on a metal may 
set the allene stereochemistry selectively since substrate control is unlikely due to the 
distal nature of the prenyl group. 
Scheme 4.15 Plan to Synthesize Vinylallenes via Decarboxylation 
 
We used intermediate 53 from the elimination chemistry (Scheme 4.11) and attached an 
allyl ester by deprotonation (Scheme 4.16). Next, Pb (IV)-mediated alkynylation
113
  
Scheme 4.16 Synthesis of Allyl Ester Alkyne 71 
 
installed the requisite enyne between the β-keto ester to give alkynylated 71 in 5:1 dr. 
Assignment of the major product was by analogy to a related example
114
 as no useful 
NOEs were observed. Examination of models show 72 should be disfavored since esters 
have a larger A value than alkynes and would prefer to be equatorial (Figure 4.3). Efforts 
to derivatize 71 and assign the structure unambiguously are ongoing.  
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Figure 4.3 Spartan AM1 Models of Alkyne Ester Diastereomers 
 
We then took substrate 71 and subjected it to a range of Pd(0) decarboxylation conditions 
(Table 4.1). We initially looked at different PHOX ligands (e.g. entry 1) and did not 
observe any desired product for the phenyl catalyst with Meldrum’s acid as scavenger. 
Recently, we have switched to a less nucleophilic scavenger (N,N-dimethyl barbituric 
Table 4.1 Screen of Decarboxylation Conditions of Epoxy Alkyne Ally Ester 71 
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acid) and hope to avoid decomposition issues. We also screened a variety of bidentate 
phosphines, including BINAP. In these cases, we saw low conversion in general and 
when the reaction was pushed by heating or increasing equivalents we observed 
decomposition. Iridium also has precedent for decarboxylation reactions;
 115
 however, we 
saw decomposition with BINOL and phosphoramidite as ligand. 
For iso-A82775C (67) we will ultimately require an additional hydroxyl group 
which we could install through α-hydroxylation of vinylogous ester 76 (Scheme 4.17). 
Davis oxaziridine 77 and LiHMDS gave the desired product 78 in good yield which 
could then be taken through the DIBAL-H reduction step to the γ-hydroxy enone 79.  
Scheme 4.17 Synthesis of Hydroxy Enone 79 
  
Attempts to epoxidize prenyl hydroxy enone 79 have thus far met with failure (Table 
4.2). Sodium hydroxide and hydrogen peroxide conditions useful for substrate 53 this  
Table 4.2 Screen of Conditions for Nucleophilic Epoxidation 
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time led to decomposition (entry 4). We have also evaluated some iminium protocols
116
 
and found that the reaction did not proceed at all (entry 6). Finally, trityl hydroperoxide 
nucleophilic epoxidation
117
 has possibly given some trace epoxide at -40 °C but raising 
the temperature has only led to decomposition (entry 3). We are currently exploring 
conditions to optimize this reaction. 
We reasoned that the prenyl group may interfere with epoxidation, possibly by 
steric effects to perturb the electronics of the enone substrate or by further reaction of the 
nucleophilic olefin, and thus set out to make the corresponding allyl analogue 85. This 
was easily accomplished through the same sequence by switching prenyl bromide for 
Scheme 4.18 Synthesis and Reactivity of Allyl Hydroxy Enone  
 
allyl bromide (Scheme 4.18). Nucleophilic epoxidation with NaOH/H2O2 in this case led 
to a 3:1 mixture of desired epoxide 86 and starting material 85. These compounds were 
found to be inseparable so we are attempting to push this to full completion, although we 
also have great interest in developing a method to synthesize enantioenriched epoxide 86.   
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4.4 Studies towards Maldoxin 
 We initiated studies towards maldoxin (94) by developing a method to synthesize 
biaryl ester 93 (Scheme 4.19). Bromination of the commercially available benzoic acid 
87 gave known compound 88. Copper-mediated hydroxylation
118
 afforded catechol 89 in 
good yield. We were able to esterify 89, mono-protect through treatment with MOMCl, 
and chlorinate to complete the synthesis of MOM protected catechol 90.
119
 This 
compound was then coupled to dioxanone 92 through a photochemical esterification.
120
  
Scheme 4.19 Synthesis of a Biaryl Ester 
 Examination of a model of compound 93 shows that the phenols on the left hand 
ring appear to be hydrogen bonded to carbonyls (Figure 4.4). We reasoned we could 
exploit this feature and selectively activate the phenol on the right hand ring with an 
oxidant.  We conducted a number of studies to access maldoxin (94) from substrate 93;  
Figure 4.4 Spartan DFT Model of Lowest Conformer of Biaryl Ester 93  
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however, in general, use of hypervalent iodine reagents and solvents gave decomposition. 
We attempted to replicate Snider’s condition which was used to synthesize maldoxin (94) 
from pestheic acid (95) (Scheme 4.20).
121
 However, we only observed decomposition 
with both TFE and HFIP as solvent. Competitive oxidation of the other two hydroxyl  
Scheme 4.20 Snider’s Endgame for Maldoxin 
 
groups may have been the source of this problem. It is also possible that the unstable 
intermediate 96 decomposed before cyclization could occur. A racemic variant of 
Ishihara’s oxidative cyclization procedure, using tetrabutylammonium iodide as the 
hypervalent iodine source and hydrogen peroxide as the oxidant, was also attempted, with 
no success.
122
 Specifically, while monitoring by TLC new spots were formed, but after  
Scheme 4.21 Attempts to Synthesize Maldoxin via Oxidative Dearomatization 
 
 
 
workup only starting material was left, leading to our postulation that interaction with the 
acidic silica may have catalyzed a reaction on the TLC plate. Unfortunately, attempts to 
investigate this possibility resulted in decomposition of phenol 96.  
Due to the failure for biaryl ester 93 to dearomatize and cyclize, we set out to 
synthesize an appropriate biaryl ether (Scheme 4.22). This approach would then line up 
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with Snider’s synthesis where they showed that a carboxylic acid can spirocyclize to 
access maldoxin.
120
 The substrate may have the chlorine already installed or we believed 
we could introduce it after the cross coupling reaction.  
Scheme 4.22 Future Plan For Ullmann Reaction 
 
We were able to make various partners for the cross coupling reaction as shown in 
Scheme 4.23. Methyl dioxanone 97 could be made in an analogous fashion to 92 
(Scheme 4.19) and then triflated to give compound 98 in high yield. Pd-catalyzed 
Scheme 4.23 Synthesis of Different Electrophiles 
stannylation of 98 gave 99, which was further reacted with NIS to afford iodide 100. All 
of our attempts (e.g. Cu salts) with triflate 98 resulted in starting material, so we decided 
to investigate Chan-Lam type coupling
123
 using stannane 99 (Scheme 4.24). A range of 
amine bases to activate the copper were used; unfortunately no conversion was detected. 
In this case, we used substrate 101 to avoid any competitive insertions into the C-Cl bond.  
Scheme 4.24 Chan-Lam Coupling Attempts 
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In a control experiment, we found that iodo dioxanone 100 underwent cross 
coupling with t-butyl phenol 103 using Cu(I) (Scheme 4.25). We were able to make 
model compound 104 but all attempts using phenol 101 as a coupling partner failed. 
Scheme 4.25 Model Cross Coupling Reactions 
 
We reason that there are significant steric interactions between 100 and 101 that prevent 
successful reductive elimination. Strategies are being pursued that may alleviate some of 
the bulky groups on compound 101. These include reduction of the ester to aldehyde 107 
and alcohol 108 (Figure 4.5). We will also investigate alternative protecting groups to a 
MOM group. For the dioxanone partner, changing the electronics to dioxane 109 or using 
the hydroxy benzyl alcohol derivative 110 may allow for an effective cross coupling.  
Figure 4.5 Proposed Coupling Partners 
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A range of ligands were screened with Cu(I) and Pd(II) sources (Figure 4.6). Cristau and 
coworkers have reported that oximes such as 114 can catalyze mild Ullmann couplings
124
 
yet we saw no conversion even under microwave conditions. Likewise, Buchwald’s 
conditions to couple phenols and aryl iodides using picolinic acid
125
 111 failed as well as 
Pd-mediated reactions such as Tang’s with phosphine ligand BI-DIME 115.126 
Figure 4.6 Evaluation of Ligands for Phenyl Ether Synthesis  
 
We also recently considered a C-H activation strategy. The overall plan is shown 
in Scheme 4.26. Direct C-H activation of benzoic acid 117 with phenol 92 would allow 
for access to 118. The latter compound should then be set up for a dearomatization 
reaction and if the chlorine is installed at a late stage, it might even allow for a kinetic 
resolution of dechloromaldoxin (120) using chiral alkaloid catalysis.
127
 This would allow 
for an asymmetric synthesis of maldoxin (94) which is important for high selectivity in 
the IDDA reaction as shown in Kobayashi’s studies (Chapter 3).  
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Scheme 4.26 C-H Activation Strategy to Synthesize Maldoxin 
 
Precedent for C-H activation of benzoic acids comes mainly from the Yu lab.
128
 The 
Baran and Yu groups were able to utilize late stage C-H methylation of a benzoic acid to 
access hongoquercin A (123) (Scheme 4.27).
129
 Pd(II) combined with a dual oxidant 
system of benzoquinone and silver carbonate gave good yields of o-methylated products.  
Scheme 4.27 C-H Methylation Strategy to Synthesize Hongoquercin A 
 
Both phenol 117 and MOM-protected 125 were made from commercial 124 (Scheme 
4.28). We envisioned the MOM group could serve as a directing group for Pd(II).
130
  
Scheme 4.28 Synthesis of Differentially Protected Benzoic Acid Substrates 
 
We then set out to screen conditions (Table 4.3). Using standard conditions with Pd(II)  
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Table 4.3 Screening of Conditions for C-H Activation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
salts and NaOAc as base led mostly to decomposition. This result was obtained both with 
and without amino acids as ligand. Variation of the oxidant was not effective with those 
besides PIDA leading to no conversion. Cesium carbonate was found to be a milder base 
than NaOAc but no joined products were isolated after methylation of the resulting ester. 
NMR experiments with stoichiometric Pd to potentially observe C-H insertion were 
unsuccessful. 
 
Catalyst Oxidant Solvent Base Temp (
o
C) Result 
Pd(OAc)2 Ag2CO3 PhCH3 NaOAc 80 Decomposition 
Pd(TFA)2 Ag2CO3 DMA NaOAc 100 Decomposition 
Pd(OPiv)2 Ag2CO3 DMA NaOAc 80 Starting material 
Pd(TFA)2 Benzoquinone 
  
PIDA 
DMA Cs2CO3 80 Starting material 
Pd(TFA)2 DMA Cs2CO3 80 Decomposition 
Pd(OAc)2 Ag2CO3 tBuOH Cs2CO3 80 Starting material 
Pd(OAc)2 o-Chloranil DCE Cs2CO3 80 Starting Material 
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4.5 Future Directions 
 If direct C-H activation for maldoxin (94) fails, we plan to use a directing group 
to enhance the reactivity. Amide oxazolines have been reported,
131
 and we may be able to 
use either Cu(II) or another metal (e.g. Pd(0)) conditions to synthesize biaryl ether 
compounds such as 127 (Scheme 4.29). 
Scheme 4.29 Directing Group Plan for C-H Activation 
  
 We will continue to pursue decarboxylations, preferably on a substrate with a γ-
hydroxy group. In the case that we do isolate an alkyne product rather than an allene (c.f. 
Table 4.1, entry 2), we have a plan to isomerize to our desired product. Among a number 
of base catalyzed options, Fagnou’s enantioselective Ag(I)/JosiPhos approach132 is the 
most desirable since we wish to make the allene in diastereoselective fashion (Scheme  
Scheme 4.30 Fagnou’s Alkyne to Allene Isomerization 
 
4.30). Fagnou and coworkers were able to isomerize amides 128 to the corresponding 
allene 129 in very high yield and ee with JosiPhos 130 as ligand.  
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Once we have achieved a workable epoxidation on either prenyl substrate 79 or 
allyl 85, we will employ the same steps as before to make the corresponding allyl ester 
alkyne 131 after protecting the hydroxy group (Scheme 4.31). Decarboxylation and 
isomerization would make vinylallenone 134 which could either be reduced to iso-
A82775C (67) or dimerized to pestalofone C (46). If the allyl substrate was employed, 
then a Grubbs metathesis to install the prenyl would be carried out at some stage. 
Epoxide 132 would hopefully be enantioenriched or able to be kinetically resolved and 
the corresponding steps would ideally take place diastereoselectively to allow for a 
selective synthesis of the natural products.  
Scheme 4.31 Planned Synthesis of iso-A82775C (67) and Pestalofone C (46) 
 
4.6 Conclusion  
 In summary, we have explored a variety of routes towards vinylallene-derived 
natural products and focused our efforts on iso-A82775C (67) and maldoxin (94). A 
biaryl ester substrate failed to give maldoxin (94). Other options involving cross coupling 
and C-H activation approaches are being pursued towards construction of a biaryl ether. 
An elimination strategy employing a model enol phosphate was pursued to provide the 
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carbocyclic core of pestalofone C (46); however, attempts to conduct this chemistry using 
an epoxy substrate led to decomposition. We have pursued decarboxylation studies and 
have initial results to synthesize the γ-hydroxy epoxide needed for iso-A82775C (67) and 
higher order molecules. Along with the goal of synthesizing these natural products, our 
studies have paved the way for development of methodologies such as enantioselective 
epoxidation of α-substituted enones and alkyne to allene isomerizations.  
4.7 Experimental Section 
General Information: 
1
H NMR spectra were recorded at 300, 400, or 500 MHz at 
ambient temperature with CDCl3, CD3OD, C6D6, or DMSO-d6 (Cambridge Isotope 
Laboratories, Inc.) as solvents. Data for 
1
H NMR are reported as follows: chemical shift, 
integration, multiplicity (o = overlapping, s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet) and coupling constants in Hz. 
13
C NMR spectra were recorded at 75.0, 
100.0, or 125 MHz at ambient temperature with the same solvents unless otherwise 
stated. Chemical shifts are reported in parts per million relative to the deuterated solvents. 
All 
13
C NMR spectra were recorded with complete proton decoupling. Infrared spectra 
were recorded on a Nicolet Nexus 670 FT-IR spectrophotometer. High-resolution mass 
spectra were obtained in the Boston University Chemical Instrumentation Center using a 
Waters Q-TOF API-US mass spectrometer. Melting points were recorded on a Mel-temp 
Temp apparatus (Laboratory Devices). Analytical LC-MS was performed on a Waters 
Acquity UPLC (Ultra Performance Liquid Chromatography) (Waters MassLynx Version 
4.1) with a Binary solvent manager, SQ mass spectrometer, Water 2996 PDA 
(PhotoDiode Array) detector, and ELSD (Evaporative Light Scattering Detector). An 
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Acquity UPLC BEH C18 1.7 μm column was used for analytical UPLC-MS. Preparative 
HPLC separations were carried out on a Gilson PLC 2020 Personal Purification System 
using a Sunfire C18 column.  
(Z)-3-Methyl-1-(2-oxocyclohexylidene)but-2-en-1-yl diphenyl 
phosphate 45: Phosphate 45 was prepared from known compound 39. Compound 39 
(1.00 g, 5.55 mmol, 1.0 equiv) was dissolved in THF (20 mL, 0.28 M) and cooled to -78 
o
C. LiHMDS (1.0 M in THF, 6.7 mL, 6.67 mmol, 1.2 equiv) was then added and the 
reaction stirred for 30 minutes. Then diphenyl chlorophosphate (1.2 mL, 5.55 mmol, 1.0 
equiv) was added and the reaction was slowly warmed to rt. The reaction was quenched 
after 12 h using 10 mL of aqueous ammonium chloride. The crude product was purified 
by flash chromatography using a gradient of EtOAc/Hex (9:1to 1:1) to obtain pure 
product 45 (1.6 g, 3.88 mmol, 70%). Yellow oil; Rf = 0.34 (EtOAc/Hex 1:4); IR νmax 
2937, 1591, 1490, 1189, 1009 cm
-1
; 
1H NMR (400 MHz) δ 7.31 (o, 5H), 7.18 (o, 5H), 
6.32 (s, 1H), 2.50 (o, 2H), 2.32 (o, 2H), 2.03 (s, 3H), 1.73 (s, 3H), 1.70 (o, 2H), 1.59 (o, 
2H); 
13
C NMR (100 MHz, CDCl3) δ 193.3, 155.0, 150.3, 148.7, 129.9, 129.8, 129.6, 
126.5, 125.6, 125.4, 125.4, 125.3, 125.2, 120.1, 120.0, 119.9, 119.7, 28.4, 27.6, 25.3, 
22.6, 21.5, 21.0; HR-MS: m/z Calcd. for C23H25O5P [M+Na]: 435.1337, Found 435.1318 
(-1.9 ppm). 
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(Z)-Diethyl (3-methyl-1-(2-oxocyclohexylidene)but-2-en-1-yl) 
phosphate 44: Phosphate 44 was prepared from known compound 39. Compound 39 
(600 mg, 3.33 mmol, 1.0 equiv) was dissolved in THF (12 mL, 0.28 M) and cooled to -78 
o
C. LiHMDS (1.0 M in THF, 4.0 mL, 4.00 mmol, 1.2 equiv) was then added and the 
reaction stirred for 30 minutes. Then diethyl chlorophosphate (0.53 mL, 3.66 mmol, 1.1 
equiv) was added and the reaction was slowly warmed to rt. The reaction was quenched 
after 12 h using 10 mL of aqueous ammonium chloride. The crude product was purified 
by flash chromatography using a gradient of EtOAc/Hex (95:5 to 1:3) to obtain pure 
product 44 (600.0 mg, 1.90 mmol, 57%). Yellow oil; Rf = 0.46 (EtOAc/Hex 1:4); IR νmax 
2995, 1716, 1650, 1443, 1272, 1080 cm
-1
; 
1H NMR (400 MHz) δ 6.32 (s, 1H), 4.07 (m, 
4H), 2.41 (o, 2H), 2.24 (o, 2H), 2.07 (s, 3H), 1.85 (s, 3H), 1.67 (o, 2H), 1.54 (o, 2H), 1.26 
(o, 6H); HR-MS: m/z Calcd. for C15H25O5P [M+H]
+
: 317.1440, Found 317.1517 (+7.7 
ppm). 
6-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)cyclohex-2-en-
1-one 78: Hydroxy prenyl cyclohexenone 78 was prepared from known vinylogous ester 
76. Compound 76 (500 mg, 2.57 mmol, 1.0 equiv) was dissolved in THF (12 mL, 0.21 
M) and cooled to -78 
o
C. LiHMDS (1.0 M in THF, 3.9 mL, 3.86 mmol, 1.5 equiv) was 
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then added and the reaction was slowly warmed to -30 
o
C. The reaction was then 
recooled to -78 
o
C and Davis oxaziridine 77 (805 mg, 3.08 mmol, 1.2 equiv) in 2 mL of 
THF was added. The reaction was then warmed to 0 
o
C and quenched after 12 h using 10 
mL of aqueous ammonium chloride. The crude product was purified by flash 
chromatography using a gradient of EtOAc/Hex (1:9 to 100%) to obtain pure product 78 
(410 mg, 1.95 mmol, 76%). Yellow oil; Rf = 0.25 (EtOAc/Hex 1:1); IR νmax 2931, 1732, 
1447, 1331, 1165 cm
-1
; 
1H NMR (400 MHz) δ 5.00 (dd, J= 7.7, 7.7 Hz, 1H), 4.69 (dd, J= 
7.7, 3.8 Hz, 1H), 3.97 (s, 3H), 2.94 (d, J= 7.7 Hz, 2H), 2.65 (o, 2H), 2.35 (o, 2H), 2.19 (o, 
2H), 2.08 (o, 2H), 1.68 (s, 3H), 1.63 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 198.3, 169.2, 
131.7, 122.0, 120.2, 62.4, 56.0, 31.4, 29.7, 25.7, 21.4, 17.7; HR-MS: m/z Calcd. for 
C12H18O3 [M+ H
+
]: 211.1256, Found 211.1342 (+8.6 ppm). 
4-Hydroxy-2-(3-methylbut-2-en-1-yl)cyclohex-2-en-1-one x: Hydroxy 
enone 79 was prepared from 78. Compound 78 (650 mg, 3.09 mmol, 1.0 equiv) was 
dissolved in toluene (20 mL, 0.15 M) and cooled to -78 
o
C. DIBAL-H (1.0 M in toluene, 
4.6 mL, 4.64 mmol, 1.5 equiv) was then added and the reaction was slowly warmed to 0 
o
C. The reaction was then quenched after 2 h using 10 mL of 1 M HCl. It was stirred for a 
further 2 h and then extracted using EtOAc. The crude product was purified by flash 
chromatography using a gradient of EtOAc/Hex (1:9 to 100%) to obtain pure product 79 
(150 mg, 0.83 mmol, 27%). Yellow oil; Rf = 0.22  (EtOAc/Hex 1:9); IR νmax 3487, 2964, 
226 
 
2929, 1674, 1260, 1081, 1037, 799 cm
-1
; 
1H NMR (400 MHz) δ 6.67 (m, 1H), 5.09 (dd, 
J= 7.4, 7.4 Hz, 1H), 3.78 (br. s, 1H), 2.47 (o, 3H), 2.36 (m, 2H), 1.84 (m, 2H), 1.71 (s, 
3H), 1.61 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 200.7, 145.9, 136.5, 134.0, 120.3, 72.9, 
31.5, 27.4, 25.7, 24.7, 17.6; HR-MS: m/z Calcd. for C11H16O2 [M+H
+
]: 181.1229, Found 
181.1234 (+0.5 ppm). 
Allyl 1-(3-methylbut-2-en-1-yl)-2-oxo-7-
oxabicyclo[4.1.0]heptane-3-carboxylate 69: Known prenyl epoxide 53 (400 mg, 2.22 
mmol, 1.0 equiv) was dissolved in THF (6 mL, 0.37 M) and cooled to -78 
o
C. LiHMDS 
(1.0 M in THF, 3.3 mL, 3.33 mmol, 1.5 equiv) was then added and the reaction was 
slowly warmed to -30 
o
C. The reaction was then recooled to -78 
o
C and allyl 
chloroformate (0.32 mL, 3.02 mmol, 1.4 equiv) was added. The reaction was then 
warmed to 0 
o
C and quenched after 2 h using 5 mL of aqueous ammonium chloride. The 
crude product was purified by flash chromatography using a gradient of EtOAc/Hex (1:9 
to 100%) to obtain pure product 69 (420 mg, 1.59 mmol, 72%). Yellow oil; Rf = 0.5 
(EtOAc/Hex 1:9); IR νmax  2918, 1745, 1646, 1232, 839 cm
-1
; 
1
H NMR (400 MHz) Major 
form is enol δ 12.47 (s, 1H), 5.93 (m, 1H), 5.26 (o, 4H), 5.12 (m, 1H), 3.43 (m, 1H), 2.80 
(o, 2H), 2.45 (o, 3H), 2.10 (o, 3H), 1.71 (s, 3H), 1.64 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 171.9, 169.3, 135.1, 131.9, 118.2, 117.6, 97.6, 65.1, 60.5, 56.8, 28.1, 25.8, 21.8, 
18.0, 16.8; HR-MS: m/z Calcd. for C15H20O4 [M+H
+
]: 265.1440, Found 265.1435 (-0.5 
ppm). 
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Allyl 1-(3-methylbut-2-en-1-yl)-3-(3-methylbut-3-en-1-
yn-1-yl)-2-oxo-7-oxabicyclo[4.1.0]heptane-3-carboxylate 71: 2-methylbut-1-en-3-yne 
70 (0.35 mL, 3.68 mmol, 1.0 equiv) was dissolved in THF (12 mL, 0.3 M) and cooled to 
-78 
o
C. n-BuLi (2.5 M, 1.6 mL, 4.0 mmol, 1.1 equiv) was then added and the reaction 
was slowly warmed to -30 
o
C. Lead tetraacetate (1.79 g, 4.05 mmol, 1.1 equiv) was then 
added and the reaction was then recooled to -78 
o
C. Allyl ester 69 (574 mg, 2.2 mmol, 
0.59 equiv) was then added in 2 mL of THF and the reaction was then warmed to 0 
o
C 
and quenched after 12 h using 5 mL of aqueous ammonium chloride. The crude product 
was purified by flash chromatography using a gradient of EtOAc/Hex (1:9 to 100%) to 
obtain pure product 71 (400 mg, 1.22 mmol, 33%). Yellow oil; Rf = 0.48 (EtOAc/Hex 
1:9); IR νmax  3428, 2963, 1750, 1725, 1615, 1448, 1259, 1025, 799 cm
-1
; 
1
H NMR (400 
MHz) δ 5.92 (m, 1H), 5.30 (o, 4H), 5.01 (m, 1H), 4.69 (o, 2H), 3.42 (m, 1H), 2.82 (dd, J= 
7.7, 7.7 Hz, 1H), 2.54 (m, 1H), 2.33 (o, 2H), 2.21 (m, 1H), 1.95 (m, 1H), 1.89 (s, 3H), 
1.67 (s, 3H), 1.62 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 195.9, 177.8, 166.9, 135.9, 
131.5, 125.9, 123.2, 118.3, 116.3, 89.4, 81.6, 66.5, 61.4, 60.8, 55.1, 28.8, 25.8, 23.2, 20.4, 
18.0; HR-MS: m/z Calcd. for C20H24O4 [M+H
+
]: 329.1753, Found 329.1763 (+1.0 ppm). 
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 Methyl 2,3-dihydroxy-5-methoxybenzoate S1: 2,3-Dihydroxy-5-
methoxybenzoic acid (8.1 g, 44.0 mmol, 1 equiv) was dissolved in methanol (200 mL, 
0.22 M). Concentrated sulfuric acid (8.2 mL, 154 mmol, 3.5 equiv) was added, and the 
solution was stirred at 80 °C for 24 hours. Water was added, and the product was 
extracted with dichloromethane, washed with saturated sodium bicarbonate and brine, 
and the solvent evaporated to yield the crude product. Silica-gel column chromatography 
using 20% ethyl acetate in hexanes yielded pure product S1 (4.0 g, 20.02 mmol, 46%).
 
Brown oil; Rf = 0.56 (1:4 EtOAc/Hexanes); IR νmax 1679, 1489, 1316, 1227, 1165, 1047 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 10.48 (s, OH); 6.83 (d, J = 3.0 Hz, 1H); 6.79 (d, J = 
3.0 Hz, 1H); 5.67 (s, OH); 3.96 (s, 3H); 3.76 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 
170.7, 152.4, 145.9, 143.9, 111.7, 108.9, 102.6, 55.9, 52.7; HR-MS: m/z Calcd. for 
C9H10O5 [M+H
+
]: 199.0528, Found 199.0599 (+7.1 ppm). 
 Methyl 2-hydroxy-5-methoxy-3-(methoxymethoxy)benzoate 
101:  Methyl 2,3-dihydroxy-5-methoxybenzoate S1 (0.50 g, 2.5 mmol, 1 equiv) in 
dichloromethane (25 mL, 0.1 M), methyl chloromethylether (1.31 mL, 7.5 mmol, 3 
equiv) was added at 0 °C. The reaction was warmed to room temperature overnight, 
quenched with saturated ammonium chloride, extracted three times with ethyl acetate, 
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and dried over sodium sulfate. The product was purified with a 10-20% ethyl acetate: 
hexanes solution using column chromatography, yielding the product 101 (500 mg, 2.1 
mmol, 82%). Yellow oil; Rf = 0.62 (1:4 EtOAc/Hexanes); IR νmax 1675, 1445, 1154, 
1029 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 10.68 (s, OH); 6.99 (d, J = 3.0 Hz, 1H); 6.94 
(d, J = 3.0 Hz, 1H);  5.23 (s, 2H); 3.94 (s, 3H); 3.75 (s, 3H); 3.51 (s, 3H); 
13
C NMR (125 
MHz, CDCl3) δ 170.5, 151.5, 147.5, 146.4, 111.9, 111.6, 103.9, 95.5, 56.2, 55.7, 52.3; 
HR-MS: m/z Calcd. for C11H14O6 [M+Na]: 265.0688, Found 199.0686 (-0.2 ppm). 
 Methyl 5-methoxy-3-(methoxymethoxy)-2-
(((trifluoromethyl)sulfonyl)oxy)benzoate S2:  Compound 101 (100 mg, 0.41 mmol, 1 
equiv) in CH2Cl2 (2 mL, 0.21 M) was cooled to 0 
o
C. Triethyl amine (0.09 mL, 0.62 
mmol, 1.5 equiv) and triflic anhydride (0.08 mL, 0.45 mmol, 1.1 equiv) were then added 
and the reaction stirred for 1 hour. The reaction was quenched by addition of 1 mL of 1M 
HCl and extracted with ethyl acetate. The crude product was purified by flash 
chromatography using a gradient of EtOAc/Hex (1:9 to 100%) to obtain pure product S2 
(110 mg, 0.29 mmol, 71%). Yellow oil; Rf =0.55 (1:4 EtOAc/Hexanes); IR νmax 3362, 
1725, 1597, 1418, 1199, 605 cm
-1
; 
1H NMR (400 MHz, CDCl3) δ 7.08 (d, J= 3.1 Hz, 
1H), 7.02 (d, J= 3.1 Hz, 1H), 5.22 (s, 2H), 3.93 (s, 3H), 3.82 (s, 3H), 3.50 (s, 3H); 
13
C 
NMR (100 MHz, CDCl3) δ 164.5, 158.9, 150.5, 131.9, 125.8, 118.6 (q, J= 323.2 Hz), 
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107.5 (d, J= 80.8 Hz), 95.5, 56.6, 55.9, 55.9, 52.7; HR-MS: m/z Calcd. for C12H13O8SF3 
[M+H
+
]: 375.0283, Found 373.0362 (+7.9 ppm). 
 Methyl 4-chloro-2-hydroxy-5-methoxy-3-
(methoxymethoxy)benzoate 90: Compound 101 (0.100 g, 0.413 mmol, 1 equiv) was 
dissolved in DMF (0.8 mL, 0.2 M) at room temperature.
 
N-chlorosuccinimide (71 mg, 
0.531 mmol, 1.3 eq) dissolved in 0.4 mL DMF was added dropwise. The reaction was 
heated to 40 °C and stirred for 48 hours. Ethyl acetate was added to the reaction, which 
was then washed with water and dried over sodium sulfate. The solvent was evaporated, 
and the product was purified using column chromatography with 10-30% ethyl acetate in 
hexanes to give product 90 (86 mg, 0.31 mmol, 74%) was recovered. Yellow oil; Rf = 
0.62 (1:4 EtOAc/Hexanes); IR νmax 2957, 1742, 1441, 1204, 1033 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ: 9.11 (s, OH); 7.01 (s, 1H); 5.23 (s, 2H); 4.00 (s, 3H); 3.86 (s, 3H); 3.54 
(s, 3H); HR-MS: m/z Calcd. for C11H13ClO6 [M+H
+
]: 277.0401, Found ( ppm). 
 5-Hydroxy-2,2,7-trimethyl-4H-benzo[d][1,3]dioxin-4-one 97: 
2,6-Dihydroxybenzoic acid (0.500 g, 2.95 mmol, 1 equiv), DMAP (37 mg, 0.30 mmol, 
0.1 equiv), and acetone (0.57 mL, 7.75 mmol, 2.6 equiv) were dissolved in 
dimethoxyethane (15 mL, 0.2 M) and cooled to 0 °C. Then, thionyl chloride (0.66 mL, 
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8.9 mmol, 3 equiv) was added and the reaction warmed to room temperature overnight. 
Then, it was quenched with saturate sodium bicarbonate, extracted three times with ethyl 
acetate, dried over sodium sulfate, and the solvent was evaporated. Purification with a 5-
10% solution of ethyl acetate in hexanes using column chromatography yielded pure 
product 97 (0.375 g, 1.80 mmol, 61%). White solid; Rf =0.22 (1:9 EtOAc/Hexanes); IR 
νmax 1689, 1383, 1205, 1090 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ: 10.23 (s, OH); 6.46 (s, 
1H); 6.27 (s, 1H); 2.31, (s, 3H); 1.73 (s, 6H). 
13
C NMR (125 MHz, CDCl3) δ 165.4, 
161.1, 155.3, 150.1, 111.2, 108.0, 107.1, 96.9, 25.7, 22.5; HR-MS: m/z Calcd. for 
C11H12O4 [M+H
+
]: 209.0814, Found 209.0807 (-0.7 ppm). 
 2,2,7-Trimethyl-5-(tributylstannyl)-4H-benzo[d][1,3]dioxin-4-
one 99: Pd(PPh3)4 (75 mg, 0.066 mmol, 0.075 equiv), lithium chloride (0.422 g, 9.96 
mmol, 11 equiv), and hexamethylstannane (0.75 mL, 1.5 mmol, 1.7 equiv) were added to 
a flask equipped with a reflux condenser. Triflate 98 (0.300 g, 0.88 mmol, 1 equiv) was 
added in dioxane (7.2 mL, 0.12 M), and the reaction was heated to 90 °C for 12 hours. 
Hexanes were then added to the reaction, and the mixture was filtered through Celite®. 
After filtering through a basic alumina plug, the crude product was purified on a column 
of KF and silica, using 5% ethyl acetate in hexanes. pure product 99 (0.356 g, 0.76 mmol, 
66%) was isolated. Black oil; Rf =0.52 (1:4 EtOAc/Hexanes); IR νmax 2921, 1729, 1457, 
1046, 659 cm
-1
. 
1
H NMR (300 MHz, CDCl3) δ: 6.85 (s, 1H); 6.80 (s, 1H); 2.43 (s, 3H); 
1.73 (s, 6H); 1.48(m, 12 H); 1.30 (td, J = 12.0 Hz, J = 6.0 Hz, 6H); 0.89 (t, J = 6 Hz, 9H). 
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13
C NMR (125 MHz, CDCl3) δ 157.4, 150.3, 148.7, 118.1, 117.7, 111.5, 108.2, 106.8, 
30.8, 27.7, 25.9, 25.7, 13.9, 10.2. 
 5-Iodo-2,2,7-trimethyl-4H-benzo[d][1,3]dioxin-4-one 100:  
Stannane 99 (0.150 g, 0.32 mmol, 1 equiv) was dissolved in THF (6.4 mL, 0.05 M). N-
iodosuccinimide (0.216 g, 0.96 mmol, 3 equiv) was added, and the reaction was stirred at 
room temperature for 24 hours.  Ethyl acetate was added to the reaction, which was then 
washed with water and dried over sodium sulfate. The solvent was evaporated, and the 
product was purified using column chromatography with 5% ethyl acetate in hexanes to 
give pure product 100 (0.080 g, 0.25 mmol, 79%). Rf =0.52 (1:4 EtOAc/Hexanes); IR 
νmax 2871, 1745, 1423, 1202, 1022 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 6.85 (s, 1H); 
6.80 (s, 1H); 2.43 (s, 3H); 1.74 (s, 6H). 
13
C NMR (125 MHz, CDCl3) δ 157.2, 148.5, 
139.9, 117.9, 117.5, 106.7, 105.6, 29.5, 25.5, 21.2. 
 5-Hydroxy-7-methyl-2,2-diphenyl-4H-benzo[d][1,3]dioxin-4-one 
S3: 2,6-Dihydroxybenzoic acid (1.5 g, 8.9 mmol, 1 equiv), DMAP (109 mg, 0.89 mmol, 
0.1 equiv), and benzophenone (4.23 g, 23.2 mmol, 2.5 equiv) were dissolved in 
dimethoxyethane (45 mL, 0.2 M) and cooled to 0 °C. Then, thionyl chloride (1.95 mL, 
26.7 mmol, 3 equiv) was added and the reaction warmed to room temperature overnight. 
Then, it was quenched with saturate sodium bicarbonate, extracted three times with ethyl 
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acetate, dried over sodium sulfate, and the solvent was evaporated. Purification with a 5-
10% solution of ethyl acetate in hexanes using column chromatography yielded a 3:1 
mixture of benzophenone to product S3 (3.36 g, 3.82 mmol, 43%). White solid; Rf = 0.54 
(1:9 EtOAc/Hexanes); 
1
H NMR (300 MHz, CDCl3) δ: 10.02 (s, OH); 7.54-7.63 (m, 4H); 
7.32-7.40 (m, 6H); 6.47 (s, 1H); 6.38 (s, 1H); 2.30 (s, 3H). 
13
C NMR (125 MHz, CDCl3) 
δ 165.5, 161.2, 155.8, 150.3, 139.3, 129.4, 128.6, 126.4, 111.6, 108.4, 107.4, 98.6, 22.6; 
HR-MS: m/z Calcd. for C21H16O4 [M+H]
+
: 333.1049, Found 333.1115 (+6.6 ppm). 
 5-(Methoxymethoxy)-7-methyl-2,2-diphenyl-4H-
benzo[d][1,3]dioxin-4-one 92: To a 3:1 solution of benzophenone: dioxinone S3 (3.36 g, 
3.82 mmol, 1 equiv) in dichloromethane (21 mL, 0.18 M), methyl chloromethylether 
(0.43 mL, 5.7 mmol, 1.5 equiv) was added at 0 °C. The reaction was warmed to room 
temperature overnight, quenched with saturated ammonium chloride, extracted three 
times with ethyl acetate, and dried over sodium sulfate. The product was purified with a 
10-30% ethyl acetate: hexanes solution using column chromatography, yielding pure 92 
(1.24 g, 3.26 mmol, 86%). White solid; Rf = 0.33 (1:4 EtOAc/Hexanes); IR νmax 3380, 
1747, 1620, 1452, 1248, 1112 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 10.02 (s, OH); 7.54-
7.59 (m, 4H); 7.29-7.37 (m, 6H); 6.63 (s, 1H); 6.58 (s, 1H); 5.21 (s, 2H); 2.32 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ: 168.8; 167.9; 167.6; 148.3; 139.8; 128.9; 128.4; 126.4; 
111.1; 110.0; 106.8; 103.1; 94.8; 56.5; 22.4; HR-MS: m/z Calcd. for C23H20O5 [M+Na]: 
399.1208, Found 399.1207 (-0.1 ppm). 
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 Methyl 2-((2-hydroxy-6-(methoxymethoxy)-4-
methylbenzoyl)oxy)-5-methoxy-3-(methoxymethoxy)benzoate S4: To a degassed 
solution of  MOM chloride 90 (0.050 g, 0.18 mmol, 1 equiv) in degassed 
dichloromethane (0.72 mL, 0.25 M) was added sodium hydride (7.2 mg, 0.18 mmol, 1 
equiv) at 0 °C. The reaction was warmed to room temperature and stirred for 30 minutes. 
Then dioxinone 92 (0.136 g, 0.36 mmol, 2 equiv) was added to the solution, along with 2 
drops of acetonitrile to dissolve the phenolate. The reaction was photolyzed for 4 hours 
with 300 nm light. The solvent was subsequently evaporated, and the product was 
purified using column chromatography with a gradient of 5 to 30% ethyl acetate in 
hexanes solution.  Pure product S4 (0.036 g, 0.077 mmol, 59%) was isolated. Yellow oil; 
Rf = 0.31 (1:4 EtOAc/Hexanes); IR νmax 2956, 1738, 1673, 1573, 1214, 1149, 1025, 760 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 10.85 (s, OH); 6.96 (s, 1H); 6.51 (m, 2H); 5.21 (s, 
2H); 5.17 (s, 2H); 3.92 (s, 3H); 3.81 (s, 3H); 3.49 (s, 3H); 3.45 (s, 3H); 2.33 (s, 3H); 
 13
C 
NMR (125 MHz, CDCl3) 168.3; 164.2; 163.4; 158.4; 153.9; 148.6; 147.7; 130.9; 128.9; 
128.4; 112.4; 107.4; 102.16; 100.56; 95.3; 94.8, 56.7, 56.5, 56.4, 52.8, 29.9. 
Methyl 2-((2,6-dihydroxy-4-methylbenzoyl)oxy)-3-
hydroxy-5-methoxybenzoate 93: Compound S4 (13 mg, 0.028 mmol, 1 equiv) was 
235 
 
dissolved in a 1:1 methanol: diethyl ether solution (0.56 mL, 0.05 M). Then 4M HCl 
solution in dioxane (50 uL, 0.02 mmol, 0.75 equiv) was added at 0 °C. The reaction was 
warmed to room temperature and stirred for 2 hours, after which the solvent was 
evaporated and the product purified using column chromatography with a 30% ethyl 
acetate: hexanes solution.  Deprotected product 93 was obtained (8.8 mg, 0.023 mmol, 
82%). Yellow oil; Rf = 0.28 (1:4 EtOAc/Hexanes); IR νmax 2955, 2923, 2854, 1736, 1645, 
1465, 1258, 1025 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ: 10.76 (s, OH); 9.45 (s, 2OH); 
9.17 (s, 2OH); 7.32 (s, 1H); 6.74 (s, 1H); 6.39 (m, 2H); 4.04 (s,3H); 3.91 (s, 3H); 3.91 (s, 
3H); 3.87 (s, 3H); 2.30 (s, 3H);  
1
H NMR (300 MHz, CD3OD) δ: 6.76 (s, 1H); 6.36 (m, 
2H); 3.88 (s, 3H); 3.78 (s, 3H); 2.26 (s, 3H). 
2-Allyl-6-hydroxy-3-methoxycyclohex-2-en-1-one 84: Hydroxy allyl 
cyclohexenone 84 was prepared from known vinylogous ester 83. Compound 83 (2.0 g, 
12.0 mmol, 1.0 equiv) was dissolved in THF (20 mL, 0.6 M) and cooled to -78 
o
C. 
LiHMDS (1.0 M in THF, 14.4 mL, 14.4 mmol, 1.2 equiv) was then added and the 
reaction was slowly warmed to -30 
o
C. The reaction was then recooled to -78 
o
C and 
Davis oxaziridine 77 (3.8 g, 14.4 mmol, 1.2 equiv) in 6 mL of THF was added. The 
reaction was then warmed to 0 
o
C and quenched after 12 h using 10 mL of aqueous 
ammonium chloride. The crude product was purified by flash chromatography using a 
gradient of EtOAc/Hex (1:9 to 100%) to obtain pure product 84 (1.5 g, 8.2 mmol, 68%). 
Yellow oil; Rf = 0.23 (EtOAc/Hex 1:1); IR νmax 1607, 1365, 1245, 1035, 910 cm
-1
; 
1
H 
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NMR (500 MHz) δ 5.77 (m, 1H), 4.97 (dd, J= 17.0, 2.0 Hz, 1H), 4.90 (dd, J= 10.5, 2.0 
Hz, 1H), 4.71 (dd, J= 7.3, 3.3 Hz, 1H), 3.98 (s, 3H), 3.01 (o, 2H), 2.67 (m, 1H), 2.35 (m, 
1H), 2.20 (m, 1H), 2.11 (m, 1H); 
13
C NMR (100 MHz, CDCl3) δ 197.9, 169.8, 135.8, 
118.4, 114.5, 62.4, 56.1, 31.4, 29.8, 26.3; HR-MS: m/z Calcd. for C10H14O3 [M+H]
+
: 
183.0943, Found 183.1028 (+9.5 ppm). 
2-Allyl-4-hydroxycyclohex-2-en-1-one 85: Hydroxy enone 85 was 
prepared from 84. Compound 84 (1.5 g, 8.2 mmol, 1.0 equiv) was dissolved in toluene 
(16 mL, 0.5 M) and cooled to -78 
o
C. DIBAL-H (1.0 M in toluene, 9.1 mL, 9.1 mmol, 1.5 
equiv) was then added and the reaction was slowly warmed to 0 
o
C. The reaction was 
then quenched after 2 h using 10 mL of 1 M HCl. It was stirred for a further 2 h and then 
extracted using EtOAc. The crude product was purified by flash chromatography using a 
gradient of EtOAc/Hex (1:9 to 100%) to obtain pure product 85 (650 mg, 4.3 mmol, 
52%). Yellow oil; Rf = 0.30  (EtOAc/Hex 1:9); IR νmax  cm
-1
; 
1H NMR (500 MHz) δ 6.70 
(br. s, 1H), 5.79 (m, 1H), 5.00 (o, 2H), 2.91 (o, 2H), 2.41 (o, 2H), 2.33 (o, 2H), 1.96 (o, 
2H); 
13
C NMR (125 MHz, CDCl3) δ 198.9, 145.8, 138.0, 135.8, 116.2, 38.4, 33.5, 26.1, 
23.1; HR-MS: m/z Calcd. for C9H12O2 [M+H]
+
: 153.0837, Found 153.0922 (+8.5 ppm). 
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4.8 Select Spectra 
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